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I. MyeLoDySPLaSTIC SyNDRoMe (MDS) 
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic 
disorders that are characterized by ineffective hematopoiesis, peripheral blood cytopenias, 
and a propensity to transform into acute leukemia. Morphologic dysplasia, identified by 
examination of the bone marrow, is a defining feature of MDS and is an important criterion 
for disease classification. 
The World Health Organization (WHO) currently discriminates seven distinct pathologic 
subtypes of MDS that are based on these morphologic features, the percentage of bone 
marrow cells that are blasts, and the number of affected hematatopoietic lineages (Tefferi 
and Vardiman 2009; Vardiman et al. 2009). 
One distinctive feature of this malignancy is the presence of increased apoptosis in the 
bone marrow, which is, in contrast, generally hypercellular although it can also be normal or 
even hypocellular. Although significant efforts to understand the pathophysiology of MDS 
over the last years have led to the identification of key genetic and epigenetic alterations in 
patients, the definite pathogenetic mechanisms of MDS are not fully understood. Except for 
a small subset of patients that is eligible for stem cell transplantation, most MDS patients 
have a poor prognosis because frontline pharmacological therapies are not curative owing 
to the lack of well-defined molecular targets. Thus, there is an urgent need to characterize 
the molecular mechanisms involved in the pathogenesis of MDS to allow the establishment 
of good diagnostic protocols and specific, effective targeted therapies. 
1.1 Myelodysplastic syndrome with isolated del(5q)
Interstitial deletion of chromosome 5q is the most common chromosomal abnormalities in 
MDS, identified in 10% to 15% of patients (Haase et al. 2007; Bejar et al. 2011). Deletions 
of chromosome 5q in MDS are somatically acquired, heterozygous and encompass many 
genes (Ebert 2009). 
While the vast majority of patients with del(5q) MDS have large deletions, rare patients 
have smaller chromosomal deletions that have enabled geneticists to define common 
deleted regions (CDR) that are minimally necessary for a clinical phenotype. Two CDRs have 
been reported (Boultwood et al. 1994; Boultwood et al. 2002): (1) The CDR located more 
distally on chromosome 5q is minimally sufficient for the 5q-syndrome and is located at 
5q52-33. (2) The CDR located more proximal to the centromere is located on 5q31. Most 
patients have deletions which encompass both loci, but the CDR provides a starting place 
for the search for critical genes. 
Heterozygous deletions in cancer often highlight the locus of a tumor-suppressor gene, 
which undergoes homozygous inactivation, but in other cases, the disease is caused directly 
by mono-allelic deletions due to haploinsufficiency for one or more genes. Although 5q 
deletions are uniformly hemizygous, sequencing and CGH analysis failed to identify point 
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mutations or microdeletions of the retained 5q alleles (Graubert et al. 2009), nor has copy-
neutral loss of heterozygosity been demonstrated at 5q (Gondek et al. 2008; Heinrichs 
et al. 2009). The absence of homozygous genetic inactivation of genes within the 5q 
common deleted region (CDR) indicates that the pathogenesis of del(5q) MDS is caused 
by haploinsufficiency or by silencing of classical tumor suppressors (e.g. by epigenetic 
mechanisms). 
Patients with del(5q) MDS are clinically heterogeneous and can be classified into 
two broad categories on the basis of clinicopathologic features, prognosis, and response 
to specific therapy. Some patients with del(5q) display an aggressive disease course with 
increased risk of transformation to acute leukemia and a short overall survival (Kantarjian 
et al. 2009). This MDS subtype is often in the context of prior therapy with alkylating agents 
and/or radiation and is far more often accompanied by complex cytogenetic abnormalities 
and TP53 mutation (Christiansen et al. 2001). Patients with del(5q) and additional multiple 
other karyotype abnormalities show a significant lower likelihood of complete response 
to lenalidomide compared with patients who have isolated del(5q) (Mollgard et al. 2011). 
Further, factors associated with adverse prognosis include deletion of the telomeric and 
centromeric regions of 5q as well as heterozygous mutations in NPM1 or MAML1 (on 5q35 
genes) (Sportoletti et al. 2008; Jerez et al. 2012). NPM1 seems to function as a haploinsufficient 
tumor suppressor in the development of multilineage hematopoietic neoplasms in a murine 
model, thereby contributing to MDS pathogenesis (Sportoletti, Grisendi et al. 2008). 
MDS patients with del(5q) as the sole karyotypic abnormality have a relatively 
favorable prognosis, including patients with the 5q− syndrome (Greenberg et al. 2012). The 
5q-syndrome has a very distinct genotype-phenotype relationship, which was first described 
by Van den Berghe in 1974 (Van den Berghe et al. 1974). The original manuscript described 
five patients with a macrocytic anemia, dyserythropoiesis with erythroid hypoplasia, normal 
to elevated platelet counts, hypolobulated megakaryocytes and an interstitial deletion 
involving the long arm of chromosome 5. The 5q-syndrome is now classified by the World 
Health Organization (WHO 2008) as a clonal hematopoietic disorder characterized by 
macrocytic anemia, normal to elevated platelet count in the peripheral blood, normal to 
increased hypolobated (micro)megakaryocytes, and an isolated del(5q) on initial diagnostic 
evaluation. Bona fide 5q− syndrome typically has a low bone marrow blast percentage (<5%; 
Auer rodsa are not present), a female-to-male ratio of 2:1, and a low risk of transformation 
to acute myeloid leukemia (AML), in particular in comparison with other MDS subtypes 
(5–16% versus 30–45%) (Vardiman, Thiele et al. 2009). Given the stability of the disease, 
with low rates of progression to AML, iron overload from chronic transfusions is a significant 
cause of morbidity and mortality. 
A region that spans 1.5 Mb and contains 40 genes at 5q32-q33 was defined as the CDR 
for the 5q− syndrome (Boultwood, Fidler et al. 2002). A number of genes within this region 
are expressed at true haploinsufficient levels in CD34+ cells of patients with del(5q) MDS 
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(Boultwood et al. 2007). Conditional deletion of this entire region recapitulates the severe 
macrocytic anemia in a murine model (Barlow et al. 2010).
Systematic functional screening of the complete list of candidate genes within the 5q33 
common deleted region provided the first evidence for the importance of haploinsufficient 
gene expression in the del(5q) MDS pathogenesis (Ebert et al. 2008; Ebert 2011). 
1.1.1 Pathogenesis of anemia in del(5q) MDS
The ribosomal protein S14 (RPS14) gene was identified as a critical gene for the erythroid 
phenotype of the 5q-syndrome using an RNA interference screen (Ebert, Pretz et al. 2008). 
Each of 40 genes in the 5q32-33 region was targeted by short hairpin (sh) RNAs, enabling a 
systematic evaluation of the effects of decreased expression of each gene. The shRNAs were 
introduced into primary human hematopoietic stem and progenitor cells (CD34+) using 
lentiviral vectors in order to examine the effect on erythroid differentiation. Only shRNA 
targeting RPS14 caused a severe block in erythroid differentiation without affection of 
megakaryopoiesis. Forced expression of RPS14 in hematopoietic stem and progenitor cells 
purified from patients with the 5q− syndrome rescued the erythropoietic defect. Expression 
in del(5q) MDS is approximately 50% of expression in non del(5q) MDS and the non-deleted 
allele is not deleted showing that RPS14 is a haploinsufficiency disease gene.
RPS14 encodes a ribosomal protein that is of central importance for 18S precursor 
ribosomal RNA (pre-rRNA) processing and 40S ribosomal subunit formation. Inherited 
heterozygous loss-of-function mutations in at least 10 different ribosomal protein genes, 
including RPS19 and RPS24, cause Diamond–Blackfan anemia (DBA), a rare congenital 
syndrome characterized by hypoplastic anemia and macrocytosis (Narla and Ebert 2010; 
Narla and Ebert 2011). The mutations are universally heterozygous, and functional 
studies indicate that homozygous inactivation of most if not all ribosomal genes would 
not be tolerated in a mammalian cell. In aggregate, the genetic data strongly indicate 
haploinsufficiency for ribosomal genes in the pathogenesis of macrocytic anemia in both 
DBA and the 5q-syndrome. 
In both DBA and del(5q) MDS, haploinsufficiency of ribosomal genes is involved in 
the impairment of pre- rRNA processing and ribosome biogenesis and activates the p53 
pathway (McGowan et al. 2008; Dutt et al. 2011). Decreased expression of RPS14 and RPS19 
causes a dramatic increase in total p53 levels, expression of p53 target genes including p21 
and cell cycle arrest. 
Activation of p53 is mediated in large part through the actions of the human homolog 
of the mouse double minute 2 (MDM2) gene product (Raiser et al. 2014). MDM2 is an E3-
ubiquitin ligase and key negative regulator of p53. MDM2 directly binds to the DNA binding 
domain of p53 where it interferes with transcriptional activation and ubiquitinates p53, 
thereby targeting it for proteasomal degradation. Disruption of ribosome assembly results 
in the liberation of free RPs that interact with MDM2 preventing its negative regulation of 
General introduction
14
p53 (Momand et al. 1992). Several ribosomal proteins including L5, L11, L23 and S7 bind 
to the zinc finger domain of MDM2 and inhibit p53 ubiquitination and degradation while 
triggering auto-ubiquitination of MDM2 (Narla and Ebert 2010). The resulting stabilization 
of p53 appears responsible for cell cycle arrest and apoptosis of erythroid precursors in the 
5q- syndrome, manifest clinically as hypoplastic anemia. 
Pharmacologic or genetic inactivation of p53 was shown to rescue the progenitor defect 
in mouse models of the 5q− syndrome, demonstrating the central mechanistic importance 
of p53 induction in the context of ribosomal protein haploinsufficiency (Barlow, Drynan et 
al. 2010). Taken together, these data indicate that the RP-MDM2-P53 axis is critical in the 
molecular pathogenesis of the 5q- syndrome. 
It remains an open question how ribosomal haploinsufficiency causes a distinct 
erythroid-specific phenotype. p53 is a central mechanism in the erythroid differentiation 
defect in ribosomopathies. The mechanisms leading to induction of p53 are partly 
understood and have been mainly linked to the MDM2-p53 axis. The effect of ribosomal 
haploinsufficiency on protein synthesis are not completely understood. Central questions in 
del(5q) MDS specifically and in ribosomopathies are: 
1.  Does ribosomal haploinsufficiency impact protein synthesis in hematopoietic cells and in 
particular in the affected erythroid lineage?
2.  Which proteins are differentially expressed in ribosomopathies and what is their impact 
on erythroid differentiation and p53 induction
In chapter 2, we describe the phenotype of a novel, conditional Rps14 knockout mouse 
model that we have generated and address these questions. We describe a so far unexpected 
link between ribosomal haploinsufficiency and the p53-dependent erythroid differentiation 
defect.
1.1.2 Pathogenesis of megakaryocyte abnormalities in del(5q) MDS
While thrombocytopenia is common in MDS in general, some patients with del(5q) 
MDS even have an elevated platelet count and the bone marrow commonly displays 
pathognomonic, hypolobulated micromegakaryocytes (Giagounidis and Aul 2008). Patients 
with DBA do not have thrombocytosis, indicating that haploinsufficiency for a ribosomal 
gene does not generally cause elevated platelet counts or the hypolobulated and distinctive 
megakaryocyte morphology (Narla and Ebert 2010). 
An analysis of of noncoding RNA in bone marrow from MDS patients identified several 
microRNAs (miRNAs) with dysregulated expression. MiR-145 and miR-146a, were shown 
to be abundantly expressed in normal hematopoietic progenitor cell populations and were 
specifically reduced in del(5q) MDS, and are indeed localized to 5q  CDR (Starczynowski et 
al. 2010; Kumar et al. 2011). 
Depletion of both miR-145 and miR-146a in murine HSPCs results in the clinically 
relevant thrombocytosis and megakaryocyte dysplasia, mediated in part by upregulation 
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of the miR-145 and miR-146a target genes TIRAP and TRAF6 and consequently increased 
IL-6 secretion. It was suggested in these studies that miR-145 normally acts via repression 
of the transcription factor FLI1 to regulate megakaryocyte and erythroid maturation and 
differentiation. Cell culture models using patient samples demonstrated that the coordinate 
loss of miR-145 and RPS14 in CD34+ progenitors causes megakaryocyte differentiation, 
reduced erythroid colony formation, and reduced HSPC expansion, thereby recapitulating 
clinical key features of del(5q) MDS, and more specifically the 5q-syndrome. In line with this 
mechanism is the finding that patients with 5q- syndrome and decreased miR-145 levels 
demonstrate reciprocally increased expression of FLI1 (Kumar, Narla et al. 2011). The forced 
expression of miR-145 in CD34+ HSPCs purified from MDS patients mediates normalization 
of the megakaryocyte/erythroid colony ratio in patients with hemizygous del(5q), but not in 
patients with 5q diploidy.
1.1.3 Cell of origin and clonal selection 
The del(5q) deletion is present in the hematopoietic stem cell compartment and can be 
found in all lineages (Nilsson et al. 2000; Nilsson et al. 2002). Cells harboring del(5q) gain 
a clonal advantage in the bone marrow and outcompete normal hematopoiesis over time. 
Recent elegant sequencing studies in defined hematopoietic stem and progenitor cell 
populations in patients with isolated del(5q) MDS showed that the 5q-deletion is the initiating 
and potentially the only required genetic lesion for the development of del(5q) MDS and 
that the 5q deletion precedes acquisition of recurrent driver mutations in the progression of 
isolated del(5q) MDS (Woll et al. 2014). A total of 34 somatic lesions, including del(5q) and 
driver mutations, were identified in bulk bone marrow cells of 15 patients with lower-risk 
MDS and all these lesions could be tracked back to the stem cell compartment. In MDS cases 
with del(5q) and additional driver mutations, acquisition of del(5q) preceded recurrent gene 
mutations, with the exception of four MDS cases with sideroblastic anemia in which the 
del(5q) was preceded by SF3B1 gene mutations. In all cases with isolated del(5q) or RAEB1/
RCMD, the del(5q) was predicted to be the first (or only) genetic lesion. 
It is still not completely understood how genetic haploinsufficiency confers a clonal 
advantage to HSC. A systematic dissection of all genes on 5q for genes that contribute to the 
clonal advantage of the del(5q) clone has not yet been reported. 
However, murine models have provided the first functional evidence for the role of 
individual genes in the hematopoietic stem cell function and leukemia progression.
The early growth response 1 (EGR1) gene encodes a transcription factor that is a direct 
transcriptional regulator of many known tumor suppressor genes, including TP53, CDKN1A 
(p21) and PTEN (Min et al. 2008). Further, EGR1 has been shown to play a role in maintaining 
hematopoietic stem cell (HSC) quiescence and retention in the bone marrow. EGR1 is also 
located in the 5q31 CDR, was shown to be deleted in >95% of patients and is expressed at 
haploinsufficient levels (Joslin et al. 2007). In a murine model with heterozygous inactivation 
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of EGR1, HSC have increased mobilization from the bone marrow. In addition, mice with 
heterozygous loss of EGR1 develop leukemia with increased frequency and decreased 
latency in mice treated with the dealkylating agent, N-ethyl-nitrosourea (ENU) to induce 
secondary mutations comparable to therapy-related myeloid neoplasms (t-MN) (Joslin, 
Fernald et al. 2007). 
Quite a few patients, however, have deletions of substantially larger regions of 5q CDR. 
As such, other genes localized to 5q outside the CDRs probably contribute to the phenotypic 
heterogeneity and clinical presentation of patients with del(5q) MDS. APC, located on 5q23, 
is deleted in the vast majority (95%) of del(5q) MDS and encodes a negative regulator of 
β-catenin/Wnt signaling. Inactivating mutations in APC are pathogenic in colon cancer. 
Mouse models demonstrate that haploinsufficiency of Apc causes expansion of the long-
term HSC population but also exhaustion of the HSC function in secondary transplants 
(Wang et al. 2010). Similarly, mice lacking the APC(min) allele – resulting in heterozygous 
loss of function for APC- have increased repopulation ability only in primary transplants but 
decreased repopulation potential in secondary transplants (Lane et al. 2010). 
Given the role of b-Catenin in the regulation of hematopoietic stem cell renewal and 
malignancies, APC haploinsufficiency might contribute to the pathogenesis of del(5q) MDS 
through increased Wnt signaling and intranuclear b-Catenin accumulation.
Current evidence suggests that the clinical phenotype of the 5q− syndrome represents 
the compound effects of haploinsufficiency of multiple genes within the 5q33 CDR. Recent 
studies showed that combined heterozygous loss of Egr1 and Apc in mice promotes the 
pathogenesis of MDS/AML, in particular in co-operation with knockdown of Trp53 and/or 
alkylating agent therapy (Stoddart et al. 2013; Stoddart et al. 2014). 
Multiple other genes have been implicated in the pathogenesis of del(5q) MDS but 
the precise role of these genes in the phenotype of patients with del(5q) MDS has not been 
well-established. The SPARC gene is located on the CDR and homozygous deletion has been 
shown to cause thrombocytopenia in mice as well as decreased erythroid colony formation. 
SPARC has haploinsufficient expression in del(5q) MDS and treatment with lenalidomide 
increased the expression of the gene (Lehmann et al. 2007). 
It remains an open question in the field how haploinsufficiency confers a clonal 
advantage to hematopoietic cells. Studies so far suggested that Wnt signaling might play a 
central role in this process. 
Central questions in the clonal advantage of the HSC in del(5q) MDS are:
1. Can haploinsufficiency for one gene confer a clonal advantage to the HSC?
2. How does Wnt-signaling contribute to the clonal advantage in del(5q) MDS?
3. Can the identified mechanisms be targeted for eradication of the del(5q) MDS HSC? 
In chapter 3, we study the role of the casein kinase 1A1 gene (CSNK1A1). CSNK1A1 is a putative 
tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic 
syndrome (MDS) and a part of the b-Catenin destruction complex. We generated a murine 
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model with conditional inactivation of Csnk1a1 and study the hematopoietic stem cell 
expansion and the role of b-Catenin on the regulation of the hematopoietic stem cell. We 
demonstrate a mechanism in the clonal advantage of the HSC which sensitizes del(5q) MDS 
cells to therapy (Chapter 3 and Chapter 4).
1.1.4 Treatment options 
Lenalidomide has been approved by the US Food and Drug Administration for the treatment 
of low-risk MDS with del(5q). In this patient cohort, lenalidomide induces a complete 
cytogenetic response in 50% to 60%, while 55% to 70% achieve transfusion independence 
(List et al. 2006; Fenaux et al. 2011). Nevertheless, in patients with complete cytogenetic 
remission, the del(5q) clone persists in CD34+CD38−CD90+ hematopoietic stem cell fraction. 
Further, the presence of small disease subclones with TP53 mutations in biopsies before 
treatment is associated with relative resistance to lenalidomide and might also predict a 
reduced a reduced treatment response (Jadersten et al. 2009). Lenalidomide has been 
shown to inhibit the growth of MDS del(5q) erythroblasts but did not affect normal cells in 
culture (Pellagatti et al. 2007). 
The mode of action of lenalidomide has been investigated in several studies. Lenalido-
mide has been shown to upregulate several genes, including the tumor suppressor gene 
SPARC and the TGF-β family member activin A, in hematopoietic progenitor cells from patients 
with del(5q) MDS and normal individuals (Pellagatti, Jadersten et al. 2007; Venner et al. 
2013). SPARC, located at 5q32-q33 within the CDR of the 5q- syndrome, has anti-proliferative, 
anti-adhesive, and anti-angiogenic properties, all known effects of immunomodulatory 
drugs (Komrokji and List 2011). Wei et al demonstrated that lenalidomide inhibits two 
phosphatases, Cdc25C and PP2Acα. The genes for these phosphatases are located on 5q and 
are deleted in most patients with del(5q) MDS (Wei et al. 2009). Cdc25C and PP2Acα are co-
regulators of the G2-M checkpoint in the cell cycle and thus their inhibition by lenalidomide 
leads to G2 arrest and apoptosis. These data suggest that haploinsufficiency of Cdc25C and 
PP2Acα in del(5q) MDS causes an enhanced sensitivity to lenalidomide.
Lenalidomide has been shown to promote degradation of p53 by inhibiting auto-
ubiquitination of MDM2 in del(5q) MDS (Wei et al. 2013). In this study, it has been suggested 
that lenalidomide restores MDM2 functionality in the 5q-syndrome to overcome p53 
activation in response to ribosomal stress.
Lenalidomide is clearly an effective treatment for lower-risk, transfusion-dependent 
MDS patients with del(5q), however not all patients respond to lenalidomide and 
approximately half of MDS patients with del(5q) acquire resistance to the drug within two 
to three years (List, Dewald et al. 2006).
There is thus a clinical need for novel treatments for MDS patients with del(5q). It 
is crucial to understand targets of lenalidomide to find a more specific therapy leading 
to the complete elimination of the del(5q) MDS. It would be optimal to directly target 
General introduction
18
haploinsufficiency of the del(5q) MDS clone to eliminate the 5q- clone but not normal 
hematopoiesis. 
In chapter 4, we demonstrate that lenalidomide induces the ubiquitination and 
consequent degradation of CSNK1A1 by the CRBN-CRL4 E3 ubiquitin ligase. Knockdown of 
CSNK1A1 sensitized primary CD34+ cells to lenalidomide, suggesting that haploinsufficiency 
of CSNK1A1 might increase lenalidomide sensitivity in del(5q) hematopoietic cells.
MoDeL SySTeMS FoR DISSeCTING heMaToPoIeSIS IN exTRaMeDuLLaRy 
SITeS
Hematopoietic stem and progenitor cells reside in a complex microenvironment containing 
mesenchymal progenitor cells, adipocytes, osteoblasts, endothelial cells and multiple 
components of the extracellular matrix (Scadden 2007). Collectively, these cellular elements 
and the extracellular matrix constitute the hematopoietic niche that regulates the size of 
the hematopoietic stem and progenitor cell pool and their fate. 
It was shown that mesenchymal stromal cells play a critical role in the function and self-
renewal of hematopoietic stem and progenitor cells (Crisan et al. 2008; Mendez-Ferrer et 
al. 2010; Scadden 2012; Medyouf et al. 2014). Mesenchymal stromal cells as precursors of 
mesenchymal cell types in the bone marrow niche as adipocytes, osteoblasts and fibroblasts 
represent important, defining cell types of the niche. 
A number of studies have been conducted to understand the components of the 
hematopoietic niche where the stem cell resides and proliferates. 
Three major components have been defined which distinguish the bone marrow niche 
from other types of mesenchymal tissues: 1) mesenchymal stromal cells, 2) extracellular 
matrix, mainly collagen I and 3) cells with osteogenic potential that ensure the mineral 
content of the bone (Leisten et al. 2012). In vivo, primitive hematopoietic stem and 
progenitor cells reside in close association with the endosteal niche, that means in close 
proximity to the collagen I bone matrix, mesenchymal stromal cells and osteoblasts and 
their precursors, have high proliferative potential and repopulating abilities. 
The bone marrow has further emerged as an attractive therapeutic target for cellular 
and molecular therapies that aim to modulate the host’s blood and immune system but also 
for the treatment of MDS (Raaijmakers and Scadden 2008; Raaijmakers et al. 2010). A deeper 
understanding of the mechanism that governs HSPC trafficking and engraftment is essential 
to improve the clinical effectiveness of hematopoietic transplantation, the development of 
new oncotherapies, and the targeting of bone marrow therapeutics.
A major challenge in probing the bone marrow microenvironment is that the 
experimental platforms to do so are non-physiological and/or low-throughput in nature. In 
vitro models using transwell chambers have been explored to understand HSPC migration, 
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but these experiments do not account for the complexity of this tissue and its components 
(Jorda et al. 2002). 
Comparable to the components which have been described to distinguish the bone 
from other mesenchymal tissues, necessary components for the regulation of hematopoietic 
stem and progenitor cells have been described (Wright et al. 2001; Lapidot et al. 2005; Wilson 
and Trumpp 2006; Kiel and Morrison 2008). These components include (1) a specialized 
sinusoidal vasculature, (2) non-hematopoietic cells that support retention and engraftment 
by direct cell–cell interactions and by the secretion of soluble and insoluble factors, and 
(3) a sponge-like geometry that concentrates hematopoietic cells and molecules within 
the cavity. In vivo experiments using adoptive transfer or parabiotic mouse models retain 
these components and are the gold standard for studying hematopoietic cell trafficking in a 
physiological setting. Although these methods provide valuable insight into migration and 
functional engraftment of HSPCs, in situ analysis of the dynamics of cells in the bone marrow 
remain elusive because of the anatomical inaccessibility and opacity of bone. Intravital 
imaging of calvarial bone marrow has been developed to capture an unprecedented level of 
HSPC dynamics in the bone marrow and has contributed significantly to our understanding 
of hematopoietic niches (Sipkins et al. 2005; Lo Celso et al. 2009). Aside from the likelihood 
that calvarial bone may not represent other classical marrow cavities, a key limitation 
with this approach and other in vivo studies is that the bone marrow microenvironment is 
determined by the host’s genetics with little opportunity for manipulating cell populations 
in a controlled fashion. These limitations also restrict the modeling of human-specific 
environmental interactions.
It was thus the goal of the study described in chapter 5 to to build a reproducible and 
accessible structure that can be used to create localized microenvironments with controlled 
and defined variables for experimentation. Ectopic implants that recreate key features of a 
tissue are an intermediate approach that can offer a tremendous advantage to the study 
and manipulation of a microenvironment for basic and applied research (Krebsbach et al. 
1997; Chen et al. 2011). Investigators, including ourselves, have attempted to make tissue-
engineered structures that resemble bone (Sacchetti et al. 2007; Schneider et al. 2010; 
Schneider et al. 2010; Song et al. 2010), but considerable improvements are needed to 
allow adoption of these constructs in hematopoietic cell biology. 
In the current study it was our goal to focus on important design criteria including (1) the 
opportunity for reproducible and user-defined properties such as the choice of substrate, 
extracellular matrix, cell types, and degradability; (2) the ability to induce vascularisation; (3) 
accessibility and suitability for complementary histological/cytological analysis; and, most 
importantly, (4) the functional ability to capture and retrieve endogenous hematopoietic 
cells efficiently.
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aBSTRaCT 
Heterozygous deletion of RPS14 occurs in del(5q) MDS and has been linked to impaired 
erythropoiesis, characteristic of this disease subtype. We generated a murine model 
with conditional inactivation of Rps14 and demonstrated a p53-dependent erythroid 
differentiation defect with apoptosis at the transition from polychromatic to orthochromatic 
erythroblasts resulting in age-dependent progressive anemia, megakaryocyte dysplasia, 
and loss of hematopoietic stem cell (HSC) quiescence. Using quantitative proteomics, we 
identified significantly increased expression of proteins involved in innate immune signaling, 
particularly the heterodimeric S100a8/S100a9 proteins in purified erythroblasts. S100a8 
expression was significantly increased in erythroblasts, monocytes and macrophages and 
recombinant S100a8 was sufficient to induce an erythroid differentiation defect in wild-
type cells. We rescued the erythroid differentiation defect in Rps14 haploinsufficient HSCs 
by genetic inactivation of S100a8 expression. Our data link Rps14 haploinsufficiency to 
activation of the innate immune system via induction of S100A8/A9 and the p53-dependant 
erythroid differentiation defect in del(5q) MDS.
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INTRoDuCTIoN
Isolated, interstitial deletion of Chromosome 5q in patients with myelodysplastic syndrome 
(MDS) is associated with a clinical phenotype termed the 5q- syndrome that is characterized 
by a severe macrocytic anemia, a normal or elevated platelet count with hypolobated 
micromegakaryocytes and a low rate of progression to acute myelogenous leukemia1-3. The 
severe macrocytic anemia in del(5q) MDS patients has been linked to haploinsufficiency of 
the ribosomal protein small subunit 14 (RPS14)4. In a screen of the 5q33 common deleted 
region associated with the 5q- syndrome, only shRNAs targeting the RPS14 gene caused a 
severe block in erythroid differentiation, while forced overexpression of RPS14 in cells from 
MDS patients with the 5q deletion rescued erythropoeisis4. 
Germline, heterozygous inactivating mutations or deletions of RPS19 and other 
ribosomal protein genes cause Diamond-Blackfan anemia (DBA), a disorder that, like del(5q) 
MDS, is characterized by macrocytic anemia5-9. Decreased expression of individual ribosomal 
proteins, including RPS19 and RPS14, increases p53 levels and p53 target gene expression 
in cell lines, primary human hematopoietic progenitor cells, and patient samples10-12. 
Pharmacologic or genetic inactivation of p53 rescues the differentiation defect of progenitor 
cells in multiple model systems7,8,10,13.
Several in vivo models of ribosome dysfunction have been described14. A murine model 
with hematopoietic-specific heterozygous deletion of Rps6 recapitulated the erythroid 
phenotype of del(5q) MDS and DBA that is rescued by p53 inactivation, though RPS6 
inactivation has not been described in either DBA or MDS7,8,15. To model del(5q) MDS, a 
mouse was generated wherein a series of DNA segments syntenic to the commonly deleted 
region on human chromosome 5, including Rps14, was conditionally deleted from the 
hematopoietic stem cell compartment13. Heterozygous loss of this region resulted in a 
macrocytic anemia and dysplastic megakaryocytes, thereby recapitulating aspects of the 
5q-syndrome. The smallest deleted segment tested that maintained the erythroid defect 
included Rps14 and 7 other genes.
In order to investigate the hematologic phenotype and molecular consequences 
specific to Rps14 haploinsufficiency in vivo, and to explore the role of this gene in del(5q) 
MDS, we generated a murine model with conditional Rps14 inactivation.
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8/S100A9
28
ReSuLTS
Rps14 haploinsufficiency induces a p53-dependent erythroid differentiation 
defect in late-stage erythroblasts
We generated a conditional Rps14 knockout model in which exons 2-4 are flanked by loxP 
sites (Suppl. Fig. 1a). Following crosses to Mx1Cre+ transgenic mice, we induced Rps14 
excision in hematopoietic cells by poly(I:C) treatment and confirmed haploinsufficient 
expression of Rps14 (Suppl. Fig. 1b, c). Mice with Rps14 haploinsufficiency in hematopoietic 
cells developed a progressive anemia (Fig. 1a; Suppl. Fig. 1d, e). At approximately 550 days 
of age, the reticulocyte count of Rps14 haploinsufficient mice decreased precipitously and 
was associated with death in a subset of mice (Fig. 1a, b). 
We next determined whether Rps14 haploinsufficiency causes a discrete, stage-specific 
defect in erythroid development. We characterized the stages of erythropoiesis by flow 
cytometry on the basis of Ter119 and CD71 expression (Supplementary Fig. 1d). Rps14 
haploinsufficient mice had impaired erythropoiesis at the transition from CD71+Ter119+ 
basophilic and early chromatophilic erythroblasts (RII) to CD71intermediate/lowTer119+ poly/
orthochromatophilic erythroblasts and enucleated erythrocytes (RIII/RIV), (Fig. 1c). Rps14 
haploinsufficient mice had significant splenomegaly with repression of the white pulp 
due to an expansion of the early erythroid compartment (Fig. 1d; Suppl. Fig. 1i). Younger 
mice, 22 weeks after excision, also had impaired differentiation at the RIII/IV transition 
(p<0.001) with a decrease in quiescence of cells in the RI population (p>0.001,); (Suppl. Fig. 
1f, g), together suggesting that younger Rps14 haploinsufficient mice induce compensatory 
increase in erythropiesis causing a delay in development of severe anemia. To determine 
whether the anemia is driven by Rps14 haploinsufficiency in hematopoietic cells but not in 
the bone marrow stroma, we generated mixed bone marrow chimeras (Suppl. Fig. 1h). Wild-
type mice transplanted with Rps14 haploinsufficient hematopoietic cells developed anemia 
with kinetics similar to untransplanted mice, confirming that the phenotype is caused by 
excision of Rps14 in hematopoietic cells.
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Figure 1: Rps14 haploinsufficiency results in a p53-mediated erythroid differentiation defect. (a) Hemoglobin 
levels (Hb) and % of reticulocytes in the peripheral blood from Rps14-/+Mx1Cre+ mice in comparison to Mx1Cre+ 
wild-type controls. (mean±SD, n=10; *p<0.05). (b) Kaplan-Meier survival curve of Rps14-/+Mx1Cre+ (n=10) and 
Mx1Cre+ control mice (n=10). Time point 0 is the day of the first of three poly(I:C) inductions. (c) Frequency of 
RI-RIV erythroid progenitor populations (RI: CD71highTer119-; RII: CD71highTer119+; RIII: CD71intermediateTer119+; RIV: 
CD71-Ter119+) among viable bone marrow cells in Mx1Cre+ and Rps14-/+Mx1Cre+ mice 18 months after poly(I:C); 
(mean±SD, n=5; **p<0.001). (d) Relative spleen to body weight [%] of Mx1Cre+ and Rps14-/+Mx1Cre+ mice 18 
months after poly(I:C); (mean±SD, n=5; **p<0.001). (e) Hb level and reticulocyte counts in the peripheral time 
blood at serial time points before and after 25mg/kg Phenylhydrazine injection (mean±SD, n=8; *p<0.05). (f) Cell 
pellets of lineage-negative HSPCs subjected to erythroid differentiation in vitro for 5 days. (g) Quantification of 
different erythroid differentiation stages 5 days after induction of erythroid differentiation (mean±SD; n=3 biological 
replicates; **p<0.001). (h) Quantification of p21 and Rps14 transcript levels by quantitative real-time PCR in cells 
exposed for 5 days to erythroid differentiation. Data are normalized to expression in Mx1Cre+ control cells (n=5 
biological replicates; mean±SD). (i) Kaplan-Meier survival curve after treatment with 35mg/kg Phenylhydrazine 
on two consecutive days (day 0 and day 1) of Rps14-/+Mx1Cre+ (n=10), p53-/+Mx1Cre+ (n=10), Rps14-/+p53-/+Mx1Cre+ 
(n=10) and Mx1Cre+ control mice (n=10). (j) Frequency of RIII and RIV erythroid progenitor populations among 
viable bone marrow cells in 10-12 week old Rps14-/+Mx1Cre+ (n=14), p53-/+Mx1Cre+ (n=5), Rps14-/+p53-/+Mx1Cre+ 
(n=5) and Mx1Cre+ control mice (n=8) characterized by differential CD71 and Ter119 expression 9 days after the 
first treatment with 25mg/kg Phenylhydrazine (mean±SD; **p<0.001). Unpaired two-sided t-test (a-i) or multiple 
group comparison (i, j) using analysis of variance with posthoc Tukey correction were applied for statistical analysis.
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Supplementary figure 1: Targeting construct and consequences of Rps14 haploinsufficiency on the erythroid 
phenotype. (a) Schematic of the targeting construct. The Rps14 target region is 2.12 Kb and includes exon 2-4. 
The region was designed such that the 5’ homology arm extends about 5.76 Kb 5’ to the single LoxP. The 3’ 
homology arm ends 3’ to the loxP/FRT flanked Neo cassette and is 2.76 Kb long. The loxP/FRT flanked Neo cassette 
was inserted 255 bp downstream of exon 4. The single loxP site was inserted 379 bp upstream of exon 2. The 
total size of the targeting construct (including vector backbone and Neo cassette) was 14.74 Kb. (b) Excision PCR 
confirming the removal of the targeted region 10 days after poly(I:C) injection in Rps14-/+Mx1Cre+ but not Mx1Cre+ 
control cells. (c) Quantification of Rps14 transcript levels by quantitative real-time PCR in lineage-negative bone 
marrow cells 10 days after poly(I:C) injection. Data are normalized to expression in Mx1Cre+ control cells (n=8; 
mean±SD, **p<0.001). (d) Representative flow blot for the gating strategies of the RI-RIV erythroid progenitor 
populations by CD71 and Ter119 staining. Region I (CD71highTer119intermediate) reflects proerythroblasts, region II are 
basophilic erythroblasts (CD71highTer119+), region III represents late basophilic and chromatophilic erythroblasts 
(CD71intermediateTer119+) and region IV orthochromatophilic erythroblasts (CD71-Ter119+) (according to Socolovsky et 
al. 2001). (e) Mean corpuscular volume (MCV) of red blood cells in the peripheral blood from Rps14-/+Mx1Cre+ mice 
in comparison to Mx1Cre+ wild-type controls. (mean±SD, n=10; *p<0.05). (f) Quantification of the frequencies of 
the RI-RIV population in Mx1Cre+ and Rps14-/+Mx1Cre+ mice 22 weeks after poly(I:C); (mean±SD, n=10 for Mx1Cre+; 
12 for Rps14-/+Mx1Cre+; *p<0.05; **p<0.001). (g) Cell cycle analysis using combined Ki67 and Hoechst staining 
within cells stained with CD71 and Ter119. Representative flow plots and quantification of the frequencies of RI 
cells within the G0, G1 and S-G2-M phase in Mx1Cre+ and Rps14-/+Mx1Cre+ mice 22 weeks after poly(I:C). (mean±SD, 
n=10 for Mx1Cre+; 12 for Rps14-/+Mx1Cre+; *p<0.05; **p<0.001). (h) Hemoglobin kinetics in wild-type recipient 
mice (CD45.1) that were transplanted with Mx1Cre+ and Rps14-/+Mx1Cre+ whole bone marrow cells 4 weeks 
after poly(I:C). (n=5; mean±SD, **p<0.001). (i) Representative macroscopical and histopathological images of 
spleens in Mx1Cre+ and Rps14-/+Mx1Cre+ mice 18 months after poly(I:C); (mean±SD, n=5; **p<0.001). HE-staining, 
4x magnification. (j) Annexin-positive/DAPI-negative, apoptotic cells within the RI-RIII population at day 9 after 
Phenylhydrazine treatment in Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ control mice (n=5), (*p<0.05). (k) Representative 
spleen histopathology in Rps14-/+Mx1Cre+, p53-/+Mx1Cre+, Rps14-/+p53-/+Mx1Cre+ and Mx1Cre+ control mice. Relative 
spleen to body weight [%] of Mx1Cre+ and Rps14-/+Mx1Cre+ mice 9 days after the first treatment with 25mg/kg 
Phenylhydrazine in Rps14-/+Mx1Cre+ (n=14), p53-/+Mx1Cre+ (n=5), Rps14-/+p53-/+Mx1Cre+ (n=5) and Mx1Cre+ control 
mice (n=8) (mean±SD; *p<0.05). (l) Frequency of RI and RII erythroid progenitor populations among viable bone 
marrow cells in Rps14-/+Mx1Cre+ (n=5), p53-/+Mx1Cre+ (n=5), Rps14-/+p53-/+Mx1Cre+ (n=5) and Mx1Cre+ control mice 
(n=8) characterized by differential CD71 and Ter119 expression (mean±SD; **p<0.001). 
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We next examined the effect of Rps14 haploinsufficiency on stress erythropoiesis by 
inducing hemolysis with phenylhydrazine (PH) treatment in vivo. Following acute hemolytic 
stress, Rps14 haploinsufficient mice developed more severe anemia and had a delayed 
reticulocyte response compared to Mx1Cre control mice (Fig. 1e). The RI population 
(CD71+Ter119−) was significantly increased in Rps14-/+Mx1Cre+ mice, while the RIV 
population (CD71lowTer119high) was significantly decreased, highlighting a terminal erythroid 
differentiation defect consistent with induction of apoptosis in the RIII (CD71intermediateTer119+) 
population (Fig. 1h, Supp. Fig. 1j). Rps14-/+Mx1Cre+ mice were characterized by significant 
splenomegaly with effacement of the normal spleen architecture and expansion of the red 
pulp (p<0.05; Supp. Fig. 1k). 
To analyze the effect of Rps14 haploinsufficiency on erythroid differentiation in the 
absence of in vivo compensatory mechanisms, we analyzed erythroid differentiation 
of lineage-negative hematopoietic stem and progenitor cells (HSPC) in vitro. After 5 
days, Mx1Cre+ HSPCs differentiated into hemoglobinized CD71-Ter119+ cells while Rps14 
haploinsufficient cells did not terminally differentiate (Fig. 1f-g). This terminal differentiation 
defect was accompanied by a significant reduction in cell proliferation, decrease in cell 
viability, and induction of the p53 downstream target p21 (Fig. 1h). 
The p53 pathway is activated by decreased expression of ribosomal protein genes and 
has been linked to the erythroid defect in other models of ribosome dysfunction7,8,10,13. We 
found that compound haploinsufficiency for p53 and Rps14 prevented mortality from high 
dose PH (35mg/kg, Fig 1i). Following treatment with lower PH dose (25mg/kg), compound 
haploinsufficiency for p53 normalized the erythropoietic recovery and spleen size changes 
caused by Rps14 haploinsufficiency (Fig. 1j; Suppl. Fig. 1k, l). In aggregate, these experiments 
demonstrate that Rps14 haploinsufficiency causes a p53-dependent terminal erythroid 
differentiation defect.
Rps14 haploinsufficiency alters hematopoietic stem and progenitor cells
We next evaluated whether Rps14 haploinsufficiency alters hematopoiesis more broadly. 
In a histopathological analysis of the bone marrow, we found that 18-month old Rps14 
haploinsufficient mice had a slightly decreased cellularity, diffuse hemosiderin deposition, 
and significantly increased numbers of hypolobulated micro-megakaryocytes, consistent 
with the pathognomonic morphology in del(5q) MDS patients (Fig. 2a; Suppl. Fig. 2a, b). 
Rps14 haploinsufficient mice had a mild thrombocytosis and platelet dysplasia in peripheral 
blood smears (Suppl. Fig. 2c). The white blood cell counts (WBC) were normal (Suppl. Fig. 
2d). While the HSPC compartment was not altered in young Rps14 haploinsufficient mice 
(Suppl. Fig. 2e), long-term hematopoietic stem cells (LT-HSCs; lineagelowckit+Sca1+CD48-
CD150+) and multipotent progenitor cells (MPPs; lineagelowckit+Sca1+CD48+CD150-) were 
significantly increased in the bone marrow at 18 months (Fig. 2c). To analyze whether the 
expansion of LT-HSCs might be due to exit from quiescence and enhanced LT-HSC cycling, 
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we performed cell cycle analysis on HSPCs. In comparison with Mx1Cre+ controls, Rps14 
haploinsufficient LT-HSCs had a significantly lower percentage of cells in the G0 phase of 
cell cycle, and a significantly higher percentage of cells in the cycling G1 as well as S-G2-M 
fraction, consistent with exit from quiescence (Fig. 2c). As the telomere length reflects the 
replicative history of a cell, we measured telomere length in bone marrow cells from Rps14 
haploinsufficient and Mx1Cre+ control mice. Rps14 haploinsufficient bone marrows had 
significantly shorter telomeres than Mx1Cre+ control mice (Suppl. Fig. 2i; p<0.001). 
We next examined the capacity of HSPCs to reconstitute hematopoiesis following 
transplantation. We transplanted whole bone marrow cells from 18 month old Rps14-
/+Mx1Cre+ and Mx1Cre+ controls into 6-8 week old CD45.1 recipient mice. Rps14-/+Mx1Cre+ 
mice died 6-7 weeks after transplantation with reduced hemoglobin (Hb) levels and an 
erythroid differentiation block from RII to RIII/IV, comparable to the differentiation block 
observed in the primary mice (Fig. 2d). The Rps14-/+Mx1Cre+ mice had a significant decrease 
in both LT- and ST-HSCs and an increase in MPPs (Fig. 2e and Suppl. Fig. 2f), but no decrease 
in the chimerism in the bone marrow (Suppl. Fig. 2g). 
 Since Rps14 haploinsufficiency leads to a significant increase in LT-HSCs in primary 
mice, we examined the functional capacity of Rps14 haploinsufficient cells in a competitive 
repopulation assay. We transplanted Rps14fl/+Mx1Cre+ or Mx1Cre+ bone marrow cells in 
competition with an equal number of age-matched CD45.1 competitor BM cells into lethally 
irradiated CD45.1 recipient mice (Fig. 2f). Four weeks after transplantation, mice were 
treated with poly(I:C) to induce hemizygous Rps14 inactivation. Rps14 haploinsufficient cells 
out-competed CD45.1 competitor cells in the primary transplant, while Mx1Cre+ control cells 
had no competitive advantage (Fig. 2f). To determine the long-term repopulation potential, 
whole bone marrow cells from primary recipients were transplanted into secondary 
recipients. In the first transplant, the contribution of Rps14 haploinsufficient bone marrow 
cells was stable and showed a significantly higher chimerism than Mx1Cre+ controls. By 
32 weeks in the secondary transplant, we observed a progressive decrease in the Rps14 
chimerism to levels comparable to Mx1Cre+ control cells in the bone marrow. 
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Figure 2: Rps14 haploinsufficiency alters hematopoietic stem and progenitor cells
(a) Bone marrow histopathology in HE-stained bone marrow sections (40x magnification; scale bar 50µm) 18 
months after the first poly(I:C) injection in Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ mice (n=4), representative pictures 
are shown. (b) Frequency of MPPs (lineagelowckit+Sca1+CD48+CD150-), ST-HSCs (lineagelowckit+Sca1+CD48-CD150-) 
and LT-HSCs (lineagelowckit+Sca1+CD48-CD150+) 18 months after the first poly(I:C) injection in Rps14-/+Mx1Cre+ (n=5) 
and Mx1Cre+ mice (n=4); (mean±SD; *p<0.05). (c) Cell cycle was analyzed by combined proliferation (Ki67) and cell 
cycle (Hoechst33342) staining in permeabilized LT-HSCs from bone marrow (GO: Ki67-Hoechst-; G1: Ki67+Hoechst-; 
S-G2-M: Ki67+Hoechst+); (mean±SD; n=5; **p<0.001). (d) Whole bone marrow cells from primary 18 months old mice 
were transplanted in 6-8 week old SJL/CD45.1 recipient mice (n=5). Hemoglobin levels (Hb) in the peripheral blood 
from chimeric Rps14-/+Mx1Cre+ mice in comparison to Mx1Cre+ wild-type controls 6 weeks after transplantation 
and frequency of the RI-RIV erythroid progenitor populations (RI: CD71highTer119-; RII: CD71highTer119+; RIII/IV: 
CD71intermediate/lowTer119+) in CD45.1 mice transplanted with aged Mx1Cre+ and Rps14-/+Mx1Cre+ bone marrow cells 
6 weeks after transplantation. (e) Representative flow plots of the HSC compartment of populations defined as 
MPPs, ST-HSCs and LT-HSCs in CD45.1 mice transplanted with old Mx1Cre+ (n=4) and Rps14-/+Mx1Cre+ (n=5) bone 
marrow cells 6 weeks after transplantation. ((f) Identical numbers of Rps14-/+Mx1Cre+ and Mx1Cre+ controls were 
mixed in equal ratios (approximately 50:50) and transplanted in lethally irradiated CD45.1 recipients. Time point 
0 reflects the first bleeding 4 weeks after transplantation (engraftment) before inducing the excision of Rps14 
by poly(I:C) injections. After 24 weeks, bone marrow was harvested and transplanted for secondary transplants. 
(mean±SD, n=5; *p<0.05). (g) Donor chimerism (CD45.2) of the HSC (MPP, ST-HSC, LT-HSC) compartment (mean±SD, 
n=5; *p<0.05). (h) Hemoglobin levels (Hb) in the peripheral blood from chimeric Rps14-/+Mx1Cre+ or Mx1Cre+ mice 
64 weeks after engraftment (40 weeks after secondary transplantation). (mean±SD, n=5; *p<0.05). Unpaired two-
sided t-test was applied for statistical analysis.
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Given the progressive decrease in Rps14 chimerism, we evaluated HSC abundance. In 
multipotent progenitors cells, the frequency of Rps14 haploinsufficient cells was significantly 
higher than WT counterparts, whereas no differences were observed in ST- and LT-HSCs 
(Fig. 2g). In differentiated lineages, we observed significant myeloid skewing of Rps14 
haploinsufficient cells, reflected by increased chimerism within the Gr1+CD11b+ population. 
In contrast, chimerism within lymphoid populations did not differ significantly from Mx1Cre+ 
control chimerism; (Suppl. Fig. 2h). The chimerism of Ter119+ erythroid cells was significantly 
decreased in mice transplanted with Rps14 haploinsufficient bone marrow (Suppl. Fig. 2h), 
highlighting the distinct erythroid phenotype. Mice transplanted with equivalent numbers 
of Rps14 haploinsufficient and wild type bone marrow cells succumbed to a severe anemia 
(Fig. 2h) in the setting of relatively preserved whole blood chimerism suggesting that Rps14 
haploinsufficiency might have cell-extrinsic effects that suppress erythropoiesis. 
In aggregate, Rps14 haploinsufficiency causes impaired terminal erythroid differen-
tiation, an increase in hematopoietic stem cell frequency with myeloid skewing, and age-
dependant loss of the HSC function. Overall, this hematopoietic phenotype resembles 
alterations during HSC aging and inflammation in the bone marrow16-18. 
Ribosomal haploinsufficiency leads to global reduction in protein synthesis
Having established a mouse model that faithfully recapitulates the cardinal features of 
del(5q) MDS, we sought to understand how heterozygous deletion of Rps14, a component 
of the 40S ribosomal subunit, alters ribosome assembly and protein synthesis. 
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Supplementary fi gure 2: hematological phenotype of Rps14 haploinsuffi  cient mice. (a) Histopathological overview 
of the spinal part of the bone marrow in Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ mice (n=4) 18 months aft er the fi rst 
poly(I:C) injecti on. HE-staining. 4x magnifi cati on. (b) Representati ve high-power magnifi cati on pictures (100x with 
oil) of HE-stained bone marrows from Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ mice (n=4) 18 months aft er the fi rst 
poly(I:C) injecti on. (c) Representati ve peripheral blood smear, May-Gruenwald-Giemsa staining and platelet counts 
in the peripheral blood from Rps14-/+Mx1Cre+ mice in comparison to Mx1Cre+ wild-type controls. (mean±SD, n=10; 
*p<0.05). (d) White blood cell (WBC) count in the peripheral blood from Rps14-/+Mx1Cre+ mice in comparison to 
Mx1Cre+ wild-type controls. (mean±SD, n=10; *p<0.05). (e) Representati ve fl ow plots and frequency of MPPs (li
neagelowckit+Sca1+CD48+CD150-), ST-HSCs (lineagelowckit+Sca1+CD48-CD150-) and LT-HSCs (lineagelowckit+Sca1+CD48-
CD150+) in Mx1Cre+ and Rps14-/+Mx1Cre+ mice 22 weeks aft er poly(I:C). (f) Whole bone marrow cells from primary 
18 months old mice were injected in 6-8 week old SJL/CD45.1 recipient mice. Frequency of MPPs (lineagelowcki
t+Sca1+CD48+CD150-), ST-HSCs (lineagelowckit+Sca1+CD48-CD150-) and LT-HSCs (lineagelowckit+Sca1+CD48-CD150+) 6 
weeks aft er transplantati on in Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ mice (n=4); (mean±SD; *p<0.05). (g) Whole 
bone marrow donor chimerism (CD45.2) and donor chimerism in MPPs, ST-HSCs and LT-HSCs of 18 months old 
whole bone marrow cells from Rps14-/+Mx1Cre+ and Mx1Cre+ mice 6 weeks aft er transplantati on. (h) Lineage 
donor (CD45.2) chimerism of competi ti ve transplants 64 weeks aft er engraft ment (40 weeks aft er secondary 
transplantati on). (mean±SD, n=5; *p<0.05). (i) Confocal Q-FISH to measure the telomere length in Rps14-/+Mx1Cre+ 
and Mx1Cre+ bone marrows 18 months aft er poly(I:C). (n=5 mice; n=12979 telomeres measured for Mx1Cre+ and 
n=11935 telomeres measured for Rps14-/+Mx1Cre+; **p<0.001). Representati ve confocal images showing telomeres 
in nucleated, DAPI-positi ve cells
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Figure 3: Reduced protein synthesis in Rps14 haploinsufficient cells. (a) OP-Puro incorporation in bone marrow 
(BM) cells in vivo 1 h after administration in 20 week old Mx1Cre+ control cells or Rps14-/+Mx1Cre+ cells [(16 weeks 
after the first injection of poly(I:C)]. Quantification of OP-Puro fluorescence reflecting protein synthesis rate in 
hematopoietic stem and progenitor cells relative to unfractionated bone marrow. Relative protein synthesis and 
quantification of OP-Puro fluorescence in erythroid RI-RIV progenitor populations relative to unfractionated bone 
marrow (mean±SD, n=5; **p<0.001; Unpaired two-sided t-test was applied for statistical analysis). (b) Polysome 
profiles from sort-purified lineagelowCD71highTer119+ erythroid progenitor cells in Mx1Cre+ control cells or Rps14-
/+Mx1Cre+ cells. The x-axis shows the distance along the gradient. The arbitrary Y-axis shows the relative absorbance. 
Data are representative of 3 independent experiments (each n=3 biological replicates). (c) Proteomic analysis of 
induced changes in protein expression of Rps14 haploinsufficient sort-purified lineagelowCD71highTer119+ erythroid 
progenitor cells relative to Mx1Cre+ cells (300µg protein for each technical replicate=4 biological replicates). Log2 
ratios and scatter plot for individual proteins for replicate 1 and 2, where each dot represents a unique protein. 
The upper right quadrant represents proteins that are significantly up-regulated by Rps14 haploinsufficiency in 
replicate 1 and 2 (Rep 1 and 2) relative to Mx1Cre+ control cells. Detailed statistical methods for the proteomic 
analysis are described in the methods section.
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Supplementary fi gure 3: Reduced protein synthesis in Rps14 haploinsuffi  cient cells. (a) OP-Puro incorporati on in 
bone marrow (BM) hematopoieti c stem and progenitor cell populati ons in vivo 1 h aft er administrati on. 
Quanti fi cati on of OP-Puro fl uorescence refl ecti ng protein synthesis rate in hematopoieti c stem and progenitor cells 
relati ve to unfracti onated bone marrow. Relati ve protein synthesis relati ve to unfracti onated bone marrow 
(mean±SD, n=5; **p<0.001). (b) Representati ve fl ow blots showing the gati ng strategy for determinati on of OP-
Puro incorporati on in erythroid progenitor cell populati ons. (c) Volcano plot showing the log fold change of protein 
expression (X-Axis) to the –log10 adjusted p-value. Orange dots highlight all ribosome associated proteins, blue 
dots S100a proteins and the red dot Rps14. 
We fi rst analyzed whether Rps14 haploinsuffi  ciency induces quanti tati ve changes in 
protein synthesis using a fl uorogenic assay (O-propargyl-puromycin; OP-Puro) to visualize 
protein synthesis in vivo19. We administered a single intraperitoneal injecti on of OP-Puro 
(50 mg/kg) and measured OP-Puro incorporati on as a refl ecti on of total protein translati on 
in a defi ned period of ti me. Overall, OP-Puro incorporati on was signifi cantly reduced in 
Rps14-/+Mx1Cre+ cells relati ve to wild-type cells. The reducti on in protein synthesis was most 
striking in erythroid progenitor cells (Fig. 3a; Suppl. Fig. 3a-b), consistent with the erythroid 
diff erenti ati on block in these cells and the erythroid-specifi c requirement for high levels of 
ribosome biogenesis, ribosome acti vity, and protein translati on20. 
To determine whether the Rps14 haploinsuffi  ciency specifi cally infl uences ribosomal 
subunit/polysome formati on, we performed sucrose gradient analysis of intact polysomes 
from FACS-purifi ed erythroid progenitor cells (lineagelowCD71high-intermediateTer119+, RII-III). 
We observed intact formati on of polysome subunits (Fig. 3b), as expected given the rather 
mild, age-dependent phenotype. These fi ndings indicate that while protein synthesis is 
impaired, the ribosomes that are assembled functi on normally. Ribosomal subunits that fail 
to assemble into an intact 80S ribosome may be rapidly degraded, as has been described 
previously 21-23. 
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Gene symbol Protein name logFC adj. p-value
S100a8 Protein S100-A8 2.057 0.0019735
Pglyrp1 Peptidoglycan recognition protein 1 2.013 0.00197349
Retnlg Myeloid cysteine-rich protein 1.905 0.00197349
Mgp Matrix Gla protein 1.826 0.005770276
S100a9 Protein S100-A9 1.4595 0.002959553
Ltf Lactotransferrin 1.4575 0.005587191
Lcn2 Neutrophil gelatinase-associated lipocalin 1.4005 0.002959553
Chi3l1 Chitinase-3-like protein 1 1.397 0.004868785
Camp Cathelin-related antimicrobial peptide 1.3705 0.003652307
Ngp OS=Mus musculus GN=Ngp E=2 SV=1 1.3565 0.003848308
apobr Apolipoprotein B receptor 1.2345 0.004214127
Lrg1 Leucine-rich HEV glycoprotein 1.201 0.007654588
Padi4 Protein-arginine deiminase type-4 1.198 0.005221609
hp Haptoglobin 1.1555 0.01958689
Lyz2 Lysozyme C-2 1.1315 0.033817984
anxa1 Annexin A1 0.997 0.009836916
ear2 Eosinophil cationic protein 2 0.9915 0.170633883
Gys1 Glycogen [starch] synthase, muscle 0.924 0.025785806
Mmp9 Matrix metalloproteinase-9 0.907 0.05404763
Gda Guanine deaminase 0.8985 0.025569514
Nfrkb Nuclear factor related to kappa-B-binding protein 0.8675 0.01958689
aldh3b1 Aldehyde dehydrogenase family 3 member B1 0.865 0.021200077
S100a11 Protein S100-A11 0.8115 0.04566109
Itgb2 Integrin beta-2 0.7905 0.037963425
Itgam Integrin alpha-M 0.8055 0.026112389
Ncf2 Neutrophil cytosol factor 2 0.771 0.037963425
Supplementary Table 1: Differentially expressed proteins identified by iTRAQ-based mass spectrometry (adjusted 
p-value of <0.05)
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8/S100A9
40
Ribosomal haploinsufficiency induces increased levels of proteins involved in innate 
immune function 
To determine whether specific proteins are differentially expressed in Rps14 haploinsufficient 
erythroid progenitor cells and to elucidate a mechanism for the severe erythroid 
differentiation defect, we performed quantitative proteomics. We purified erythroid 
progenitor cells (lineagelowCD71high-intermediateTer119+, RII-III) and used isobaric tags for relative 
and absolute quantification (iTRAQ)-based mass spectrometry (Fig. 3c). We detected 3,524 
proteins with at least two unique peptides and ratios per replicate. Of these, 26 proteins 
were differentially expressed (adjusted p-value of <0.05; Supplementary table 1). Ribosome-
associated proteins had decreased expression, consistent with global reduction in protein 
synthesis but intact polysome formation (Suppl. Fig. 3c). In Rps14 haploinsufficient cells, 
proteins involved in innate immune system activation were most enriched, including S100a8 
and S100a9. In MDS patients, S100A9/CD33 pathway and innate immune activation have 
been implicated in disease pathogenesis 24,25. 
To validate that Rps14 haploinsufficiency induces expression of innate immune 
response proteins, we examined S100a8 expression by immunohistochemistry in bone 
marrows of Rps14 heterozygote knockout mice and Mx1Cre+ controls (Fig. 4a; Suppl. Fig. 
4d). S100a8 expression was significantly increased in Rps14 haploinsufficient bone marrows 
and distinct clusters of S100A8 expressing cells were identified (Fig. 4a). We confirmed that 
S100a8 protein and mRNA expression were increased in lineage-negative bone marrow 
cells (Fig. 4b). We simultaneously analyzed surface marker staining and intracellular S100a8 
staining to quantify S100a8 expression in defined cell populations. We found significantly 
increased S100a8 in the erythroid progenitor populations affected by the differentiation 
block (Gr1-CD11b-CD71highTer119high and Gr1-CD11b-CD71lowTer119high; RIII-RIV population), 
and in monocytes and macrophages of Rps14 haploinsufficient bone marrows (Fig. 4d-e; 
Suppl. Fig. 4a-b). 
Figure 4: S100a8 is significantly up-regulated in Rps14 haploinsufficient bone marrows, is regulated by p53 
induction, and is necessary for the erythroid differentiation defect. (a) Immunohistochemical staining of S100a8 
in bone marrows from Mx1Cre+ and Rps14-/+Mx1Cre+ mice 8 weeks after the induction of the Rps14 excision with 
poly(I:C); representative pictures are shown (n=5). Scale bar 100µm. (b) Quantification of S100a8 in lineage-negative 
bone marrow cells by quantitative real-time PCR (mean±SD, n=5; *p<0.05). Data are normalized to expression in 
Mx1Cre+ control cells 8 weeks post poly(I:C). Western blot on protein lysates from Mx1Cre+ and Rps14-/+Mx1Cre+ 
lineage-negative bone marrow cells. Data are representative of 3 independent experiments. (c) Mean fluorescence 
intensity (MFI) in CD11b-Gr1- erythroid progenitor populations characterized by CD71 and Ter119 expression (RI-
RIV). (mean±SD, n=5; *p<0.05). Mean fluorescence intensity (MFI) of S100a8 expression in Gr1+CD11+ granulocytes, 
Gr1-CD11b+ monocytes and F4/80+ macrophages (mean±SD, n=5; *p<0.05). (d) Co-immunofluorescent staining of 
F4/80 (green), p53 (dark blue) and S100a8 (red) on cytospins of Rps14-/+Mx1Cre+ and Mx1Cre+ bone marrow cells 
12 weeks after the induction of the Rps14 excision with poly(I:C). Inserts highlight areas of magnification shown 
in the lower panel. Scale bar: 20µm. Data are representative of 3 independent experiments. (e) Percentage of 
p53 and S100a8 co-expressing cells in RI-III erythroid progenitor cells from Rps14-/+Mx1Cre+ and Mx1Cre+ mice 
12 weeks after the induction of the Rps14 excision with poly(I:C), (mean±SD, n=5; *p<0.05). (f) Representative 
histograms showing S100a8 expression in the RIII erythroid progenitor cell population and mean fluorescence 
intensity (MFI) of S100a8 expression in F4/80+ macrophages and RIII erythroblasts in Mx1Cre+, p53-/-, Rps14-
/+Mx1Cre+ and Rps14-/+p53-/- Mx1Cre+ mice 6 days after induction of hemolysis with Phenylhydrazine (mean±SD,
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n=5; *p<0.05; *p*<0.001). (g) Fluorescence intensity normalized to background signals of inflammatory cytokines 
in bone marrows from Mx1Cre+ and Rps14-/+Mx1Cre+ mice 12 weeks after the induction of the Rps14 excision with 
poly(I:C). Log10 scale. (mean±SD, n=4; **p<0.001). (h) Ckit+ HSPCs were transduced with lentiviral shRNAs (n=5 
each) targeting Tnfa, S100a8 and Tlr4 and a luc control. Transduced cells were selected with puromycin and induced 
to undergo erythroid differentiation for 5 days in vitro. The frequency of RIV erythroid progenitor populations in 
the culture is shown (mean±SD, **p<0.001). Circles represent the median of three replicates for each individual 
shRNA (n=5). The mean of all shRNAs targeting a given gene is shown with a grey bar or red bar. (i) Representative 
histogram presentation and mean fluorescence intensity (MFI) of p53 expression in the RIII population of HSPCs 
transduced with shRNA targeting Tnfa, S100a8 and Tlr4 and luc control after 5 days of erythroid differentiation in 
vitro. (mean±SD, **p<0.001, n=5). Circles represent the median of three replicates for each individual shRNA (n=5). 
The mean of all shRNAs targeting a given gene is shown with a grey bar or red bar. (j) Representative histograms 
in F4/80+ macrophages and in the RIII population and mean fluorescence intensity (MFI) of S100a8 expression 
in macrophages of HSPCs transduced with shRNA targeting Tnfa, S100a8 and Tlr4 and luc control after 5 days of 
erythroid differentiation in vitro. (mean±SD, **p<0.05, **p<0.001, n=5). Circles represent the median of three 
replicates for each individual shRNA (n=5). The mean of all shRNAs targeting a given gene is shown with a grey bar 
or red bar. Unpaired two-sided t-test (b, c, e; h-j) or multiple group comparison by analysis of variance with posthoc 
Tukey correction (f) were applied for statistical analysis.
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Supplementary fi gure 4: S100a8 is signifi cantly up-regulated in Rps14 haploinsuffi  cient bone marrows, is 
regulated by p53 inducti on, and is necessary for the erythroid diff erenti ati on defect. (a) Gati ng strategy for 
validati ng the up-regulati on of S100a8 in erythroid progenitor populati ons (CD71/Ter119) and Gr1/CD11b-positi ve 
cells. Whole bone marrow was stained with Gr1, CD11b, Ter119 and CD71. Erythroid progenitors were gated from 
the non-myeloid cell populati on (Gr1-CD11b-). Representati ve fl ow blot showing S100a8 positi ve cells within the 
RIV populati on in Rps14-/+Mx1Cre+ and Mx1Cre+mice (red: Rps14-/+Mx1Cre+ and grey). Quanti fi cati on of the 
frequency of S100a8 expressing cells within the RIV populati on. (mean±SD, n=5; *p<0.05). Histogram showing 
S100A8 expression in the RIV populati on. (b) Histograms depicti ng S100a8 expression in granulocytes 
(Gr1highCD11b+), monocytes (Gr1lowCD11b+) and macrophages (CD11b+F4/80+). (c) Histograms showing S100a8 
expression in transplant experiments of 18 months old whole bone marrow cells in young recipients (compare 
Figure 2) 6 weeks aft er transplantati on. Mean fl uorescence intensity (MFI) of S100a8 in the RIII populati on and in 
monocytes in Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ mice (n=4); (mean±SD; **p<0.001). (d) S100a8 (green) 
immunofl uorescence on lineage-depleted whole bone marrows of Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ mice (n=4). 
Nuclei are highlighted by DAPI staining. (e) Mean fl uorescence intensity (MFI) of S100a8 expression in Gr1+CD11+ 
granulocytes, Gr1-CD11b+ monocytes, F4/80+ macrophages and RII-RIV erythroblasts in Mx1Cre+, p53-/-, Rps14-
/+Mx1Cre+ and Rps14-/+p53-/- Mx1Cre+ mice 12 weeks aft er poly(I:C) (mean±SD, n=3; *p<0.05; *p*<0.001). 
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Supplementary information for figure 4 
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Quantification (qt-RT-PCR) of Rps14, S100a8, Tnfa, Gata1 and Klf1 expression in sort-purified RII/III erythroblasts 
(dark red) and F4/80+ macrophages (green). The expression values are relative to Mx1Cre+ control cells which were 
normalized to 1. (mean±SD, n=5; *p<0.05). (g) Intensity of expression of 40 cytokines detected by the cytokine 
expression array compared to negative and positive control. Fluorescence intensity normalized to background 
signals of inflammatory cytokines in bone marrows from Mx1Cre+ and Rps14-/+Mx1Cre+ mice 12 weeks after the 
induction of the Rps14 excision with poly(I:C). Log10 scale. (mean±SD, n=4). (h) Mean intensity fluorescence (MFI) 
of TLR4 on monocytes and macrophages [mean±SD, n=4 (MxCre), n=5 Rps14); *p<0.05)]. (i) Knockdown validation 
of shRNA targeting Tnfa, S100a8 and Tlr4 in ckit+ HSPC 6 days after transduction and selection with Puromycin 
compared to HSPC transduced with luc control shRNA. Efficient knockdown was confirmed for each of the 5 shRNA 
applied in the experiments. A1-5, C2-6 and E8-E12 highlights the different shRNA that were tested in the experiment 
(3 replicates per shRNA). (j) Cell pellets of ckit+ HSPC derived from either Mx1Cre+ and Rps14-/+Mx1Cre+ mice and 
transduced for 48 hours with shRNA and then subjected to erythroid differentiation in the presence of puromycin 
for additional 7 days in vitro. A1-5, C2-6 and E8-E12 highlights the different shRNA that were tested in the 
experiment (3 replicates per shRNA; representative pictures are shown).
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As we observed a rapidly developing anemia in chimeric mice transplanted with 
aged Rps14 haploinsufficient whole bone marrow cells (compare Fig. 2), we analyzed 
S100a8 expression in the bone marrow of these mice. Both monocytes and Gr1-CD11b-
CD71lowTer119high (RIV) erythroblasts in Rps14 haploinsufficient mice had dramatically 
increased expression of S100a8, suggesting that additional stress in the bone marrow, like 
transplantation or aging, potentiates the expression of S100a8 with consequent effects on 
hematopoiesis (Suppl. Fig. 4c; p<0.01).
The functional unit of mammalian erythropoiesis, the erythroblastic island, consists 
of a central macrophage that extends cytoplasmic protrusions to a ring of surrounding 
erythroblasts. As we specifically found increased S100a8 expression in both erythroblasts 
and macrophages, we examined expression of S100a8 and p53 in the erythroblastic island. 
We performed confocal imaging on Rps14 haploinsufficient bone marrow spins and Mx1Cre+ 
control cells (Fig. 4d). F4/80-positive macrophages co-expressed S100a8. In close proximity 
to macrophages, we detected a significant increase in S100a8-expressing cells in Rps14 
haploinsufficient bone marrows, some of which had induction of p53. 
To validate that p53 was induced in erythroid progenitor cells with S100a8 induction, we 
analyzed co-expression of p53 and S100a8 in erythroid progenitor cells by flow cytometry (Fig. 
4e). In the RIII population, we identified a significant induction of p53 in S100a8-expressing 
cells. Since p53 is a known regulator of S100a826-29, we analyzed the expression of S100a8 in 
Rps14 haploinsufficiency in the presence and absence of p53, as well as during steady-state 
(Suppl. Fig. 4e) and stress erythropoiesis induced by PH treatment (Fig. 4f). We detected 
significantly decreased expression of S100a8 in Rps14-/+p53-/-Mx1Cre+ macrophages and RIII 
erythroid progenitor cells, compared to p53 WT controls, indicating that the induction of p53 
by ribosomal haploinsufficiency regulates the expression of S100a8 (Fig. 4f, Suppl. Fig. 4e). 
Having shown that Rps14 haploinsufficiency affects not only erythroblasts but 
also monocytes/macrophages, we measured S100a8 mRNA expression in purified 
lineagelowCD11b-CD71high/intermediateTer119+ (RII/RIII) erythroblasts and lineagelowF4/80+ 
macrophages. Both erythroblasts and macrophages from Rps14 haploinsufficient cells had 
decreased Rps14 and increased S100a8 gene expression (Supplementary Fig. 4f; p<0.05 
F4/80+; p>0.001 RII/RIII). In addition, both erythroblasts and macrophages had elevated 
expression of the Tnfa gene, a down-stream target of the heterodimeric S100A8/A9 
complex26,30 and a powerful repressor of erythropoiesis25,31. Consistent with the impaired 
erythroid differentiation, expression of the erythroid transcription factors Klf1 and Gata1 
was decreased. 
T o investigate whether Rps14 haploinsufficiency induces an inflammatory environment 
in the bone marrow that represses erythropoiesis and hematopoiesis by cell-extrinsic 
mechanisms, we profiled levels of 40 cytokines in bone marrow serum (Fig. 4j; Suppl. Fig. 4g). 
We found 4 cytokines to be significantly increased in Rps14 heterozygous mice: macrophage-
inflammatory protein (MIP/CCL3), CXCL9, RANTES, and IL12(p40). These cytokines are 
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predominantly expressed in activated macrophages/monocytes, have negative effects on 
erythropoiesis and hematopoiesis and are significantly elevated in patients with low-risk 
MDS32-35. Recent studies have demonstrated that S100A8 and S100A9 are endogenous 
activators of Toll-like receptor-4 (TLR4)36. We found that Tlr4 expression was activated on 
both macrophages and monocytes in the bone marrow of Rps14 haploinsufficient mice but 
not on erythroblasts, suggesting that S100a8 activates macrophages and monocytes and 
drives an inflammatory environment (Suppl. Fig. 4h; p<0.05).
We examined the roles of S100a8, Trl4, and Tnfα  in causing abnormal erythropoiesis 
in Rps14 haploinsufficient mice using validated small hairpin RNAs (shRNAs) (Suppl. Fig 4i). 
We transduced ckit+ HSPCs with test and control shRNAs, induced erythroid differentiation 
in vitro, and evaluated effects using flow cytometry and hemoglobinization (Fig. 4h; Suppl. 
Fig. 4j). Knockdown of S100a8 and Tlr4 improved erythroid differentiation and reduced 
p53 induction (Fig. 4i), indicating that S100a8/Tlr4 is central to the erythropoietic defect 
of Rps14 haploinsufficiency. Tnfa knockdown had a similar, although less robust effect on 
erythropoiesis and had no effect on S100a8 expression, suggesting a pro-inflammatory role 
downstream of S100a8 (Fig. 4i-j). 
S100a8 is necessary and sufficient for the erythroid differentiation defect due to 
Rps14 haploinsufficiency 
To explore a cell non-autonomous mechanism of the erythroid differentiation defect 
by S100a8, we induced erythroid differentiation of wild-type lineage-negative HSPCs in 
the presence of recombinant S100a8 protein (rS100a8). HSPCs cultured in the presence 
of rS100a8 had a differentiation block at the RIII/RIV transition (Fig. 5a, Suppl. Fig. 5a), 
consistent with the differentiation defect in Rps14 haploinsufficient cells, with significantly 
increased p53-induction in the RII/III population (Fig. 5b).
We next used CRISPR/Cas9-mediated genetic inactivation S100a8 to validate the 
requirement for S100a8 expression in the erythroid differentiation defect of Rps14 
haploinsufficient cells. We transduced HSPCs with a lentiviral vector expressing the Cas9 
nuclease and a small guide RNA (sgRNA) targeting S100a8, then analyzed in vitro erythroid 
differentiation as above.  Compared to control non-targeting sgRNA (NTG-sgRNA:Cas9), 
CRISPR-mediated inactivation of S100a8 (S100a8-sgRNA:Cas9) in Rps14 haploinsufficient 
cells rescued terminal differentiation of hemoglobinized RIV erythroid cells (Fig. 5c). We 
confirmed efficient introduction of frameshift insertion/deletion mutations and reduced 
protein-level expression of S100a8 in myeloid and erythroid cells (Fig. 5d; Suppl. Fig. 5c).
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Figure 5: S100a8 is essential for the erythroid differentiation defect due to Rps14 haploinsufficiency 
Lineage negative wild-type HSPCs were subjected to erythroid differentiation for 5 days in the presence of vehicle 
or S100a8 recombinant protein (rS100a8). Cell pellets 5 days after induction of differentiation (representative 
picture of 5 biological replicates is shown) and frequency of RI-RIV erythroid progenitor populations in the culture. 
(mean±SD, n=5 biological replicates; **p<0.001). (b) Intracellular flow cytometry for p53 expression within the 
RII/RIII populations in erythroid differentiation culture in vitro in presence or absence of recombinant S100a8. 
Representative histograms of p53 expression and mean fluorescence intensity of p53 within this population 
(mean±SD, n=5 biological replicates; **p<0.001). (c) Cell pellets of ckit+ HSPCs from Rps14-/+Mx1Cre+ or Mx1Cre+ 
mice expressing S100a8 or control sgRNAs following erythroid differentiation in vitro. Representative flow plots of 
the erythroid progenitor populations characterized by CD71 and Ter119 expression (RI-RIV); (data representative 
from n=3 biological replicates are shown). (d) Representative histogram presentation of S100a8 expression 
in Gr1lowCD11b+ monocytes in the erythroid differentiation culture in vitro after 5 days from Rps14-/+Mx1Cre+ 
or Mx1Cre+ cells which were transduced with either S100a8 or control sgRNAs. The pie chart represents the 
mutations introduced by the S100a8 sgRNA:Cas9 transduced cells after sequencing of S100a8 high, intermediate, 
and low fractions. (e) ckit+ HSPCs were transduced with a lentiviral vector expressing Cas9 and an sgRNA targeting 
S100a8 or control sgRNAs (non-targeting guide, NTG) and were transplanted 24 hours after infection into lethally 
irradiated wild-type recipients. 6 weeks after transplantation, recovered hematopoiesis in the transplanted mice 
was confirmed and PH was injected to induce hemolysis. 6 days after the first dose of PH, the bone marrow was 
harvested. Representative flow plots of the RI - RIV erythroid progenitor populations (mean±SD, n=5; **p<0.001; 
*p<0.05). (f) Representative histograms depicting GFP expression, representing cells transduced with control- or 
S100a8 sgRNA:Cas9 in the RIV population (mean±SD, n=5; **p<0.001). (g) p53 immunohistochemistry in bone 
marrows from Rps14-/+Mx1Cre+ or Mx1Cre+ mice transduced with either control control or S100a8 sgRNA:Cas9. 
Scale bar: 50µm. (h) Quantification of the mean fluorescence intensity (MFI) of intracellular staining with p53 and 
S100a8 in erythroid progenitor populations (RIII and IV) in bone marrows from Rps14-/+Mx1Cre+ or Mx1Cre+ mice 
transduced with either control or S100a8 sgRNA:Cas9. (mean±SD, n=5; *p<0.05; **p<0.001). (i) Quantification of 
the mean fluorescence intensity (MFI) of intracellular staining with Tlr4 in macrophages (CD11b+F4/80+), monocytes 
(CD11b+F4/80-) and in erythroid progenitor populations (RIII) in bone marrows from Rps14-/+Mx1Cre+ or Mx1Cre+ 
mice transduced with either control or S100a8 sgRNA:Cas9. (mean±SD, n=5; *p<0.05; **p<0.001). Unpaired two-
sided t-test (a-b) or multiple group comparison (e-i) using analysis of variance with posthoc Tukey correction were 
applied for statistical analysis. 
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We next determined whether S100a8 is necessary for the erythroid differentiation 
defect in Rps14 haploinsufficiency in vivo after PH-induced hemolysis (Fig. 5e-i). We 
transplanted HSPCs expressing either S100a8-sgRNA:Cas9 or control NTG-sgRNA:Cas9 into 
lethally irradiated wild-type recipients and treated with PH 6 weeks later. In contrast to 
controls, S100a8-sgRNA:Cas9 expression in Rps14+/-Mx1Cre+ hematopoietic cells rescued 
the ablation of the RIV population (Fig. 5e; Suppl. Fig. 5e-f), leading to a marked positive 
selection of Cas9:sgRNA-GFP+ RIV cells (Fig. 5f); reduced induction of p53 and S100a8 in 
erythroid cells (Fig. 5g, h; Suppl. Fig. 5g); decreased the frequency of Tlr4-expressing 
macrophages (Fig. 5i; Suppl. Fig. 5d, e, g); and reduced the induction of Tnfα (Suppl. Fig. 
5h). These data demonstrate the role of S100a8 in the induction of a p53-dependent 
erythroid differentiation defect and the increase in Tlr4-expressing macrophages in Rps14 
haploinsufficiency. 
To examine the cell-intrinsic effect of S100a8 in Rps14 haploinsufficiency, we purified 
RII erythroblasts and measured the effect of S100a8 inactivation on terminal differentiation 
in the absence of myeloid cells (Suppl. Fig. 5i). Purified Rps14 haploinsufficient RII progenitor 
cells expressing a control sgRNA did not terminally differentiate and underwent apoptosis, 
while those expressing S100a8-sgRNA:Cas9 differentiated into hemoglobinized, terminally 
differentiated erythroid cells, demonstrating that S100a8 directly affects erythroid 
progenitor cells by intrinsic mechanisms. 
To examine whether S100a8 has cell-extrinsic effects, we analyzed S100a8 and p53 
induction in wild-type competitor cells (CD45.1), as well as Mx1Cre+ or Rps14 (CD45.2) 
haploinsufficient cells, in competitive transplant studies (Suppl. Fig. 5j). Induction of 
S100a8 expression was restricted to CD45.2 Rps14 haploinsufficient cells (p<0.05). In 
contrast, we observed p53 induction in both the CD45.1 competitor cells and CD45.2 
Rps14 haploinsufficient cells (p<0.05), indicating that increased S100a8 expression in Rps14 
haploinsufficient exerts a pro-apoptotic effect on wild-type cells that may drive progressive 
anemia in a cell-extrinsic fashion, even in the setting of preserved whole bone marrow 
chimerism. In summary, these data demonstrate that S100a8 exerts both cell-intrinsic cell-
extrinsic effects on erythropoiesis.
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Supplementary fi gure 5: S100a8 is essenti al for the erythroid diff erenti ati on defect due to Rps14 haploinsuffi  ciency 
(a) ckit+ wild-type HSPCs were transduced with S100a8 overexpression vectors or empty vector. 48 hours aft er 
transducti on, GFP+ cells were sort-purifi ed and subsequently subjected to erythroid diff erenti ati on for 5 days. 
Frequency of RI-RIV erythroid progenitor populati ons in the culture aft er 5 days. (mean±SD; **p<0.001). (b) Mean 
fl uorescence intensity (MFI) of S100a8 in the monocytes, lymphocytes, LK and LSK in Rps14-/+Mx1Cre+ (n=5) and 
Mx1Cre+ mice (n=4). (c) Quanti fi cati on of mean fl uorescence intensity of S100a8 relati ve to the negati ve control 
(=1) Gr1lowCD11b+ monocytes and (mean±SD, n=3 biological replicates; **p<0.001) confi rming the downregulati on 
of S100a8 aft er transducti on with S100a8 sgRNA/Cas9 or NTG. (d) ckit+ HSPCs were transduced with a lenti viral 
vector expressing Cas9 and an sgRNA targeti ng S100a8 or control (non-targeti ng guide) and were transplanted 24 
hours aft er infecti on into lethally irradiated wild-type recipients. 6 weeks aft er transplantati on, recovered 
hematopoiesis in the transplanted mice was confi rmed and PH was injected to induce hemolysis. 6 days aft er the 
fi rst dose of PH, the bone marrow was harvested. Representati ve fl ow plots of the macrophage (CD11b+F4/80+) and 
monocyte (CD11b+F4/80-) populati on in Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ mice (n=5) transduced with either 
control:Cas9 or S100a8 sgRNA:Cas9 6 days aft er inducti on of hemolysis with PH. Quanti fi cati on of the erythroid 
progenitor populati ons (RI-III; RIV is shown in main fi gure 5) and macrophage and monocyte populati on. mean±SD, 
n=5; *p<0.05. (e) Quanti fi cati on of the MFI of S100a8 expression in macrophages. (mean±SD, n=5). (f) HE-staining 
of bone marrows from Rps14-/+Mx1Cre+ or Mx1Cre+ mice transduced with either control:Cas9 or S100a8 sgRNA:Cas9. 
HL=hemolysis; inserts show enucleated red blood cells. Scale bar: 50µm. (g) Histograms showing representati ve 
expression of p53 and S100a8 in RIII erythroblasts and Tlr4 expression in macrophages. (h) Tnfa was determined in 
enzyme linked immunosorbent assay (ELISA) in the bone marrow serum in in Rps14-/+Mx1Cre+ (n=5) and Mx1Cre+ 
mice (n=5) transduced with either control:Cas9 or S100a8 sgRNA:Cas9, 6 days aft er inducti on of hemolysis with PH. 
(i) Lineage-negati ve cells from Rps14-/+Mx1Cre+ (n=3) and Mx1Cre+ mice (n=3) were purifi ed using bead-separati on 
and transduced with control:Cas9 or S100a8 sgRNA:Cas9. Aft er 48 hours, positi vely transduced, GFP+CD71+Ter119low-
intermediate RI/RII erythroid progenitor cells were sort-purifi ed and subjected to erythroid diff erenti ati on in vitro for 
another 48 hours. Representati ve cell pellets harvested aft er 48 hours are shown as well as representati ve fl ow 
plots of CD71/Ter119 staining. (j) Aged Rps14 or Mx1Cre+ control whole bone marrow cells (18 months) were mixed 
in a 1:1 competi ti on and the expression of S100a8 and p53 was analyzed aft er 4 months when the mice presented 
with progressive anemia. S100a8 and p53 expression was analyzed by intracellular fl ow cytometry in  competi tor 
cells (CD45.1) and Rps14 haploinsuffi  cient or Mx1Cre+ cells (CD45.2), respecti vely, in the RII/III populati on or 
macrophages. The gati ng on the CD45.1 and CD45.2 within the RII/III populati on is shown representati vely and 
representati ve histograms analyzing S100a8 or p53 expression are presented. The mean fl uorescence intensity of 
S100a8 and p53 within these populati ons and in the CD45.1/CD45.2 fracti on within the F4/80+ macrophage 
compartment was quanti fi ed. (mean±SD; *p<0.05; **p<0.001).
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Frequency of S100a8-positive cells in del(5q) MDS human bone marrows positively 
correlates with disease severity
To examine whether ribosomal haploinsufficiency leads to activation of S100A8 in patients 
with del(5q) MDS, we performed immunofluorescence for S100A8 and the erythroid marker 
glycophorin A (GlyA) on bone marrow biopsies from non-MDS controls (normal) and MDS 
patients with and without del(5q) (Fig. 6; Suppl. Table 2; Suppl. Fig. 6a, b). In non-MDS 
controls, rare S100A8 expressing cells were interspersed in the hematopoietic marrow. In 
del(5q) MDS, S100A8-positive were positioned in the marrow in groups of greater than 5 
cells. The frequency of S100A8-expressing nucleated cells was significantly increased in 
del(5q) MDS bone marrow biopsies compared to non-MDS bone marrows (Suppl. Fig. 6b). 
GlyA-positive early erythroid progenitor cells occasionally co-expressed S100A8 (Fig. 
6a, insert), just as seen in the Rps14 haploinsufficient murine model. In aggregate, these 
data indicate that impaired erythropoiesis in the bone marrow of del(5q) MDS patients is 
associated with aberrant expression of S100A8.
Figure 6: S100a8-frequency is significantly increased in del(5q) MDS human bone marrows compared to non-
MDS controls. (a) Representative images of co-immunoflurescent staining of Glycophorin A (GlyA), S100A8 and 
DAPI as a nuclear staining in healthy (non-MDS; n=15), del(5q) MDS patients (n=21) and normal karyotype MDS 
(non del(5q), n=9). DAPI (blue), S100A8 (green), GlyA (magenta). Insert depicts S100A8 and GlyA expressing cells. 
Scale bars: 100µm. Immunofluorescence for all patients is shown in Supplementary Figure 6. (b) Quantification of 
S100A8+ cells as a percentage of DAPI-positive nucleated bone marrow cells (S100A8 frequency in the nucleated 
marrow). (mean±SD, p<0.001). Unpaired two-sided t-test was applied for statistical analysis.
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Supplementary fi gure 6: Images of co-immunofl urescent staining of Glycophorin A (GlyA), S100A8 and DAPI as a 
nuclear staining in normal bone marrows (n=15), del(5q) MDS (n=20) pati ents and normal karyotype MDS (non 
del(5q); n=9) and. DAPI (blue), S100A8 (green), GlyA (magenta). Scale bars: 100µm. 
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DISCuSSIoN 
Anemia is the most common hematologic manifestation of MDS, particularly in patients with 
del(5q) MDS. In a novel conditional knockout mouse model of Rps14, we found that Rps14 
haploinsufficiency is sufficient to cause a p53-dependent erythroid differentiation defect 
with apoptosis resulting in age-dependent progressive anemia, megakaryocyte dysplasia, 
and loss of hematopoietic stem cell (HSC) quiescence. In an unbiased proteomic analysis, we 
identified a link between Rps14 haploinsufficiency and induction of the danger associated 
molecular pattern (DAMP) heterodimer S100A8/S100A9 in monocytes, macrophages, 
and erythroblasts. Our studies link the p53-dependent erythroid differentiation defect 
to induction of S100A8 and an inflammatory environment produced by monocytes and 
macrophages, demonstrating that ribosomal haploinsufficiency exerts both cell intrinsic and 
extrinsic effects on erythroblasts and on hematopoiesis. 
S100A8/S100A9 is induced during inflammatory processes including infection, 
autoimmunity, and cancer26,36,37. In addition to granuloyctes and macrophages, which 
produce these proteins under steady-state conditions, other cell types induce S100A8/
S100A9 expression in response to stress30. We found significant induction of S100A8 in 
both CD11b+ monocytes and F4/80+ macrophages and concomitant increased expression 
of S100A8 in late-stage erythroblast, which was associated with p53 induction. Spatially, 
erythroid progenitor cells interact with a central macrophage in the erythroblastic island. 
Our data indicate that disruption of the regulatory mechanisms in the erythroblastic island 
contribute to the erythroid differentiation defects in Rps14 haploinsufficient bone marrows. 
S100A9 activation has been described in MDS patient samples24,38 and myeloid-derived 
suppressor cells (MDSC) driven by the S100A9/CD33 pathway perturb hematopoiesis24. 
Based on our data we posit that S100A8/S100A9 are induced as a stress response upon 
ribosomal haploinsufficiency in monocytes, macrophages, and erythroblasts and contribute 
to the MDS phenotype. 
S100A8/A9 is an endogenous TLR4 ligand upstream of TNFa leading to NF-kB activation 
and secretion of pro-inflammatory cytokines37. Our data demonstrate that S100a8 acts 
upstream of Tlr4 and Tnfa in the Rps14 haploinsufficiency erythroid differentiation defect. Of 
note, RPS14 and miR-145 are universally co-deleted in the 5q- syndrome, and both converge 
on TLR4 signaling25,40-44, highlighting the cooperating effects of genes on 5q.
S100 proteins participate in an autoregulatory feedback loop with p53, serving both 
as upstream drivers of p53 transcription and as direct downstream p53 transcriptional 
targets26-29. Consistent with these reports, our data demonstrate that p53 is required for 
induction of S100a8 expression in Rps14 haploinsufficient cells, and that recombinant 
S100a8 is sufficient to induce p53 activity in erythroid progenitor cells, leading to a block in 
terminal erythroid differentiation.  
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Specific cytokines are elevated in the serum of MDS patients33 and these inflammatory 
signals can alter proliferation and apoptosis of MDS HSPCs 45,46. Indeed, chronic immune 
stimulation, coupled with senescence-dependent changes48 in both HSPCs and the BM 
microenvironment49 may be central to disease pathogenesis25,41,50. Our analysis of Rps14 
haploinsufficient HSCs suggests that inflammatory cues induced by Rps14 haploinsufficiency 
impact HSC aging and quiescence17,18,43,47. In patients with chronic inflammation, cytokines 
in bone marrow have been associated with inhibition of erythropoiesis51. In particular, TNFa 
expression has been implicated in erythroid defects observed in patients with DBA31 and is 
up-regulated in the bone marrow serum of MDS patients 52,53. TNF-receptor associated factor 
6 (TRAF6) activation, as a target of miRNA145 and miRNA146a, also induces myelodysplasia 
in a mouse model. 
Deletion of the long arm of chromosome 5 leads to haploinsufficient expression of 
numerous genes. Based on our data we posit that the DAMP heterodimers S100A8/
S100A9 are induced as a stress response upon ribosomal haploinsufficiency in monocytes, 
macrophages, and erythroblasts and contribute to the MDS phenotype. S100A8/A9 is 
an endogenous TLR4 ligand up-stream of TNFa leading to NF-kB activation and secretion 
of pro-inflammatory cytokines1. Our data demonstrate that S100a8 induced by Rps14 
haploinsufficiency acts upstream of TLR4 in the erythroid differentiation defect. Of note, 
RPS14 and miR-145 are universally co-deleted in the 5q- syndrome and both converge on 
acting up- or downstream of TLR4 signaling2-7, highlighting cooperating effects of genes on 5q. 
Our data further demonstrate that p53 is required for induction of S100a8 expression 
in Rps14 haploinsufficient cells, and that recombinant S100a8 is sufficient to induce p53 
activity in differentiating erythroid progenitor cells leading to a block in terminal erythroid 
differentiation. It was shown in recent reports that S100 proteins can be intracellularly 
located and regulate cell growth, cell-cycle progression and apoptosis by interacting with 
the relevant intracellular signal-regulation pathways. S100 proteins can interact with p53 
and affect p53 transcriptional activity, resulting in expression changes of p53 target genes1.
Our data indicate an unexpected link between haploinsufficiency for a ribosomal gene, 
Rps14, activation of S100A8/S100A9 and other inflammatory molecules, and inhibition of 
erythropoiesis.  Inhibition of this process, potentially through pharmacologic targeting of 
S100A8/S100A9, could improve red blood cell production in del(5q) MDS. These findings 
underscore a molecular link between the genetic abnormalities in MDS patients, activation 
of the innate immune system, and ineffective hematopoiesis that characterizes the disease. 
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blasts hemoglobin ANC platelets ferritin
Pat. Nr IPSS-Score WHO frequency %  g/dl  /µl  /nl (GPT/l)  ng/ml
5q-2 intermediate-1 MDS, isolated 5q 0 9 7936 634 1938
5q-6 low risk RCMD, 5q- 0 9 n.a. 423 954.3
5q-12 low risk MDS, isolated 5q 0 6.279 1290 146 1324.2
5q-13 low risk MDS, isolated 5q 0 8.694 5860 136 1238.2
5q-21 low risk MDS, isolated 5q 0 10.626 5930 546 2424.8
5q-23 low risk RA, 5q- 0 8.3 4950 218 8867
5q-27 intermediate-1 MDS, isolated 5q 0 10.143 1480 102 1745.1
5q-29 intermediate-1 MDS, isolated 5q 0 7.728 1350 69 6471.4
5q-30 low risk RA, 5q- 0 10.5 7700 674 691.9
5q-35 low risk MDS, isolated 5q 1 8.7 1630 429 454.4
5q-51 intermediate-1 MDS, isolated 5q <1 8.7 1240 70 515.3
5q-52 n.d. RCMD 3 10.3 1600 287 1880.2
5q-53 intermediate-1 RCMD, isolated 5q 4 8.4 1000 467 274.8
5q-68 n.d. MDS, isolated 5q <5 11.3 2360 579 383.7
5q-69 low risk MDS, isolated 5q 1 8.2 1870 384 168
5q-70 low risk MDS, isolated 5q 3.5 8.9 2420 199 n.d.
5q-71 low risk RAEB I, isolated 5q 2 8.4 980 360 275.5
5q-7 low risk MDS, isolated 5q 0 8.6 1240 280 5880
5q-9 intermediate-1 MDS, isolated 5q n.d. 6.7 1782 160 1758
5q-67 low risk RCMD; 5q- 0 11.1 11200 640 316.5
5q-72 low risk RCMD; 5q- n.d. n.d. n.d. n.d. n.d.
Non5q-1 intermediate-1 RAEB I 0 8.3 2100 117 427.9 
Non5q-2 low risk RCMD 0 13.8 140 198 148.1 
Non5q-3 intermediate-1 RARS 0 8.8 2390 42 2743.0 
Non5q-4 intermediate-2 RAEB II 0 8.1 730 160 2645.0 
Non5q-5  low risk RCMD 0 11.6 5400 31 n.a. 
Non5q-6  intermediate-1 RCMD 0 6.9 900 28 533.2 
Non5q-7  low risk RCMD 0 11.2 3900 282 182.0 
Non5q-8  intermediate-2 RAEB I 0 6.8 770 95 379.3 
Non5q-9  n.a. RCMD 0 10 n.a. 172 n.a. 
Non5q-10 intermediate-1 NA 0 8.7 2600 329 845.5
normal-7157 n.a. n.a. 0 15.3 5100 227 n.d.
normal -3248 n.a. n.a. 0 12.1 2700 249 n.d.
normal - 71 n.a. n.a. 15.1 2400 184 n.d.
normal- 1348 n.a. n.a. 0 15.3 3400 210 n.d.
normal -8840 n.a. n.a. 0 16.2 6500 190 n.d.
normal - 6588 n.a. n.a. 0 15.2 3800 200 n.d.
normal - 1329 n.a. n.a. 0 13.1 3600 180 n.d.
normal- 11551 n.a. n.a. 0 13.9 4000 212 n.d.
normal -11641 n.a. n.a. 0 13.5 3100 247 n.d.
normal - 969 n.a. n.a. 0 15.2 4900 244 n.d.
normal -6746 n.a. n.a. 0 16.6 4600 166 n.d.
normal -4962 n.a. n.a. 0 13.3 2300 140 n.d.
normal -1188 n.a. n.a. 0 13.6 3100 205 n.d.
normal -8900 n.a. n.a. 0 14.1 4400 167 n.d.
normal -7846 n.a. n.a. 0 12.5 4000 247 n.d.
Supplementary table 2: Clinical data for bone marrow biopsies included in the study.
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MeThoDS
Generation of Rps14 conditional knockout mouse and mouse 
experiments
The Rps14 target region is 2.12 Kb and includes exon 2-4. Briefly, a 10.64 Kb region used to 
construct the targeting vector was first subcloned from a positively identified C57BL/6 BAC 
clone (RP23: 205B18). The region was designed such that the 5’ homology arm extends 
about 5.76 Kb 5’ to the single LoxP. The 3’ homology arm ends 3’ to the loxP/FRT flanked 
Neo cassette and is 2.76 Kb long. The loxP/FRT flanked Neo cassette was inserted 255 bp 
downstream of exon 4. The single loxP site, containing engineered ApaLI and Bcl I sites for 
southern blot analysis, was inserted 379 bp upstream of exon 2. The targeting vector was 
confirmed by restriction analysis after each modification step. P6 and T7 primers anneal to 
the backbone vector sequence and read into the 5’ and 3’ ends of the BAC sub-clone. N1 
and N2 primers anneal to the 5’ and 3’ ends of the LoxP/FRT Neo cassette and sequence 
the SA and LA, respectively. The BAC was subcloned into a ~2.4kb backbone vector (pSP72, 
Promega) containing an ampicillin selection cassette for retransformation of the construct 
prior to electroporation. A pGK-gb2 loxP/FRT Neo cassette was inserted into the gene. 
The targeting construct was linearized using NotI prior to electroporation into ES cells. 
The total size of the targeting construct (including vector backbone and Neo cassette) is 
14.74 Kb. Targeted iTL IC1 (C57BL/6N) embryonic stem cells were microinjected into Balb/c 
blastocysts. Resulting chimeras with a high percentage black coat color were mated to wild-
type C57BL/6N mice to generate F1 heterozygous offspring. Tail DNA was analyzed from 
pups with black coat color. A PCR was performed to detect presence of the distal LoxP site 
using the ‘LEVI 3’ (5’- GTG ATC TCA ACG CAG GTG TGT AGC -3’) and ‘SDL2’ (5’- TAA CAG 
CAT GGA AGT CGG GTC TCA -3’) primers. This reaction amplifies a wild type product 474 
bp in size. The presence of a second PCR product 73 bp greater than the wild type product 
indicates a positive LoxP PCR. 
Chimeric mice were generated by standard methods. The Neo cassette was deleted 
by crossing with transgenic FLP1 recombinase mice purchased from Jackson Lab (Strain:B6.
Cg-Tg(ACTFLPe)9205Dym/J). Rps14 littermate mice were genotyped by PCR with primers 
reverse (5’–GTG ATC TCA ACG CAG GTG TGT AGC-3’) and forward (5’-TAA CAG CAT GGA 
AGT CGG GTC TCA-3’) using the following parameters: 95ºC for 3 min, followed by 35 cycles 
of 95ºC for 30 sec, 60ºC for 1 min, and 72ºC for 1 min. Following confirmation of germline 
transmission, mice were crossed with the Mx1-cre mouse strain (Jackson: 002527). To excise 
Rps14 exon 2-4, 6-8 week old Rps14 conditional mice (and Mx1Cre+ mice as controls) were 
given three rounds of 200 µg of poly(I:C) (GE Healthcare Life Sciences) using intraperitoneal 
injections. Excision after Cre recombination was confirmed by PCR with primers to detect 
a floxed portion of the construct (Ndel 2: 5’-GTA TCT CCA ATG GTC AGC AAT CAC GG-3’ and 
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LEVI: 5’- GTG ATC TCA ACG CAG GTG TGT AGC -3’). The knockout size is 511bp in size and a WT 
size of 623bp. For Qt-RT-PCR, I use the following Taqman probes were used: Rps14 mCG6028 
Taqman expression Assay (Assay ID Mm00849906_g1; Life Technologies # 4331182). Rps14 
haploinsufficient mice were further bred to p53 null mice (Jackson stock number 00813). 
Animals were monitored two to three times a week for the presence of disease by general 
inspection and palpation. Peripheral blood was collected from the retro-orbital cavity using 
an EDTA- treated glass capillary and automated total and differential blood cell counts 
were determined using Hemavet 950 (Drew Scientific). Following sacrifice, mice were 
examined for the presence of abnormalities, and organs were collected for further cell and 
histopathological analysis. Due to the experimental design, the genotypes of the mice could 
not be blinded or randomized. The group size was chosen based on our experience with 
conditional murine knockout models of genes on 5q in order to detect a disease typical 
fold change as significant54. All groups of mice (controls and studied genotypes) were age- 
and sex-matched. Mouse experiments were performed according to an IACUC approved 
protocol at Children’s Hospital Boston.
Flow cytometry and cell isolation 
Bone marrow (BM) cells were isolated by flushing and crushing pelvis, hind leg bones and 
vertebrae with mortar and pestle in PBS (GIBCO) supplemented with 2% heat inactivated 
fetal bovine serum (FBS) and Penicillin/Streptomycin (GIBCO). Whole bone marrow was lysed 
on ice with red blood cell (RBC) lysis solution (Invitrogen/Life Technologies), and washed 
in PBS (GIBCO) with 2% FBS. Single-cell suspensions of spleen were prepared by pressing 
tissue through a 70µm cell strainer followed by red blood cell lysis. Cells were labeled with 
monoclonal antibodies in 2% FBS/PBS for 30 min on ice. For flow cytometric analysis and 
isolation of specific hematopoietic progenitors, cells were incubated with combinations of 
antibodies zo the following cell surface markers, conjugated to FITC, Pe, APC, PercP-Cy5.5, 
APC-Cy7 (APC-efluor780), Pe-Cy7, Alexa Fluor 700, Pacific blue (efluor450) or biotin: CD3 
(17A2), CD5 (53-7.3), CD11b (M1/70), Gr1 (RB6-8C5), B220 (RA3-6B2), Ter119 (TER119), 
CD71 (C2), ckit (2B8), Sca1 (D7), CD34 (RSM34), CD16/32 (93), CD150 (TC15-12F12.2), CD48 
(HM48-1), CD45.1 (A20), CD45.2 (104). For sorting of lineage-negative cells, lineage markers 
included CD3, CD5, CD11b, Gr1 and Ter119. For sorting of erythroid progenitor cells, the 
lineage cocktail did not include Ter119. All reagents were acquired from BD Biosciences, 
eBiosciences, or BioLegend. To increase the sorting efficiency, whole bone marrow samples 
were either lineage-depleted or ckit enriched using paramagnetic microbeads and an 
autoMACS magnetic separator (Miltenyi Biotec).  Cell Sorting was performed on a FACSAria 
flow cytometer (BD Biosciences), data acquisition was performed on an LSR II or Canto II (BD 
Biosciences). Data were analyzed by FlowJo (Tree Star) software.  
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Long-term Competitive repopulation assays
In competitive bone marrow transplantation studies, 2x106 freshly isolated bone marrow 
cells were transplanted in competition with 2x106 freshly isolated CD45.1+ bone marrow 
cells via tail vein injection into female lethally irradiated 6-8 week old (10.5 Gy) CD45.1+ 
recipient mice. The donor cell chimerism was determined in the peripheral blood four 
weeks after transplantation before the excision of Rps14 was induced by poly(I:C) injection 
(week 0) as well as every four to eight weeks. Red blood cells were lysed (Invitrogen/Life 
Technologies) and the remaining cells were stained with antibodies against CD45.2, CD45.1, 
Gr1, CD11b, CD3, CD19 (eBio1D3) to assess the donor cell engraftment. For secondary 
transplants, 5x106 bone marrow cells collected from primary recipients were transplanted 
into lethally irradiated CD45.1 recipient mice. 
In vivo measurement of protein synthesis
One hundred microliter of a 20mM solution of O-Propargyl-Puromycin (OP-Puro; life 
technologies) were injected intraperitoneally and mice injected with PBS were used as 
controls. Bone marrow and spleen were harvested after one hour and then kept on ice. 3x106 
cells were stained with antibodies against cell surface markers, fixed in 1% paraformaldehyde, 
and permeabilized in PBS with 3% fetal bovine serum and 0.1% saponin. The azide-alkyne 
cyclo-addition was performed using the Click-iT Cell Reaction Buffer Kit (Life Technologies) 
and azide conjugated to Alexa Fluor 488 (Life Technologies) at 5µM final concentration for 
30 minutes. Cells were washed twice again and then analyzed by flow cytometry. ‘Relative 
rates of protein synthesis’ were calculated by normalizing OP-Puro signals to whole bone 
marrow after subtracting autofluorescence background as described by Singer et al19.
Methylcellulose assays
48 hours after viral transduction, 15,000 ckit+ cells were sorted and plated in semi-solid 
methylcellulose culture medium (M3434, StemCell Technologies) and incubated at 37°C in a 
humidified atmosphere. Colony formation was assessed 7 days after plating. 
shRNa and sgRNa:CRISPR Cas9 vector construction, virus production and transduction
Lentivirally expressed shRNAs in the pLKO.1 backbone vector (puromycin resitance) were 
obtained from the RNAi Consortium at the Broad Institute. S100A8 guide RNA (gRNA; 
forward 5’-CAC CGA ATT GTG GTA GAC ATC AAT G-3’; reverse 5’-AAA CCA TTG ATG TCT ACC 
ACA ATT C-3’) were cloned into pL-CRISPR.EFS.GFP (http://www.addgene.org/57827) using 
BsmBI restriction digestion. Lentiviral particles were produced by transient transfection 
of 293T cells with lentivirus plasmid together with pSPAX and VSVG packaging plasmids 
using TransIT-LT (Mirus). Lentiviral particles were concentrated using ultracentrifugation. 
Ckit+ or lineage-negative cells were cultured in StemSpan SFEM (StemCell Technologies) 
supplemented with 50 ng/ml murine Thpo and 50 ng murine Scf (both Peprotech) for 24 h 
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and then transduced with concentrated lentiviral supernatant in presence of 2 μg/ml 
Polybrene using spin-infection for 90 minutes at 2,200rpm at 37C. 
Sequencing analysis of CRISPR variants
To assess the proportion and diversity of CRISPR variants, we performed PCR amplicon deep 
sequencing of bulk genomic DNA at the S100a8 sgRNA target site (chr3:90669574-90669596; 
mm9 genome build) using the primers S100a8-g1-F: GGACACTCAGTAGTGACCATTT and 
S100a8-g1-R: GAGTAACTGCAGCTCCCATC. After addition of sample indexes and sequencing 
adaptors, the product was subjected to 150 nucleotide paired-end sequencing on an Illumina 
MiSeq, producing approximately 100,000 reads per sample. Reads were then aligned to the 
genomic reference and grouped according to specific insertion and deletion sequences.
In vitro erythroid differentiation
Total bone marrow cells were labeled with biotin-conjugated a-lineage antibodies, consisting 
of α-CD3e, α-CD11b, α-CD45R/B220, α-Ly6G/Ly6C and α-TER-119 (BD Pharmingen, San 
Diego, CA) and purified using anti-biotin beads and negative selection on the AutoMACS 
(Miltenyi). Purified cells were then seeded in fibronectin-coated (2µg/cm2) tissue-culture 
treated polystyrene wells (BD Discovery Labware, Bedford, MA) at a cell density of 105 per 
ml. Erythroid differentiation was carried out according to modified, published protocols55. 
The erythropoietic medium consisted of IMDM supplemented with Epo at 10 units/ml, 
10ng/ml SCF (Peprotech), 10µM dexamethasone (Sigma), 15% FBS, 1% detoxified BSA, 
200µg/ml holotransferrin (Sigma, St. Louis, MO), 10µg/ml recombinant human insulin 
(Sigma), 2mM L-glutamine, 10-4 ß-mercaptoethanol and penicillin/streptomycin. After 48 
hours the medium was replaced by maintenance medium consisting of IMDM with 20% 
FBS, 2mM L-glutamine and 10-4 b-mercaptoethanol. Recombinant S100a8 (mouse, Abnova 
P4345) protein was used where indicated in concentrations of 1µg/ml. 
Phenylhydrazine treatment
Phenylhydrazine (PH) was purchased from Sigma and injected subcutaneously at two 
consecutive days (day 0 and 1) at the dose of 35 or 25 mg/kg as previously described56. 
Peripheral blood was collected 4 days before the start of treatment and at day 3, 6 and 9. PH 
treatment experiments were carried out in 8-12 week old mice. 
Polysome profiling
For polysome profiling of primary erythroid progenitor cells, whole bone marrow was 
lineage-depleted (CD3, CD5, B220, Gr1, CD11b) using microbeads and the autoMACS 
as described above and stained for Ter119 and CD71. Erythroid progenitor cells 
(lineagenegativeCD71highTer119intermediate/high) were sort-purified in pure FCS, cultured for 1 hours 
in IMDM with 20% FCS and 2mM L-glutamine at 37°C at humidified conditions. Cells (ca. 
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3x106) were then harvested, spun down and incubated with 100µg/ml of cycloheximide 
for 10 minutes at 37°C, washed with ice-cold PBS containing 100µg/ml of cycloheximide 
and lysed in 300ul 5mM Tris (pH7.4), 2.5mM MgCl2, 1.5mM KCl. Gradients were poured 
using a Biocomp Gradient Station. Polysomes were separated on a 10-50% linear sucrose 
gradient containing 20mM HEPES-KOH (pH 7.4). 5mM MgCl
2
, 100mM KCL, 2mM DTT and 
100µh/ml cycloheximide and centrifuged at 36,000 rpm for 2 hours in a Beckman Coulter 
L8-M centrifuge with SW40Ti rotor. Gradients were fractionated using a Gilson FC-203B 
fractionator. Absorbance at 254nm was used to visualize the gradients using a BioRad EM-1 
Econo UV monitor.
iTRaQ labeling of peptides and basic reversed phase (brp) fractionation
20 million RII/RIII erythroblasts (4 biological replicates per 1 technical/process replicate) 
were sort-purified and resuspended in 500µl lysis buffer (8M Urea, 50 mM Tris HCl, 1 mM 
EDTA, 75 mM NaCl, aprotinin, leupeptin, PMSF, NaF, PIC2, and PIC3; all Sigma), vortexed on 
ice and spun at 20,000xg for 10 min at 4 oC. 300ug protein of each sample were reduced 
(2 uL 500 mM DTT, 30 minutes, RT), alkylated (4 uL 500 mM IAA, 45 minutes, dark) and 
digested using 2ug of sequencing grade trypsin overnight with shaking at room temperature 
(Suppl. Table 3). The samples were then quenched with 20 uL 10% FA and desalted on10 
mg SepPak columns. Desalted peptides were labeled with iTRAQ reagents according to 
the manufacturer’s instructions (AB Sciex, Foster City, CA). Peptides were dissolved in 
30 µl of 0.5 M TEAB pH 8.5 solution and labelling reagent was added in 70 ul of ethanol. 
After 1 h incubation the reaction was stopped with 50 mM Tris/HCl pH 7.5. Differentially 
labelled peptides were mixed and subsequently desalted on a 30 mg SepPak column.Basic 
Reversed Phase fractionation and subsequent concatenation of the differentially labelled 
and combined peptides was performed as described by Mertins et al.57 with the following 
amendments: the Zorbax 300 Å Extended-C18 column used was 2.1x150mm with a 3.5µm 
bead size (Agilent).  
Mass Spectrometry analysis
Reconstituted peptides were separated on an online nanoflow EASY-nLC 1000 UHPLC 
system (Thermo Fisher Scientific) and analyzed on a benchtop Orbitrap Q Exactive mass 
spectrometer (Thermo Fisher Scientific). The peptide samples were injected onto a capillary 
column (Picofrit with 10 μm tip opening / 75 μm diameter, New Objective, PF360-75-10-N-5) 
packed in-house with 20 cm C18 silica material (1.9 μm ReproSil-Pur C18-AQ medium, Dr. 
Maisch GmbH, r119.aq). The UHPLC setup was connected with a custom-fit microadapting 
tee (360 μm, IDEX Health & Science, UH-753), and capillary columns were heated to 50 °C 
in column heater sleeves (Phoenix-ST) to reduce backpressure during UHPLC separation. 
Injected peptides were separated at a flow rate of 200 nL/min with a linear 80 min gradient 
from 100% solvent A (3% acetonitrile, 0.1% formic acid) to 30% solvent B (90% acetonitrile, 
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0.1% formic acid), followed by a linear 6 min gradient from 30% solvent B to 90% solvent B. 
Each sample was run for 120 min, including sample loading and column equilibration times. 
The Q Exactive instrument was operated in the data-dependent mode acquiring HCD MS/
MS scans (R=17,500) after each MS1 scan (R=70,000) on the 12 top most abundant ions 
using an MS1 ion target of 3x 106 ions and an MS2 target of 5x104 ions. The maximum ion 
time utilized for the MS/MS scans was 120 ms; the HCD-normalized collision energy was 
set to 27; the dynamic exclusion time was set to 20s, and the peptide match and isotope 
exclusion functions were enabled. 
Quantification and identification of peptides and proteins
All mass spectra were processed using the Spectrum Mill software package v4.2 pre-
release (Agilent Technologies) which includes modules developed by us for iTRAQ -based 
quantification. Precursor ion quantification was done using extracted ion chromatograms 
(XIC’s) for each precursor ion. The peak area for the XIC of each precursor ion subjected 
to MS/MS was calculated automatically by the Spectrum Mill software in the intervening 
high-resolution MS1 scans of the LC-MS/MS runs using narrow windows around each 
individual member of the isotope cluster. Peak widths in both the time and m/z domains 
were dynamically determined based on MS scan resolution, precursor charge and m/z, 
subject to quality metrics on the relative distribution of the peaks in the isotope cluster 
vs. theoretical. Similar MS/MS spectra acquired on the same precursor m/z in the same 
dissociation mode within +/- 60 sec were merged.  MS/MS spectra with precursor charge 
>7 and poor quality MS/MS spectra, which failed the quality filter by not having a sequence 
tag length > 1 (i.e., minimum of 3 masses separated by the in-chain mass of an amino acid) 
were excluded from searching. For peptide identification MS/MS spectra were searched 
against mouse Uniprot database to which a set of common laboratory contaminant proteins 
was appended. Search parameters included: ESI-QEXACTIVE-HCD scoring parameters, 
trypsin enzyme specificity with a maximum of two missed cleavages, 40% minimum 
matched peak intensity, +/- 20 ppm precursor mass tolerance, +/- 20 ppm product mass 
tolerance, and carbamidomethylation of cysteines and iTRAQ labeling of lysines and 
peptide n-termini as fixed modifications. Allowed variable modifications were oxidation of 
methionine, N-terminal acetylation, Pyroglutamic acid (N-termQ), deamidated (N), Pyro 
Carbamidomethyl Cys (N-termC), with a precursor MH+ shift range of -18 to 64 Da. Identities 
interpreted for individual spectra were automatically designated as valid by optimizing score 
and delta rank1-rank2 score thresholds separately for each precursor charge state in each 
LC-MS/MS while allowing a maximum target-decoy-based false-discovery rate (FDR) of 1.0% 
at the spectrum level. In calculating scores at the protein level and reporting the identified 
proteins, redundancy is addressed in the following manner: the protein score is the sum of 
the scores of distinct peptides. A distinct peptide is the single highest scoring instance of 
a peptide detected through an MS/MS spectrum. MS/MS spectra for a particular peptide 
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may have been recorded multiple times, (i.e. as different precursor charge states, isolated 
from adjacent brp fractions, modified by oxidation of Met) but are still counted as a single 
distinct peptide. When a peptide sequence >8 residues long is contained in multiple protein 
entries in the sequence database, the proteins are grouped together and the highest scoring 
one and its accession number are reported. In some cases when the protein sequences 
are grouped in this manner there are distinct peptides which uniquely represent a lower 
scoring member of the group (isoforms or family members). Each of these instances spawns 
a subgroup and multiple subgroups are reported and counted towards the total number 
of proteins. iTRAQ ratios were obtained from the protein-comparisons export table in 
Spectrum Mill. To obtain iTRAQ protein ratios the median was calculated over all distinct 
peptides assigned to a protein subgroup in each replicate58. To assign differential expressed 
proteins we used the Limma package in the R environment to calculate moderated t-test p, 
as described previously. We also added Blandt-Altman testing to filter out proteins for 
which the CI for reproducibility was below 95%. Normalized iTRAQ ratios for the 2 biological 
replicates were filtered to retain only those deemed reproducible. Reproducible replicates 
were then subjected to a moderated t-test to assess statistical significance. This statistic is 
similar to the ordinary t-statistic, with the exception that the standard errors are calculated 
using an empirical Bayes method utilizing information across all proteins, thereby making 
inference about each individual protein more robust. The nominal p-values arising from the 
moderated t-statistic are corrected for multiple testing by controlling the false discovery 
rate (FDR), as proposed by Benjamini and Hochberg. Proteins with an FDR adjusted p-value 
of less than 0.01 were deemed to be reproducibly regulated. Statistical significance was 
assessed using only reproducible data points.
Cytokine array
To detect inflammatory cytokines in the bone marrow serum, we applied the mouse 
Inflammation Array G1 (CODE: AAM-INF-G1, 8 sample size) according to manusfacturer’s 
instructions. For detection of TNFα in the bone marrow serum, we used the TNF-alpha 
quantikine ELISA assay (R&D systems). The long bones of mice were kept on ice and flushed 
with a total of 200µl pure PBS. Cell-serum suspensions were spun down twice at 4°C at 
2,200rpm and the supernatant was harvested and then spun at 13,000rpm for 10min. The 
protein content was determined using the Pierce protein content BCA assay kit and 100µg 
protein in 100µl were used per sample.  
Western blots
Western blots were performed according to standard protocols. In brief, cell lysis was 
performed in RIPA buffer with protease/phosphatase inhibitors.  After protein quantification, 
lysates were resuspended in Laemmli Sample Buffer, and loaded to gradient gels (Criterion 
Tris-HCl Gel, 8-16%).  Proteins were transferred onto Immobilon polyvinyl difluoride (PVDF) 
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membranes. As primary antibodies S100A8 (Abcam ab92331), Rps14 (Abcam ab199273), 
Actin (EPR8484) were used. Blots were incubated with HRP-conjugated secondary antibody 
and developed using SuperSignal West Pico Chemiluminescent Substrate (Pierce).
histopathology, immunohistochemistry and immunofluorescence
For histological and immunohistochemical analyses, organs and bones were fixed in 3.7% 
formaldehyde overnight, dehydrated and prepared for paraffin embedding. Hematoxylin-
Eosin (H&E) staining was done according to routine protocols. For immunohistochemical 
stainings, the Avidin-Biotin Complex (ABC)/HRP (Dako Cytomation, K5001) was applied for 
color development using an Autostainer platform (Dako Cytomation, Glostrup, Denmark). 
Peripheral blood smears were stained with May-Grünwald-Giemsa (Sigma-Aldrich). For 
immunofluorescence studies, sternum sections were fixed in 4% paraformaldehyde on ice 
for 1 hour, then incubated in 30% sucrose in PBS at 4°C overnight. Cytospins were air-dried 
first and then fixed in 4% paraformaldehyde for 10 minutes at room temperature. OCT-
embedded (Sakura Finetek) tissues were cryosectioned into 7 μm sections and mounted 
on Superfrost slides (Fisher Scientific). For immunofluorescence stainings, sections were 
washed in 1X PBS, blocked in 10% normal goat serum (Vector Labs) and incubated with 
primary antibodies specific for S100A8 (Abcam ab92331) or p53 (Cell Signaling, 1C12) 
or CD68 (DAKO, clone PGM1). Secondary antibodies were FITC-, Cy3, or Cy5- conjugated 
(Jackson ImmunoResearch). Nuclei were then stained with DAPI (4 ́,6 ́- ́diamidino-2-
phenylindole) and mounted in Prolong Gold (Life Technologies). Images were obtained on a 
Nikon Eclipse E400 microscope (Nikon, Tokyo, Japan) equipped with a SPOT RT color digital 
camera model 2.1.1 (Diagnostic Instruments) or obtained on a confocal microscope (Nikon 
C1 eclipse, Nikon, Melville, NY).
Confocal Q-FISh
Deparaffinization and antigen retrieval paraffin-embedded bone marrow specimens was 
carried out using standard protocols. Telomere Q-FISH staining was performed as described 
previously59,60. Briefly, Telomeres were stained with Cy3-(C3TA2) PNA (Panagene, South 
Corea) followed by six further washing steps and DNA staining was done using DAPI solution 
(Sigma, US). All images of BM sections were captured within 48h after sample processing 
and stored at 4°C. Telomere length analysis was performed using the LSM710 (Zeiss, Jena, 
Germany) confocal microscope. Images were captured using 63x optical magnification with 
additional 1.2x digital zoom and multi-tracking mode on 0.5 µm steps was used to acquire 
images of DAPI and Cy3 staining. Maximum projection of 5 single consecutive steps was done 
and acquired images were used for further digital image analysis. 5 representative images 
of randomly chosen areas were captured of each bone marrow. Telomere length detection 
was carried out using Definiens software (Definiens, Germany). Nuclei and telomeres were 
detected based on the respective DAPI and Cy3 intensity. Mean nuclear background of the 
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Cy3 staining nuclei was calculated and subtracted of each detected telomere within the 
respective nucleus. Median value of all detected telomeres was used for analysis. 
Primary human samples and confocal microscopy
Patient samples originated from different study centers in Germany and this study was 
approved by according institutional review boards (University of Technology Dresden, 
Heinrich-Heine-University Düsseldorf, University Hospital RWTH Aachen, all Germany). 
Samples were deidentified at the time of inclusion. All patients provided informed consent 
and the data collection was performed in accordance with the Declaration of Helsinki. 
Criteria for inclusion of del(5q) MDS patients were: cytogenetic isolated del(5q), blast 
counts <5% in the bone marrow and International Prognostic Scoring System (IPSS) of 
low risk or intermediate-1. Patient data are summarized in supplementary table 1. Bone 
marrow biopsies were fixed for 24 hours using the Hannover Solution (12% buffered 
formaldehyde plus 64% methanol), decalcified (EDTA), dehydrated and embedded in 
paraffin. For immunofluorescence, samples were deparaffinized, hydrated using decreasing 
ethanol series and subject to heat-induced antigen retrieval using citrate buffer pH 6.0 
before proceeding to the immunofluorescence co-stainings. Sections were first blocked with 
1x Roti®-block (Carl Roth, Karlsruhe, Germany) for 1h at RT, washed with PBS-Tween and 
then incubated at 4°C overnight with a primary rabbit monoclonal anti-S100A8 antibody 
(Abcam, ab92331, 1:250). After washing steps, section were incubated for 30 minutes at 
RT with a goat anti-rabbit secondary antibody Alexa Fluor®488 conjugate (Life Technologies, 
Darmstadt, A-11034). Sections were then incubated at 4°C overnight with a primary mouse 
monoclonal anti-Glycophorin A antibody (Dako, M0819, 1:50) or anti-MPO (DAKO, A0398, 
1:300) followed by incubation for 30 minutes at RT with a donkey anti-mouse secondary 
antibody Alexa Fluor®633 or Alexa Fluor®555  conjugate (Life Technologies, Darmstadt). 
Nuclei were stained with DAPI and mounted with Vectashield® mounting media (Vector Labs, 
CA, USA). All antibodies were diluted in 0.1x Roti®-block. Fluorescence was acquired with a 
confocal laser-scanning microscope (LSM 710, Zeiss, Germany) running Zen 2012 software 
(Zeiss). A 405 nm diode laser (DAPI) and a 488 nm/ 633 nm argon laser (Alexa Fluor®488/ 
Alexa Fluor®633) were used for fluorescence excitation. Maximal intensity projections of 3 
z-stacks of 1µm each were acquired. Quantification of S100A8 in nucleated cells was done 
using Image J open source software.
Statistical analysis
Data are presented as mean±SEM. Comparison of two groups was performed using unpaired 
t-test. For multiple group comparison, analysis of variance with posthoc Tukey correction 
was applied. Statistical analyses were performed using GraphPad Prism 5.0c (GraphPad 
Software Inc., San Diego, CA). A p value of less than 0.05 was considered significant. 
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SuMMaRy 
The Casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the 
common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine 
model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency 
induces hematopoietic stem cell expansion and a competitive repopulation advantage 
whereas homozygous deletion induces hematopoietic stem cell failure. Based on this 
finding, we found that heterozygous inactivation of Csnk1a1 sensitizes cells to a CSNK1 
inhibitor relative to cells with two intact alleles. In addition, we identified recurrent somatic 
mutations in CSNK1A1 on the non-deleted allele of patients with del(5q) MDS. These 
studies demonstrate that CSNK1A1 plays a central role in the biology of del(5q) MDS and is 
a promising therapeutic target. 
SIGNIFICaNCe 
Our studies provide functional and genetic evidence indicating that CSNK1A1 plays a central 
role in the pathogenesis of del(5q) MDS. We found that heterozygous inactivation of Csnk1a1 
causes hematopoietic stem cell expansion and β-catenin activation. In addition, we found 
that Csnk1a1 haploinsufficiency sensitizes cells to casein kinase inhibition, demonstrating 
an approach for the targeting of heterozygous deletions in cancer.  While no recurrently 
mutated genes have been previously identified in genes within the common deleted regions 
of chromosome 5q, we found recurrent mutations in CSNK1A1 in a subset of del(5q) MDS 
patients. In aggregate, these findings indicate that CSNK1A1 is a promising therapeutic 
treatment for the treatment of del(5q) MDS. 
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INTRoDuCTIoN
Deletions of chromosome 5q are the most common cytogenetic abnormalities in MDS, 
and patients with isolated del(5q) have a distinct clinical phenotype (Ebert, 2011; Haase et 
al., 2007; Hasserjian, 2008).  To date, no genes within the common deleted regions (CDR) 
have been found to undergo homozygous inactivation, copy-neutral loss of heterozygosity, 
or recurrent mutation (Gondek et al., 2008; Graubert et al., 2009; Heinrichs et al., 2009; 
Jerez et al., 2012; Mallo et al., 2013). Functional studies have revealed individual genes 
that contribute cooperatively to the clinical phenotype through genetic haploinsufficiency 
(Boultwood et al., 2010; Chen et al., 2011; Ebert, 2011; Kumar et al., 2011; Lane et al., 2010; 
Starczynowski et al., 2010). Heterozygous loss of the RPS14 gene, for example, has been 
linked to impaired erythropoiesis via p53 activation (Dutt et al., 2011; Ebert et al., 2008). 
While several 5q genes have been reported to alter hematopoietic stem cell function, the 
mechanism of clonal dominance of del(5q) cells remains a critical unsolved question (Joslin 
et al., 2007; Lane et al., 2010; Min et al., 2008; Wang et al., 2010a).
CSNK1A1 encodes casein kinase 1α (CK1α), a serine/threonine kinase, and is located 
in the distal common deleted region (5q32) in del(5q) MDS. In a careful study of gene 
expression in CD34+ cells from a large cohort of del(5q) and other MDS cases, CSNK1A1 was 
one of the few genes in the del(5q) common deleted region that has approximately 50% 
normal expression (Boultwood et al., 2007). Recent studies demonstrated that CSNK1A1 
is a tumor suppressor gene in colon cancer and melanoma controlling proliferation by its 
function as a central regulator of β-catenin activity (Elyada et al., 2011; Sinnberg et al., 
2010). In hematopoiesis, stem and progenitor cells respond in a graded fashion to canonical 
Wnt/β-catenin signaling (Luis et al., 2011). Constitutive activation of β-catenin has been 
reported to increase HSC numbers followed by apoptosis, HSC depletion, and bone marrow 
failure (Kirstetter et al., 2006; Scheller et al., 2006). In contrast, less profound activation is 
associated with HSC expansion with enhanced repopulation potential (Trowbridge et al., 
2006). APC, like CK1α, is a member of the β-catenin destruction complex, and is inactivated 
in approximately 95% of cases with del(5q) MDS. Mice with heterozygous deletion of Apc 
(Wang et al., 2010a) or heterozygous for the ApcMin allele (Lane et al., 2010) have increased 
repopulation potential in primary bone marrow transplants, but decreased repopulation 
potential of secondary transplants due to loss of HSC quiescence. 
We sought to explore whether haploinsufficiency or mutation of Csnk1a1 contributes to 
the biology of del(5q) MDS. In addition, given evidence that Csnk1a1 is selectively essential 
for murine MLL-AF9 leukemia cells relative to normal hematopoietic cells (Jaras et al., 2014), 
we investigated whether CK1α is a therapeutic target in del(5q) MDS. 
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ReSuLTS
Csnk1a1 is required for adult murine hematopoiesis  
To explore the role of Csnk1a1 on hematopoietic stem cell (HSC) function, we generated 
a mouse model in which Csnk1a1 exon 3, essential for CK1α kinase function (Bidere et al., 
2009), is flanked by loxP sites. Following crosses to Mx1Cre transgenic mice, we induced 
Csnk1a1 excision in hematopoietic cells by poly(I:C), and confirmed decreased mRNA and 
protein expression (Figure 1A and S1A). 
We first examined whether Csnk1a1 plays a critical role in hematopoiesis. Homozygous 
deletion of Csnk1a1 in the hematopoietic system (Csnk1a1-/-Mx1Cre+) resulted in rapid 
lethality 5-17 days after gene excision, accompanied by a significant decrease in all peripheral 
blood counts and histologic evidence of fulminant bone marrow failure with evidence of 
ischemia in multiple organs (Figures 1B, C, D, E and S1B). 
We next examined whether the observed hematologic abnormalities were associated 
with changes in hematopoietic stem and progenitor cells. Ten days after Csnk1a1 excision, 
Csnk1a1-/-Mx1Cre+ mice had a highly significant reduction of HSC (LSK, linlowSca1+ckit+) 
including long-term (LT, linlowSca1+ckit+CD150+CD48-), short-term (ST, linlowSca1+ckit+CD150-
CD48-) HSC and multipotent progenitor cells (MPP, linlowSca1+ckit+CD150-CD48+) indicating 
that Csnk1a1 is essential for HSC survival (Figure 1F and S1C). 
CK1α is a major regulator of p53 activity, so we investigated whether Csnk1a1 ablation 
activates p53 in the bone marrow (Elyada et al., 2011; Wu et al., 2012). Homozygous, but 
not heterozygous Csnk1a1 deletion caused accumulation of p53 as well as p21, a p53 target, 
demonstrating that p53 is both present and active (Figure 1G). Consistent with this finding, 
we found that only complete ablation of Csnk1a1 led to significant induction of early and 
late apoptosis (Figure 1H and S1D). Csnk1a1-ablated HSC exited quiescence and entered the 
cell cycle, with a marked decrease in the number of Csnk1a1-/-Mx1Cre+ HSC (LSK) in G0 and a 
significant increase in S/G2/M compared to Mx1Cre+ controls (Figure 1I and S1E-F). 
Chapter 3
73
Figure 1: Conditional homozygous inactivation of Csnk1a1 results in hematopoietic stem and progenitor cell 
ablation. (A) Deletion of Csnk1a1 in whole bone marrow cells was determined 7 days after poly(I:C) induction 
by quantification of Csnk1a1 transcript levels by qt-RT-PCR. Data is presented as remaining Csnk1a1 transcript 
expression in percent relative to Mx1Cre+-control mice (mean±SD, n=3). (B) Kaplan-Meier survival curve of 
Csnk1a1-/+Mx1Cre+ (n=10), Csnk1a1-/-Mx1Cre+ (n=10) and Mx1Cre+ (n=10) control mice. Time point 0 is the day of 
the first of 3 poly(I:C) inductions. (C) Absolute numbers of white blood cells (WBC) and hemoglobin (Hb) levels in 
peripheral blood from Csnk1a1-/+Mx1Cre+, Csnk1a1-/-Mx1Cre+ and Mx1Cre+ controls 10 days after poly(I:C) induction 
(mean±SD, n=3, *p<0.05, **p<0.001). (D) Numbers of whole bone marrow cells collected from tibias, femurs and 
pelvis of Csnk1a1-/+MxCre+, Csnk1a1-/-MxCre+ 10 days after poly(I:C) induction (mean ±SD; n=3, *p<0.001). (E) 
Histological analysis of HE-stained spine from Csnk1a1-/+Mx1Cre+, Csnk1a1-/-Mx1Cre+ and Mx1Cre+ controls 10 days 
after poly(I:C). Scale bar: 200 µm. (F) Analysis of the HSC compartment, defined as LinlowSca1+ckit+ (LSK), long-term 
(LT; linlowSca1+ckit+CD48-CD150+), short-term (ST; linlowSca1+ckit+CD48-CD150-) HSC and multipotent progenitor cells 
(MPP, linlowSca1+ckit+CD48+CD150-) in the bone marrow from Csnk1a1-/+Mx1Cre+, Csnk1a1-/-Mx1Cre+ and Mx1Cre+ 
controls 10 days after poly(I:C), (mean±SD, n=5, *p<0.05, **p<0.001). (G) Western blot of whole bone marrow 
lysate 8 days after induction of poly(I:C). (H) Apoptosis was assessed in the LSK fraction from BM by Annexin V and 
7-AAD staining (early apoptosis: Annexin V+/7-AAD-; late apoptosis: Annexin V+/7-AAD+, (mean±SD, n=3, *p<0.05, 
**p<0.001). (I) Cell cycle was analyzed by combined proliferation (Ki67) and cell cycle (Hoechst 33342) staining in 
permeabilized LSK from bone marrow (G0: Ki67-/Hoechst-; S/G2/M: Ki67+/Hoechst+), (mean±SD, n=5, *p<0.05). 
(J) Immunofluorescence staining of paraffin-embedded bone marrow with an antibody against β-catenin (DAPI 
counterstaining). Asterisks highlight erythrocyte filled sinusoids. Scale bar: 20 µm. See also Figure S1.
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Figure S1: Characterizati on of primary Mx1Cre+ mice. (A) Validati on of Csnk1a1 excision aft er poly(I:C) by PCR (left ) 
and by Western Blot (right). (B) Autopsies including histopathological examinati ons in Csnk1a1-/-Mx1Cre+ mice 
revealed pale parenchymal organs and rarefi cati on of the red pulp in the spleen with extramedullar erythropoiesis 
(arrows), prominently in subcapsular localizati on. Liver and the myocardium showed signs of ischemia. In the liver 
cytoplasmati c vacuolizati on and pyknoti c nuclei were observed. Defi ned areas of the myocardium showed wavy 
fi bers with loss of transversal striati ons, parti ally with loss of the cell nucleus (arrows). HE-staining. Scale bar each 
as indicated. (C) Hematopoieti c stem and progenitor cells were analyzed by staining murine whole bone marrow 
cells with a lineage cocktail (CD3, B220, Gr1, CD11b, Ter119) and viability staining (DAPI) and either (a) classical 
stem and myeloid progenitor cell markers to dissect the LSK compartment in MPP (LSK CD48+), LT-HSC and ST-HSC 
(CD48 and CD150/Slamf1) and the LK compartment in GMP, CMP, MEP [FcgRII/III (CD16/32) and CD34] or (b) 6 
myelo-erythroid progenitor cell fracti ons of the LK compartment [CD41 (Itga2b), Endoglin (CD105), CD150 (Slamf1), 
FcgRII/III (CD16/32), Ter119]. Representati ve contour blots of Mx1Cre+ control, Csnk1a1-/+ Mx1Cre+, Csnk1a1-/- 
Mx1Cre+ stem and progenitor cells, only live cells are displayed. (D) Representati ve fl ow blots of Annexin V and 
Hoechst stained LSK cells. (E) Ki67 immunohistochemistry on paraffi  n-embedded bone marrow secti ons. Scale bar 
as indicated. (F) Representati ve contour fl ow blots of combined Ki67 (proliferati on) and Hoechst 3342 (cell cycle) 
staining gati ng on LSK cells. (G) Mesenchymal stromal cells (MSC) were negati ve for CD31 and CD45 but positi ve for 
CD29, Sca1, CD44 and CD105. The Csnk1a1 excision was confi rmed by PCR (n=4, mean±SD, *p<0.05). (H) β-catenin 
and p53 immunofl uorescence in MSC isolated from Mx1Cre+ control, Csnk1a1-/+ Mx1Cre+, Csnk1a1-/- Mx1Cre+ bone 
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marrows (DAPI counterstain: blue, β-catenin: green, p53: red. Scale bar as indicated). (I) Limiting-dilution analysis 
of long-term culture-initiating cells (LT-CIC) was applied as a quantitative method of estimating hematopoietic stem 
cell-supporting activity of MSC isolated from Mx1Cre+ controls and Csnk1a1-/+Mx1Cre+, Csnk1a1-/-Mx1Cre+, 
Csnk1a1-/+β-catenin-/+Mx1Cre+ and Csnk1a1-/+p53-/+Mx1Cre+MSC (n=10, mean±SD, *p<0.05). (J, K) Csnk1a1 
haploinsufficient mice were analyzed eight weeks after poly(I:C) i.p. injections. Csnk1a1 haploinsufficient mice had 
a rather hypocellular bone marrow, but normal blood counts (n=5, mean±SD, *p<0.05). (L) Histopathological 
evaluation revealed hypolobulated micro-megakaryocytes (arrows) but normal trilineage maturation of 
hematopoiesis. (M) Analysis of the stem cell compartment after eight weeks (n=4, mean±SD, *p<0.05). (N) Blood 
counts of aged Csnk1a1 haploinsufficient mice were analyzed 15 months after induction of poly(I:C), (n=4, 
mean±SD, *p<0.05*; **p<0.001). The peripheral blood revealed a pan-cytopenia consistent with (O) a hypocellular 
partially empty bone marrow in HE-staining. Scale bar as indicated. (P) Detailed histopathological analysis 
demonstrated a significant reduction of the myeloid and erythroid lineage, but quite intact lymphoid maturation. 
The stroma, in particular surrounding sinusoids, was prominent and significant dysplasia of small megakaryocytes 
with signs of emperipolesis and apoptosis was noted. No malignant transformation; the blast count in BM smears 
was <5%. HE staining, Scale bar as indicated. (Q) Representative lin-Sca1-ckit+ flow plots and (R) composite data of 
hematopoietic stem cell analysis by flow cytometry (lin-Sca1+ckit+, LSK cells), including long-term (lin-Sca1+ckit+CD48-
CD150+, LT-HSC) and short-term (lin-Sca1+ckit+CD48-CD150+, ST-HSC) hematopoietic stem cells (n=4, mean±SD, 
*p<0.05; **p<0.001). (S) Composite data of flow cytometry analysis of lin-Sca1+ckit- cells reflecting the stromal 
compartment (n=4, mean±SD, *p<0.05). (T, U) Cell cycle analysis of the LSK fraction by flow cytometry (n=4, 
mean±SD, *p<0.05). (V) Intracellular expression of β-catenin as well as p53 in HSC (LSK), (n=4, mean±SD, *p<0.05).
Csnk1a1 loss induces increased β-catenin levels in both hematopoietic and stromal 
cells
CK1α is a critical regulator of β-catenin (Cheong and Virshup, 2011). In our murine model, 
heterozygous and homozygous knockout of Csnk1a1 induced strong nuclear accumulation 
of β-catenin (Figure 1J). In the heterozygous knockout bone marrow, positive staining was 
predominantly in hematopoietic cells proximal to endothelial and endosteal cells, while in 
the homozygous knockout bone marrow, β-catenin nuclear accumulation was observed in 
nearly all cell types, highlighting a graded β-catenin activation by Csnk1a1 gene dosage. 
In addition, we observed a striking accumulation of β-catenin in the bone marrow 
stroma cells of heterozygous and homozygous Csnk1a1 knockout mice, consistent with 
the expression of Mx1Cre in bone marrow stroma (Walkley et al., 2007). We validated this 
finding in mesenchymal stroma cells (MSC) isolated from endosteal bone (Zhu et al., 2010) 
and confirmed Csnk1a1 excision in the stroma (Figure S1G). We found strong β-catenin 
expression in MSC from heterozygous Csnk1a1 knockout mice, and even more pronounced 
expression in homozygous knockout mice (Figure S1H). In in vitro long-term culture initiating 
cell assays, both Csnk1a1-/+Mx1Cre+ and Csnk1a1-/-Mx1Cre+ MSC had significantly impaired 
hematopoiesis-supporting capacity.  Inactivation of β-catenin rescued the effect of Csnk1a1 
loss in stromal cells  (Figure S1I). The hematopoietic effects of Csnk1a1 haploinsufficiency 
that we found in vitro were also observed in vivo. Eight weeks after pIpC treatment, we 
observed a significant reduction in bone marrow cellularity and in the percentage of LT- and 
ST-HSC in Csnk1a1-/+Mx1Cre+ mice compared to Mx1Cre+ controls (Figure S1J-M). Consistent 
with this finding, the survival of Csnk1a1-/+Mx1Cre+ primary mice was significantly impaired 
(Figure 1B). After 15 months Csnk1a1-/+Mx1Cre+ mice developed pancytopenia, a significant 
decrease in the LT-HSC and ST-HSC, and a near complete loss of myeloid progenitor cells 
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(Figure S1N-V). These results are comparable to the recently described consequences of 
constitutively active β-catenin in osteoblasts (Kode et al., 2014), though we did not observe 
any evidence of malignant transformation in Csnk1a1-/+Mx1Cre+ mice at 15 months. 
Cell intrinsic Csnk1a1 ablation leads to bone marrow failure 
Having observed that Csnk1a1 excision in primary Mx1Cre+ mice has striking effects on 
hematopoiesis, and given the cell-extrinsic effects of stromal β-catenin activation on 
hematopoietic cells (Kode et al., 2014; Lane et al., 2010; Stoddart et al., 2013; Wang et 
al., 2010a), we examined the cell-intrinsic effects of Csnk1a1 inactivation in hematopoietic 
cells using bone marrow transplantation into wild-type recipient mice. We transplanted 
whole bone marrow cells from Csnk1a1-/-Mx1Cre+ or Mx1Cre+ mice (CD45.2+) into lethally 
irradiated WT recipient mice (CD45.1+). Prior to induction of Csnk1a1 excision, 4 weeks 
after transplantation, more than 90% of peripheral blood cells in recipient mice were 
reconstituted with donor-derived CD45.2+ cells. All recipient chimeric mice reconstituted 
with Csnk1a1-/-Mx1Cre+ cells became moribund with bone marrow failure 8–14 days after 
Csnk1a1 excision (Figure 2A and S2A-C). Flow cytometric analysis revealed a complete loss 
of hematopoietic stem and progenitor cells in recipient mice. These studies confirm that a 
cell intrinsic function of Csnk1a1 is essential for hematopoiesis. 
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS
78
Figure 2: homozygous Csnk1a1 inactivation causes cell intrinsic hematopoietic stem cell ablation, while Csnk1a1 
heterozygous inactivation causes cell-intrinsic lineage expansion. (A) Donor chimerism (CD45.2) of Csnk1a1-
/+Mx1Cre+, Csnk1a1-/-Mx1Cre+ and Mx1Cre+ derived hematopoietic cells was monitored over time (mean±SD, n=7, 
**p<0.001). (B) Histomorphological analysis of transplanted Csnk1a1-/+Mx1Cre+ and Mx1Cre+ cells 8 weeks after 
poly(I:C) induction. Scale bar: 200 µm. (C) Hemoglobin (Hb) levels were followed over time (mean±SD, n=7, non-
significant). (D) White blood cell and lymphocyte count were monitored over time (mean±SD, n=7, *p<0.05, 
**p<0.001). (E) Distribution of donor derived (CD45.2+) myeloid (Gr1+/CD11b+) and T-cells (CD3+) was analyzed by 
flow cytometry in bone marrow, spleen and peripheral blood (mean±SD, n=5, *p<0.05). (F) Histomorphological 
analysis of megakaryocyte dysplasia in transplanted Mx1Cre+ and Csnk1a1-/+Mx1Cre+ 8 weeks after poly(I:C) induc-
tion. Scale bar: 100 µm.  (G) Detailed megakaryocyte morphology on cytospin preparations (May-Gruenwald-Giem-
sa staining, Oil immersion, Scale bar: 20 µm). (H) Representative ploidy analysis and quantification on CD45.2+, 
CD41+ megakaryocytes using Hoechst33342 staining on fixed and permeabilized cells. (mean±SD, n=4, *p<0.05). (I) 
Platelet counts were taken over time (mean±SD, n=7, *p<0.05). See also Figure S2.
In striking contrast to mice transplanted with Csnk1a1-/-Mx1Cre+ cells, mice transplanted 
with Csnk1a1-/+Mx1Cre+ had no change in survival compared to Mx1Cre+ control mice 
(Figure S2A). Transplanted Csnk1a1 haploinsufficient hematopoietic cells fully reconstituted 
the bone marrow, resulting in a normal to hypercellular marrow, a normal hemoglobin, 
and significantly elevated white blood cell counts with lymphocytosis (Figures 2B-D). The 
lymphocytosis was caused by an increase in T-cells, consistent with reports demonstrating 
that moderate Wnt-activation promotes T-cell differentiation (Luis et al., 2012; Luis et al., 
2011). The percentage of Gr1+CD11b+ myeloid cells (Figure 2E) and CD19+ B-cells (Figure 
S2D) was not affected.
Pathological evaluation of the Csnk1a1 haploinsufficient bone marrow revealed 
increased and mildly dysplastic hypolobulated (micro)megakaryocytes in atypical locations, 
reminiscent of the megakaryocyte morphology in del(5q) MDS (Figure 2F and S2E-F). 
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Figure S2: Related to fi gure 2. Rapid bone marrow failure aft er Csnk1a1 ablati on is an intrinsic eff ect. 
(A) Kaplan Meier survival curves over a ti me frame of 351 days [(day 0=fi rst dose of poly(I:C)]. (B) Representati ve 
histomorphological analysis of bone marrow and spleen showing an empty bone marrow and extramedullar 
hematopoiesis, respecti vely, in Csnk1a1-/- Mx1Cre+ mice 10 days aft er poly(I:C) treatment. Scale bar: 200 µm. 
(C) Representati ve fl ow plots of the CD45.1 and CD45.2 chimerism as well as the HSC compartment. (D) CD19+ 
B-cells in bone marrow (BM), spleen or peripheral blood (PB) (composite data, mean±SD, n=5, no signifi cant 
diff erences). (E) CD71/Ter119 analysis of the bone marrow showing a terminal diff erenti ati on defect from the 
polychromatophilic erythroblast stage (R3) to the orthochromatophilic erythroblast/reti culocyte stage (R4), (n=5, 
mean±SD, *p<0.05). (F) The bone appeared normo- to hypercellular in mice transplanted with Csnk1a1-/-Mx1Cre+ 
in the long-term transplant setti  ng. Micro-megakaryocytes were increased in their number (as highlighted by blue 
asterisks), hypolobulated and presented with spherical nuclei. Scale bar as indicated.
the presence of 10 ng/ml murine thrombopoieti n. Nuclear ploidy analysis of the CD41+ 
megakaryocytes revealed a shift  towards hypoploidy, consistent with hypolobati on apparent 
in cytospins of the cultures (Figure 2G, H). Over ti me, the mice developed a signifi cantly 
elevated platelet count (Figure 2I). 
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haploinsufficiency of Csnk1a1 leads to β-catenin activation and cell-intrinsic expansion 
of hematopoietic stem cells
CSNK1A1 has been reported to be a tumor suppressor gene in solid tumors due to activation 
of β-catenin (Elyada et al., 2011; Sinnberg et al., 2010). We first examined whether Csnk1a 
haploinsufficiency causes a cell-intrinsic effect on the number and function of HSC in a 
non-competitive transplantation assay. We found an increase in the percentage of the HSC-
enriched LSK compartment, in contrast to the decrease in LSK and LK cells observed in the 
setting of an abnormal microenvironment in primary Mx1Cre+ animals (Figure 1F and S1M, 
R). In particular, the proportion of LT-HSC was significantly elevated (Figure 3A). 
To analyze whether HSC expansion might be due to exit from quiescence and enhanced 
HSC proliferation, we performed cell cycle analysis on hematopoietic stem and progenitor 
cells. In comparison to CD45.2+ Mx1Cre+ control baseline hematopoiesis, CD45.2+ LSK cells 
and LT-HSC from Csnk1a1-/-Mx1Cre+ cells had a significantly lower percentage of cells in the 
quiescent G0 fraction (in LT-HSC not LSK) and a significantly higher percentage of cells in 
the cycling G1 fraction (Figure 3B) and in the S-phase as seen by BrdU incorporation (Figure 
S3A), consistent with exit from quiescence.
We next examined whether Csnk1a1 heterozygous hematopoietic stem cells have 
altered β-catenin or cyclin D1 activity, as these pathways could contribute to decreased 
quiescence. Csnk1a1-/+Mx1Cre+ hematopoietic cells, transplanted into WT mice, had 
increased nuclear β-catenin accumulation by immunohistochemistry (Figure S3B) and by 
intracellular flow cytometry (Figure 3C-E). We found increased β-catenin in the stem cell 
enriched LSK fraction. β-catenin accumulation in HSC was accompanied by significantly 
increased expression of cyclin D1, a major regulator of cell cycle progression, corroborating 
the G1-phase progression in the cell cycle of Csnk1a1 haploinsufficient cells. In the lineage-
positive fraction, the differences in β-catenin were not apparent. These experiments 
demonstrate that heterozygous Csnk1a1 inactivation is associated with increased levels of 
β-catenin in the hematopoietic stem cell. 
As heterozygous deletion of APC occurs in approximately 95% of MDS cases and APC 
and CK1ɑ are both negative regulators of β-catenin, we analyzed the combinatorial effect of 
Csnk1a1 and Apc on β-catenin levels and hematopoietic stem cell expansion (Figure S3F). 
Compound heterozygous (Csnk1a1-/+Apc-/+Mx1Cre+) hematopoietic cells were transplanted 
into lethally irradiated mice and analyzed over a period of 52 weeks. Compound 
heterozygous inactivation of Csnk1a1 and Apc resulted in significantly increased LT-HSCs, 
increased β-catenin levels, and increased activation of the cell cycle in hematopoietic stem 
cells in long-term transplants (Figure S3G-J). In aggregate, our data highlight a central role 
for β-catenin in the pathophysiology of del(5q) MDS.
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Figure 3: haploinsufficiency of Csnk1a1 leads to cell-intrinsic expansion of transplanted hematopoietic stem cells. 
(A) HSC chimerism (CD45.2) was analyzed in CD45.1 mice re-populated with Csnk1a1-/+Mx1Cre+ and Mx1Cre+ cells 8 
weeks after induction with poly(I:C) in the LSK, MPP, LT-HSC, and ST-HSC (mean±SD, n=5, *p<0.05). (B) Cell cycle was 
analyzed by combined proliferation (Ki67) and cell cycle (Hoechst 33342) staining in permeabilized LSK and LT-HSC 
from bone marrow (G0: Ki67-/Hoechst-; S/G2/M: Ki67+/Hoechst+), (mean±SD, n=5, *p<0.05). (C) Intracellular flow 
cytometry for β-catenin and cyclin D1 (FITC-labeled secondary antibody each) on the CD45.2+ viable LSK population 
(mean±SD, n=3, *p<0.05). (D) Corresponding representative flow blots to the quantitative analysis of intracellular 
β-catenin and cyclin D1, accumulation. (E) Mean fluorescence intensity (MFI) of intracellular β-catenin and cyclin 
D1 in LSK (mean±SD, n=3, *p<0.05). See also Figure S3.
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Figure S3: related to fi gure 3: expanded hSC and increased β-catenin levels in Csnk1a1-/+Mx1Cre+ and Csnk1a1-
/+Apc-/+Mx1Cre+ mice.
(A) To further analyze proliferati on changes in the expanded LT-HSC compartment in transplanted Csnk1a1 
haploinsuffi  cient cells, we performed bromodeoxyuridine (BrdU) incorporati on analysis. Mice received an initi al 
intraperitoneal injecti on of BrdU (1 mg/6 g bodyweight) 18 hours prior to sacrifi ce. BrdU incorporati on (S-phase) 
was analyzed in CD45.2+lin-Sca1+ckit+CD150+CD48- cells (LT-HSC). Quanti fi cati on and composite data of cycling BrdU+ 
LT-HSC in transplanted Csnk1a1 haploinsuffi  cient cells versus Mx1Cre+ cells (mean±SD, *p<0.05, n=4). (B) β-catenin 
immunohistochemistry on bone marrow chimeras of Mx1Cre+ and Csnk1a1-/+Mx1Cre+ transplants. Scale bar: 200 
µm. (C) Representati ve contour blots of β-catenin and cyclin D1 expression in CD45.2 LK (lin-Sca1-ckit+) cells. (D) 
Composite data depicti ng CD45.2+ LK cells expression of β-catenin and cyclin D1 in progenitor cells of Csnk1a1-
/+Mx1Cre+-derived LK cells compared to Mx1Cre+ LK cells (n=5, mean±SD, *p<0.05, **p<0.001). (E) Composite data 
of intracellular β-catenin and cyclin D1 fl ow cytometry on lineage+ cells (mean±SD, *p<0.05). (F) Lethally irradiated 
CD45.1+ recipient mice were transplanted with Csnk1a1-/+Mx1Cre+, Csnk1a1-/+Apc-/+Mx1Cre+ or Mx1Cre+ whole 
bone marrow cells. Four weeks aft er transplantati on, the gene excision was induced with poly(I:C). Morphological 
analysis of whole bone marrow cytospin preparati ons of mice transplanted with Csnk1a1-/+Mx1Cre+, Csnk1a1-
/+Apc-/+Mx1Cre+ or Mx1Cre+ show trilineage diff erenti ati on without evidence for leukemic transformati on and blast 
counts <5%. MGG staining, Scale bar 100 µm. (G) CD45.2+ chimerism of the hematopoieti c stem cell enriched 
bone marrow fracti on (mean±SD, n=5, ns). (H) HSC chimerism (CD45.2) in the whole bone marrow 336 days aft er 
inducti on with poly(I:C) including LT-HSC, ST-HSC and MPP (mean±SD, n=5, *p<0.05). (I) Representati ve fl ow blot 
and composite data of cell cycle analysis in HSC (lin-Sca1+ckit+) using Ki67 and Hoechst 3342 staining (mean±SD, 
n=5, *p<0.05). (J) Histogram analysis of intracellular β-catenin expression analysis in permeabilized LSK, quanti fi ed 
mean fl uorescence intensity (MFI) of β-catenin in LSK (mean±SD, n=5, *p<0.05) and β-catenin immunofl uorescence 
on bone marrow cytospins. (arrows, blue: DAPI counterstaining, green: β-catenin; scale bar: 80 µm).
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Csnk1a1 haploinsufficient hSCs have increased self-renewal ability in vivo
As Csnk1a1 haploinsufficiency leads to a significant increase in cycling LT-HSCs, we examined 
the functional capacity of Csnk1a1 haploinsufficient cells in a competitive repopulation 
assay. Four weeks after transplantation, mice were treated with poly(I:C) to induce Csnk1a1 
deletion. Csnk1a1 haploinsufficient cells out-competed WT cells, while Mx1Cre+ control 
cells were stable over time, and cells with homozygous Csnk1a1 inactivation were rapidly 
depleted (Figure 4A). 
To determine the long-term repopulating potential of Csnk1a1 haploinsufficient bone 
marrow, whole bone marrow cells from the primary recipients were injected into lethally 
irradiated secondary and tertiary recipients. Csnk1a1 haploinsufficient bone marrow 
cells had a significantly impaired response to the stress of transplantation, resulting in 
significantly lower numbers of CD45.2+ donors cells in the peripheral blood compared to 
Mx1Cre+ controls each 4 weeks after secondary and tertiary transplantation. However, 16 
weeks after each round of transplantation, Csnk1a1 haploinsufficient cells recovered and 
again out-competed the control cells (Figure 4A). 
Having observed a competitive advantage for Csnk1a1 haploinsufficient bone marrow 
evaluated in the peripheral blood, we next evaluated hematopoietic stem and progenitor 
cells in the setting of competitive repopulation (Figure 4B-E). At both 16 weeks following 
the primary transplant and 16 weeks following the secondary transplant, Csnk1a1 
haploinsufficient cells were significantly more abundant than their wild type counterparts in 
the percentage of LSK cells and downstream myeloid progenitor cells, Gr1+CD11b+ myeloid 
cells, and CD3+ T-cells in the bone marrow.
Csnk1a1 haploinsufficiency sensitizes cells to casein kinase 1 inhibition
Having demonstrated a selective advantage for cells with heterozygous Csnk1a1 inactivation, 
and a severe disadvantage for cells with homozygous Csnk1a1 inactivation, we postulated that 
Csnk1a1 haploinsufficiency might sensitize cells to CK1α  inhibition. Partial inhibition of CK1α 
would be expected to cause wild-type cells to have a phenotype similar to haploinsufficient 
cells, while CK1α  inhibition in cells that already have one allele inactivated would approach 
closer to complete ablation of CK1α  activity, thereby establishing a therapeutic window for 
CK1α  inhibition in del(5q) MDS cells. We tested this hypothesis using D4476, a selective 
small molecule inhibitor of CK1 (Rena et al., 2004). Since D4476 has a short half-life in vivo, 
we treated purified myeloid progenitors from Csnk1a1 haploinsufficient cells and Mx1Cre+ 
controls with D4476 in vitro.  D4476 significantly decreased viability and increased apoptosis 
in Csnk1a1 haploinsufficient cells relative to Mx1Cre+ controls at a range of concentrations, 
consistent with a therapeutic window for targeting Csnk1a1 haploinsufficient cells (Figure 
5A). 
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Figure 4: Csnk1a1 haploinsufficient hematopoietic stem cells show increased repopulating ability consistent with 
increased self-renewal. (A) Identical numbers of Csnk1a1-/+Mx1Cre+ or Csnk1a1-/-Mx1Cre+ or Mx1Cre+ controls were 
each mixed in equal ratios  (approximately 50:50; time point -4 weeks) and transplanted in lethally irradiated 
CD45.1 recipients. Percentage of CD45.2 donor cell chimerism in the whole peripheral blood from peripheral 
blood of lethally irradiated recipient animals is shown. Time (weeks) denotes the time relative to termination 
of the poly(I:C) injections (poly(I:C)=timepoint 0). After 16 weeks, bone marrow was harvested and transplanted 
for secondary transplants, and 16 weeks later for tertiary transplants in lethally irradiated mice (mean±SD, n=5, 
*p<0.05; **p<0.001). (B) Donor chimerism of total bone marrow cells performed at 16 (first competitive transplant), 
32 (secondary competitive transplant, 16 weeks after transplantation) or 48 (tertiary competitive transplant) 
weeks after poly(I:C) induction (mean±SD, n=5, *p<0.05). (C) Donor chimerism of the hematopoietic stem (LSK) 
and (D) progenitor cell compartment [linlowSca1-ckit+, LK; common-myeloid progenitors (CMP): LK CD34+CD16/32-; 
granulocyte-macrophage progenitors (GMP): LK CD34+CD16/32+; myeloerythroid progenitors (MEP):  LK CD34-
CD16/32-] performed at 16 (first competitive transplant) or 32 (secondary competitive transplant) or 48 (tertiary 
competitive transplant) weeks after poly(I:C) induction (mean±SD, n=5, *p<0.05). (E) Chimerism of hematopoietic 
lineages in the bone marrow each 16 weeks after the first, second and third competitive transplant. Composite 
data of donor (CD45.2+) granulocytes (Gr1+CD11b+), B-cells (CD19+) or T-cells (CD3+) are shown (mean±SD, n=5, 
*p<0.05). 
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Figure 5: Csnk1a1 haploinsufficiency provides a therapeutical window for the specific treatment of disease-
propagating hematopoietic stem cells. (A) Sorted hematopoietic progenitor cells (LK) were pre-stimulated for 24 
hours after the sort and treated for 72 hours with varying concentrations of D4476. Viability of cells was analyzed 
after 72 hours with the CellTitre glo assay, apoptosis by combined Annexin V and 7AAD staining discriminating early 
(Annexin V+7AAD-) and late apoptosis (AnnexinV+7AAD+) using flow cytometry. (B) 21 days after poly(I:C) treatment, 
Csnk1a1-/+Mx1Cre+ or CD45.1 bone marrow was harvested and LSK cells were sort-purified. Equal ratios of Csnk1a1-
/+Mx1Cre+ and CD45.1+ LSK were mixed and treated for 72 hours ex vivo with either D4476 or DMSO, followed by 
transplantation into lethally irradiated CD45.1 mice. The chimerism was followed over time in the peripheral blood 
(mean±SD, n=6, *p<0.05; **p<0.001). (C) The chimerism of Csnk1a1-/+Mx1Cre+ in the bone marrow was analyzed 
in the LSK and progenitor fractions after 12 weeks under DMSO or D4476 treatment conditions (mean±SD, n=6, 
**p<0.001). See also Figure S4. 
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To assess the relative effect of D4476 treatment on HSC and progenitor cell function 
in vivo, we performed a competitive repopulation experiment following ex vivo exposure to 
D4476. Purified LSK cells from Csnk1a1-/+Mx1Cre+ (CD45.2) and WT CD45.1 mice were mixed 
in a 1:1 ratio and treated ex vivo with either D4476 or DMSO control for 48 hours, followed 
by injection of the cells into lethally irradiated mice. Following DMSO treatment, Csnk1a1 
haploinsufficient cells out-competed the wild-type controls, as assessed by peripheral 
blood chimerism. In contrast, following treatment with D4476, Csnk1a1 haploinsufficient 
cells were selectively depleted. Similarly, D4476 caused a selective depletion of Csnk1a1 
haploinsufficient stem and progenitor cells in the bone marrow (Figure 5B-C) and reduced 
Csnk1a1 haploinsufficient hematopoietic stem and progenitor cells in colony-forming unit 
assays (Figure S4A). 
To examine if partial, systemic inhibition of CK1α would be tolerated in a therapeutic 
approach targeting haploinsufficiency, we analyzed the effects of global heterozygous 
Csnk1a1 inactivation. Csnk1a1-/+EIIaCre+ mice, in which heterozygous deletion of Csnk1a1 
is induced in all tissues, were born in normal Mendelian ratios without apparent 
malformations. Histopathological analysis at 6 and 10 months of age revealed structural 
integrity of organs, and blood counts were normal and stable over this period of time (Figure 
S4B-D). In aggregate, these data indicate that Csnk1a1 inhibition is an attractive therapeutic 
approach for the selective targeting of Csnk1a1 haploinsufficient cells, such as MDS cells 
with del(5q). 
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Figure S4: related to fi gure 5: Csnk1a1 germline haploinsuffi  ciency does not aff ect structural integrity of 
abdominal or thoracical organs
(A) Hematopoieti c stem cells (LSK) were sorted from Csnk1a1-/+Mx1Cre+ and Mx1Cre+ mice and subjected to 10 
µM D4476 or vehicle. Aft er 48 hours cells were harvested and methylcellulose assays were started with 3000 
LSK each. Aft er 8 days, cells were recovered from methylcellulose and re-plated on fresh methylcellulose. n=3 
biological donors and 3 technical replicates. (mean±SD, n=9, *p<0.05). (B) Genomic DNA was isolated and the 
excision of the targeted exon 3 was validated by PCR in Csnk1a1-/+EIIaCre+ and EIIaCre+ cells. (C) 6 and 10 months 
old Csnk1a1-/+EIIaCre+ mice do not diff er in their peripheral blood counts from EIIaCre+ mice (mean±SD, n=4, ns). 
(D) Histopathological comparison of lymph node, lung, myocardium, spleen, liver, kidney, pancreas, small intesti ne 
and large intesti ne in Csnk1a1-/+EIIaCre+ or EIIaCre+ mice does not show any structural abnormaliti es or diff erences 
between the two groups. Scale bar as indicated.
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Identification of recurrent somatic CSNK1A1 mutations in patients with del(5q) MDS 
In parallel with our functional studies, we performed whole-exome sequencing on MDS 
samples to identify genetic drivers of del(5q) MDS: genes that are selectively mutated in 
del(5q) MDS, or genes within the del(5q) CDRs that are recurrently somatically mutated 
in MDS cases without del(5q). We performed whole-exome sequencing on paired samples 
(MDS-derived bone marrow sample and matched normal CD3+ cells) of 21 cases: 19 del(5q) 
and 2 with normal karyotypes. We identified two cases with somatic mutations in CSNK1A1, 
both in untreated cases with del(5q) with wild-type TP53 (Table 1). 
 #1 #2 #3
age at diagnosis 85 82 65
Gender M F F
FaB RA RA RA
Karyotype 46,XY,del(5)(q13q31)  
[17]/46,XY[3]
46,XX,del(5)(q13q33) 
[14]/46,XX[6]
46,XX,del(5)(q13q33) 
[4]/46,XX[2]
IPSS-R 2, low risk 1, very low risk 1, very low risk
TP53 wild type wild type wild type
hemoglobin [g/dL] 10.6 11.8 9.5
absolute neutrophil 
count [109/l]
49.6 0.951 5.01
Platelets [cells/µl] 140,000 118,000 72,000
Table 1: Clinical data of patients with the identified somatic CSNK1A1 mutations
Both mutations caused the same amino acid change, E98K (Figure 6A). The mutations 
were confirmed to be present and somatic by Sanger sequencing (Figure 6A). 
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS
90
Figure 6: Identification and functional characterization of CSNK1A1 mutations in del(5q) MDS patients
(A) Summary of CSNK1A1 mutations identified in del(5q)MDS patients (upper panel). Sanger sequencing of 
the identified mutations on codon 98 (tumor/somatic) in comparison to germline controls (lower panel). (B) 
Kaplan-Meier survival analysis of chimeric mice transplanted with Csnk1a1-/-Mx1Cre+ hematopoietic stem and 
progenitor cells expressing Csnk1a1 cDNA, Csnk1a1 D136 cDNA or Csnk1a1 E98V cDNA. Timepoint 0 is the first 
day of poly(I:C) induction (n=5). (C) GFP expression in whole BM (left) and distribution of the different lineages 
(Gr1+CD11b+ neutrophils, CD3+ T-cells, CD19+ B-cells) in GFP+ BM cells (right). (mean±SD, n=3, *p<0.05). (D) Co-
immunofluorescent staining of β-catenin and p53 in cytospin preparations of red blood cell lysed whole bone 
marrow cells (red: β-catenin, turquoise: p53, green: GFP MIG vector, blue: DAPI). Scale bar 20 µm. (E) Quantification 
of β-catenin intensity using the mean fluorescence intensity (MFI), (mean±SD, n=3, *p<0.05). (F) Intracellular 
flow cytometry measurement of β-catenin and p53 in permeabilized whole bone marrow cells. (mean±SD, n=3, 
*p<0.05). (G) Cell cycle was analyzed by combined Ki67 and Hoechst33342 staining in permeabilized whole bone 
marrow cells. (mean±SD, n=3, *p<0.05). (H) GFP+ LSK from mice transplanted with either CSNK1A1 or CSNK1A1 
E98V-expressing Csnk1a1-/-Mx1Cre+ cells as well as Csnk1a1 haploinsufficient LSK and WT LSK were sort purified 
and exposed to vehicle, 2.5 or 10 µM D4476 for 72 hours and viability of cells was analyzed after 72 hours with the 
CellTitre glo assay (mean±SD, n=5, *p<0.05). (I) LSK (all CD45.2) isolated as in (H) were treated in competition to 
CD45.1 wild type cells in one culture well to analyze selective ablation of cells under the same culture condition. 
(mean±SD, n=5, *p<0.05). See also Figure S5 and Table S1.
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Patient 1: 46,XY,del(5)(q13q33)[16]/46,XY[4] 
 # FISH+: 71 % 
 # % 5q- Arrays: 70-80 % 
Patient 2: 46,XX,del(5)(q13q33)[14]/46,XX[6]  
# FISH+: 84.6 %  
# % 5q- Arrays: 90-100 % 
5q-deletion 
5q-deletion 
A 
Position 
Mutation 
(CDS) 
Mutation 
(Amino Acid) 
Mutation ID 
(COSM) Count reference  tissue 
98 c.292G>A p.E98K COSM1241049 1 Substitution - Missense  
Substitution - Missense  
Substitution - Missense  
Substitution - Missense  
Substitution - Missense  
Dulak esophagus adenocarcinoma  
98 c.293A>G p.E98G COSM1161523 1 lymphoid neoplasm  
140 c.418G>C p.D140H COSM1661311 1  Sato et al., 2013 kidney 
140 c.419A>C p.D140A COSM211577 1  Graubert et al., 2012 MDS 
136 c.406G>T p.D136Y COSM1064177 1  endometrium 
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Figure S5: related to fi gure 6: The identi fi ed CSNK1A1 mutati on in del(5q) MDS pati ents occurs on the remaining 
allele of chromosome 5q and is not a loss of functi on mutati on.                                                                                                                        a 
(A Single nucleoti de polymorphism arrays (SNP-A) were performed with Genome-Wide Human SNP Array 6.0. The 
percentage of the 5q-deleti on was 70-80 % in pati ent 1 and 90-100 % in pati ent 2. (B) Mutati ons of CSNK1A1 in the 
same codon as in del(5q) MDS in other malignancies/ti ssues according to the catalogue of somati c mutati ons in 
cancer [*COSMIC, htt p://cancer.sanger.ac.uk; (Dulak et al., 2013; Graubert et al., 2012; Sato et al., 2013)]. Somati c 
missense mutati ons in CSNK1A1 were identi fi ed in an adenocarcinoma of the esophagus (E98K), a Burkitt  lympho-
ma (E98 V) and a renal clear cell carcinoma (D140H). (C) GFP expression in the peripheral blood over a period of 80 
days [day 0= day of fi rst poly(I:C) injecti on; mean±SD, n=5]. (D) Analysis of the CSNK1A1(D136N) (GFP) distributi on 
in the bone marrow. (mean±SD, n=5). (E) Representati ve fl ow blot of the HSC compartment in mice transplanted 
with Csnk1a1-/-Mx1Cre+ hematopoieti c cells overexpressing CSNK1A1(D136N). (F) The bone marrow of mice trans-
planted with Csnk1a1-/-Mx1Cre+ ckit+ hematopoieti c stem and progenitor cells transduced with CSNK1A1 cDNA or 
CSNK1A1(E98V) cDNA was analyzed 12 weeks aft er inducti on of the Csnk1a1 excision by poly(I:C). Compound data 
show the distributi on of the hematopoieti c stem and progenitor cells in the GFP+ transduced bone marrow fracti on 
(mean±SD, n=3, ns). (G) Histogram showing β-catenin and p53 expression in RBC lysed, GFP+ whole bone marrow 
cells. (H) Composite data of apoptosis detected by Annexin in GFP+ whole bone marrow cells (mean±SD, n=3, ns). (I) 
Western blots showing CK1α  protein expression (Santa Cruz, Casein kinase 1a, C19) in Mx1Cre+, Csnk1a1-/+Mx1Cre+ 
as well as transduced, transplanted and sorted CSNK1A1 or CSNK1A1(E98V) expressing bone marrow cells in a 
Csnk1a1-/-Mx1Cre+ background [2 weeks aft er inducti on of poly(I:C); n=3 biological replicates]. 
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Only a fraction (75% in patient 1 and 42% in patient 2) of the non-deleted CSNK1A1 allele 
were mutated. By SNP array analysis (Figure S5A), the percentage of the del(5q) MDS clone 
was 70-80% in patient 1 and 90-100% in patient 2. These data indicate that deletion of 
chromosome 5q occurred first, and that the CSNK1A1 mutation occurred on the remaining 
allele of chromosome 5q. The mutation was identified in only less than 5% of the matched 
control samples from T cells. We analyzed an additional set of 22 MDS samples with 
isolated del(5q) and found one additional mutation, also altering the same codon (E98V). 
We examined published MDS genome-sequencing data and found one CSNK1A1 mutation, 
D140A, in a case with MDS and a normal karyotype (Graubert et al., 2012) and CSNK1A1 
D140Y in a patient with del(5q) MDS (Woll et al., 2014). Additional CSNK1A1 mutations 
were identified in the literature in other malignancies (Dulak et al., 2013; Sato et al., 2013), 
two of which are also missense mutations of codon 98, and one of codon 140 (Figure S5B). 
CSNK1A1 is therefore a gene with recurrent somatic mutations within a del(5q) CDR in MDS. 
We tested the function of the CSNK1A1 E98V mutation by retroviral expression of the 
mutant cDNA in Csnk1a1-/-Mx1Cre+ hematopoietic cells, reflecting the finding of mutations 
in del(5q) cells without a wild-type allele. Ckit+ hematopoietic cells were transduced with 
retroviruses expressing a wild type CSNK1A1 cDNA, the CSNK1A1 E98V mutation, or the 
CSNK1A1 D136N cDNA with mutational inactivation of the CK1α kinase activity (Bidere et 
al., 2009; Davidson et al., 2005; Peters et al., 1999). Four weeks after transplantation of 
transduced cells into lethally irradiated recipients, we induced excision of both endogenous 
Csnk1a1 alleles. Mice transplanted with cells expressing the kinase-dead CSNK1A1 D136N 
cDNA died rapidly as expected, as the mutant cDNA was unable to rescue the effect of the 
Csnk1a1 ablation (Figure S5C-E). In contrast, cDNA overexpressing CSNK1A1 and CSNK1A1 
E98V cDNA rescued the HSC ablation in Csnk1a1-/-Mx1Cre+ cells (Figure 6B and S5C). After 
12 weeks, the bone marrow of the recipient mice was fully reconstituted by cells transduced 
with either CSNK1A1 cDNA or CSNK1A1 E98V cDNA (Figure 6C). Cells expressing CSNK1A1 
or CSNK1A1 E98V reconstituted lineages, as well as stem and progenitor cells (Figures 6C 
and S5F). 
We next examined the cellular consequences of the CSNK1A1 E98V mutation. Csnk1a1-
/-Mx1Cre+ cells transduced with CSNK1A1 E98V cDNA, compared to cells expressing the 
wild-type cDNA, had increased nuclear β-catenin accumulation by immunofluorescence, 
and higher β-catenin accumulation by intracellular flow cytometry (Figure 6D-F and S5G). 
While expression of the kinase-dead CSNK1A1 D136N cDNA caused increased apoptosis and 
HSC ablation, the CSNK1A1 E98V cDNA did not induce p53 or apoptosis (Figure 6,D, F and 
S5G, H). Furthermore, bone marrow cells expressing CSNK1A1 E98V cDNA had an increased 
frequency of cells in the G1 phase of the cell cycle, with no change in cells in G0 (Figure 6G). 
In aggregate, these findings indicate that the codon 98 mutations are not loss-of-function, 
and do not cause increased p53 activation, but do increase β-catenin activity, providing a 
potential selective advantage to del(5q) MDS cells.
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Having demonstrated that Csnk1a1 haploinsufficient cells are sensitized to CK1 
inhibition, we tested whether CSNK1A1 E98V-expressing cells in a Csnk1a1 null background 
are more sensitive to treatment with a CK1 inhibitor than wild-type or Csnk1a1 
haploinsufficient cells. GFP+ CSNK1A1 E98V and CSNK1A1 expressing LSK cells and Csnk1a1 
haploinsufficient and wild-type LSK cells were sorted and treated with D4476 (Figure 6H). 
Treatment of Csnk1a1-/-Mx1Cre+ cells transduced with CSNK1A1 E98V cDNA were significantly 
more sensitive to the compound than Csnk1a1 haploinsufficient cells. Similar results were 
obtained from a co-culture competition assay in the presence of D4476 (Figure 6I and S5I). 
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DISCuSSIoN 
Our studies converged on a critical role for CK1α in the pathogenesis of del(5q) MDS. 
Activation of β-catenin downstream of Csnk1a1 haploinsufficiency in a murine model, and 
downstream of CSNK1A1 mutations in MDS patient samples, provides a potential mechanism 
of clonal selection. In contrast, homozygous inactivation of Csnk1a1 is not tolerated due to 
activation of p53. The sensitivity of hematopoietic cells to Csnk1a1 gene dosage provides a 
therapeutic window for targeting CK1α  in haploinsufficient cells.
In a previous study, we found Csnk1a1 to be a therapeutic target in AML, and that D4476 
selectively kills leukemic stem cells relative to normal hematopoietic stem and progenitor 
cells (Jaras et al., 2014). Both the knockdown of Csnk1a1 using shRNA and the genetically 
engineered mouse model show that reduction of Csnk1a1 expression by more than 50% has 
a negative effect on hematopoietic stem cell expansion and survival. Haploinsufficiency, in 
contrast, increases the number and function of hematopoietic stem cells. 
β-catenin is a major driver of stem cell self-renewal and neoplasia in multiple cellular 
lineages (Baba et al., 2005; Elyada et al., 2011; Willert et al., 2003; Yeung et al., 2010). 
Hematopoietic stem cells have a graded response to β-catenin, with modest levels leading 
to increased stem cell self-renewal (Baba et al., 2005), and more marked induction leading to 
stem cell exhaustion (Albuquerque et al., 2002; Kirstetter et al., 2006; Lane et al., 2010; Luis 
et al., 2011). Forced expression of β-catenin, in combination with HOXA9 and MEIS1, induces 
leukemia in progenitor cells (Wang et al., 2010b), and β-catenin is essential for leukemia cells 
driven by the MLL-AF9 oncogene (Miller et al., 2013). Histopathological studies have found 
nuclear, non-phosphorylated β-catenin expression in bone marrow specimen from de novo 
AML and MDS patients to be a predictor for clinical outcome, and these studies suggested 
an association between nuclear β-catenin expression and del(5q) MDS, though the number 
of samples studied was too small to be conclusive (Xu et al., 2008). CK1α is a member of 
the β-catenin destruction complex and is therefore a known, central regulator of β-catenin 
activity (Cheong and Virshup, 2011). In our studies, Csnk1a1 haploinsufficiency conferred 
to increased intrinsic self-renewal of HSC, with associated nuclear β-catenin accumulation, 
cyclin D1 induction, and exit from quiescence in LT-HSCs.
Increased LT-HSC proliferation and expansion was a cell-intrinsic effect in our study. 
Inactivation of Csnk1a1 in stromal cells in our model caused stromal β-catenin levels 
to increase, with consequent effects on hematopoiesis, including pancytopenia and 
hematopoietic stem and progenitor cell depletion. This observation is consistent with recent 
studies demonstrating that β-catenin accumulation in the stroma negatively regulates HSC 
maintenance and might also contribute to leukaemogenesis (Kode et al., 2014; Lane et al., 
2010). 
APC, another member of the β-catenin destruction complex, is also deleted in the 
vast majority of del(5q) MDS cases. Hematopoietic cells with Apc haploinsufficiency have 
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been shown to have enhanced repopulation potential, indicating a cell intrinsic gain of 
function in the LT-HSC population. However, in contrast to Csnk1a1 haploinsufficiency, Apc 
haploinsufficient bone marrow was unable to repopulate secondary recipients due to loss of 
the quiescent HSC population (Lane et al., 2010; Wang et al., 2010a). Different levels of Wnt 
activation may explain these findings. Similarly, deletions of Csnk1a1 and of Apc in the gut 
have significantly different effects. While Csnk1a1 deletion led to robust activation of Wnt 
target genes and proliferation without invasion, Apc deletion induced immediate dysplastic 
transformation and rapid death (Elyada et al., 2011). CK1α  has many phosphorylation 
targets that could alter stem cell function (Bidere et al., 2009; Elyada et al., 2011; Wu et 
al., 2012). As has been postulated previously, it is possible that CK1α  inactivation restrains 
hyperactive Wnt signaling through mechanisms yet to be defined.
Our sequencing studies revealed recurrent mutations in a gene located in an MDS 
common deleted region on chromosome 5q. SNP array studies have not identified any genes 
on 5q that undergo homozygous deletion in del(5q) MDS (Gondek et al., 2008; Graubert 
et al., 2009; Heinrichs et al., 2009). Indeed, our studies would indicate that homozygous 
inactivation of CSNK1A1 would be highly deleterious to a hematopoietic cell.  Although 
CSNK1A1 mutations in MDS are rare, they provide powerful evidence that these lesions 
are genetic drivers of clonal dominance. In functional studies, expression of the identified 
CSNK1A1 E98V allele, in the setting of inactivation of both wild-type alleles to mimic the 
genetic context of the mutations observed in patients, caused an induction of nuclear 
β-catenin and a significant HSC cell cycle progression compared to expression of the wild-
type CSNK1A1. Future experiments using a conditional knock-in mouse strain will be helpful 
to study the long-term hematopoietic effects of the mutant allele expressed at physiological 
levels.
Our results indicate that CSNK1A1 is a CYCLOPS (copy number alteration yielding cancer 
liabilities owing to partial loss) gene (Nijhawan et al., 2012). Heterozygous inactivation of 
Csnk1a1 sensitized cells to CK1 inhibition with D4476. The ablation of hematopoiesis in 
Csnka1a1 null cells, and the normal to enhanced hematopoiesis in Csnk1a1 haploinsufficient 
cells, provides a mechanistic basis for this therapeutic window. We demonstrated that 
systemic Csnk1a1 haploinsufficiency in our murine model does not have significant effects 
on other organs, indicating that partial pharmacologic inhibition of CK1 would likely be well 
tolerated. While D4476 does not have pharmacokinetic properties for in vivo use, and lacks 
specificity for CK1α , a more selective compound has the potential for therapeutic utility in 
the treatment of patients with myeloid malignancies associated with del(5q).
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exPeRIMeNTaL PRoCeDuReS
Generation of a Csnk1a1 conditional knockout mouse
Mouse embryonic stem (ES) cells with Csnk1a1 exon 3 targeted in a C57BL/6N genetic 
background were generated by the KOMP consortium (project ID: CSD45494). The neomycin 
/ lacZ cassette was flipped out in vitro by transfection of a plasmid expressing the flippase 
recombinase (FRT). Successful FRT recombination was validated by PCR (forward primer: 
5’-TCGCACTTGAGCTATTGGGGAGT-3’; reverse primer: 5’-AGGCATGGTAGCTCACACCTGA-3’). 
Following confirmation of germline transmission, mice were crossed with the Mx1-Cre 
mouse strain (Jackson: 002527). To excise Csnk1a1 exon 3, Csnk1a1 conditional mice were 
given three rounds of 200 µg of poly(I:C) (GE Healthcare Life Sciences) using intraperitoneal 
injections. Successful excision of Csnk1a1 exon 3 was validated using forward primer above 
and reverse 5´AGCTGGGCTACCAAGAGGCAA-3’ primer. All experiments and procedures 
were conducted in the Children’s Hospital Boston animal facility and were approved by the 
Children’s Hospital Institutional Animal Care and Use Committee.
Flow cytometry
Bone marrow (BM) cells were isolated by flushing and crushing pelvis and hind leg bones 
with PBS (GIBCO) + 2% FBS + Penicillin/Streptomycin (GIBCO). Whole bone marrow was lysed 
on ice with red blood cell (RBC) lysis solution (Invitrogen/Life Technologies), and washed in 
PBS (GIBCO) + 2% FBS. Single-cell suspensions of spleen were prepared by pressing tissue 
through a cell strainer followed by red blood cell lysis. Cells were labeled with monoclonal 
antibodies in 2% FBS/PBS for 30 min on ice (see Supplemental Experimental Procedures 
for the information on antibodies used) and analyzed using an LSRII (BD biosciences). 
Apoptosis (Annexin V apoptosis detection kit, ebioscience) and cell cycle (Ki67 cell cycle and 
proliferation kit, BD biosciences) assays were performed according to the manufacturer’s 
instructions.  
Bone marrow transplantation assays 
In transplantation assays of Csnk1a1 cells into CD45.1 wild-type mice, 5x106 freshly isolated 
whole bone marrow cells were harvested before poly(I:C) treatment, and injected into 
the tail-vein of lethally irradiated (1050 Rads) CD45.1-positive B6.SJL (Jackson) recipient 
mice without support cells. In competitive bone marrow transplantation studies, 2x106 
freshly isolated bone marrow cells were harvested and transplanted via tail vein into 
lethally irradiated CD45.1+ recipient mice together with 2x106 freshly isolated CD45.1+ 
bone marrow competitor cells in an equal ratio. Four weeks after transplantation, blood 
samples were taken and donor cell chimerism was determined by flow cytometric analysis. 
Shortly thereafter, mice were given three rounds of poly(I:C) treatment and donor blood cell 
chimerism was determined every four weeks.
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Western blots
Western blots were performed according to standard protocols. In brief, cell lysis was 
performed in RIPA buffer with protease/phosphatase inhibitors.  After protein quantification, 
lysates were resuspended in Laemmli Sample Buffer, and loaded to gradient gels (Criterion 
Tris-HCl Gel, 8-16%).  Proteins were transferred onto Immobilon polyvinyl difluoride (PVDF) 
membranes. As primary antibodies β-catenin (rabbit polyclonal, 9562, 1:500, Cell Signaling), 
p53 (mouse monoclonal, DO-1, 1:500, Santa Cruz), p21 (rabbit polyclonal, 1:200, C-19, Santa 
Cruz), Cycli n D1 (rabbit monoclonal, 1:200, SP4, Thermo Scientific) and GAPDH (rabbit 
polyclonal, 1:4000, Bethyl laboratories Inc) were applied. 
histopathology
For histological and immunohistochemical analyses, murine organs were fixed in 3.7% 
formaldehyde overnight, dehydrated and prepared for paraffin embedding. Hematoxylin-
Eosin (H&E) staining was done according to routine protocols. For immunohistochemical 
stainings, the Avidin-Biotin Complex (ABC) was applied. Peripheral blood smears were 
stained with May-Grünwald-Giemsa (Sigma-Aldrich). Images were obtained on a Nikon 
Eclipse E400 microscope (Nikon, Tokyo, Japan) equipped with a SPOT RT color digital camera 
model 2.1.1 (Diagnostic Instruments). 
Viral vector cloning 
MIG-CSNK1A1, MIG-CSNK1A1(E98V) and MIG-CSNK1A1(D136N) were flanked by Not1 and 
Xho1 sites for convenient cloning into the MIG vector backbone.
Patient samples and Sequencing
Patients included in the whole exome sequencing were diagnosed between 2008 and 2013 
at different Spanish hospitals affiliated to the MDS Spanish Group (Grupo Español de SMD, 
GESMD). Patients were diagnosed with MDS according to the French-American-British and 
2008 World Health Organization classification. Samples were deidentified at the time of 
inclusion. This study was approved by institutional review boards (Clinical Research Ethics 
Committee Institut Català de la Salut/Germans Trias i Pujol Hospital and Clinical and Ethics 
Committee Parc de Salut MAR) and performed in accordance with the declaration of Helsinki. 
All patients gave their informed written consent. Whole-exome sequencing was performed 
using paired-end reads generated from DNA libraries prepared from MDS samples (whole 
bone marrow) with matched normal samples (CD3+ lymphocytes isolated from peripheral 
blood). Whole-exome hybrid capture was carried out on 3 μg of genomic DNA, using the 
SureSelect Human Exome Kit version 3 (Agilent Technologies, Inc., Santa Clara, CA, USA). 
The captured exome library was sequenced with 100bp paired-end reads on an Illumina 
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HiSeq2000 platform (Illumina, San Diego, CA, USA). Whole-exome sequencing data were 
analyzed using an in-house bioinformatics pipeline as previously reported (BWA; GATK’s; 
VarScan2; SAMTools; SnpEff: (Koboldt et al., 2012; McKenna et al., 2010). Somatic mutations 
identified as alterations present in tumor but not in the matched CD3+ sample were validated 
by Sanger sequencing. Sanger sequencing was performed on genomic DNA isolated from 
whole bone marrow cells and CD3+ cells using GentraPuregene Cell kit (Qiagen, Valencia, 
CA, USA). Exon 3 from CSNK1A1 gene was amplified by polymerase chain reaction (PCR) 
using the following primers: forward primer: 5’-TCCTTTTGTTTCGTTAGGTGGT-3’ and reverse 
primer 5’-AAGGTTAAATAGTGATGCACAGGA-3’; amplification size: 251 bp). Single nucleotide 
polymorphism array (SNP-A) were performed with Genome-Wide Human SNP Array 6.0 
from Affymetrix. Assays were performed according to Affymetrix protocols. 
accession number
The Gene Expression Omnibus accession number for the SNP-arrays of patient 1 and 2 (with 
somatic mutations in CSNK1A1) is GSE59244.
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aBSTRaCT
Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with 
deletion of chromosome 5q (del(5q)). Here, we demonstrate that lenalidomide induces the 
ubiquitination of casein kinase 1A1 (CK1α) by the E3 ubiquitin ligase CUL4–RBX1–DDB1–
CRBN (known as CRL4CRBN), resulting in CK1α degradation. CK1α is encoded by a gene within 
the common deleted region for del(5q) MDS and haploinsufficient expression sensitizes 
cells to lenalidomide therapy, providing a mechanistic basis for the therapeutic window 
of lenalidomide in del(5q) MDS. We found that mouse cells are resistant to lenalidomide 
but that changing a single amino acid in mouse Crbn to the corresponding human residue 
enables lenalidomide-dependent degradation of CK1α. We further demonstrate that minor 
side chain modifications in thalidomide and a novel analogue, CC-122, can modulate the 
spectrum of substrates targeted by CRL4CRBN. These findings have implications for the clinical 
activity of lenalidomide and related compounds, and demonstrate the therapeutic potential 
of novel modulators of E3 ubiquitin ligases.
Main
The immunomodulatory agents (IMiDs) lenalidomide, thalidomide, and pomalidomide 
are the first drugs identified that promote the ubiquitination and degradation of specific 
substrates by an E3 ubiquitin ligase. These compounds bind CRBN, the substrate adaptor 
for the CRBN-CRL4 E3 ubiquitin ligase, and modulate the substrate specificity of the 
enzyme. In lymphoid cells, IMiDs induce degradation of two transcription factors-- IKZF1 
and IKZF3- leading to the dramatic clinical efficacy of these molecules in multiple myeloma 
and increasing interleukin-2 release from T-cells. It has not yet been determined whether 
degradation of distinct substrates may mediate additional activities in other cell types and 
whether all IMiDs have the same substrate specificity.
Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with 
deletion of chromosome 5q (del(5q), inducing cytogenetic remission in more than 50% of 
patients.5 No biallelic deletions or loss of function mutations on the remaining allele have 
been detected in any of the genes in the del(5q) common deleted region, implying that MDS 
with del(5q) is a disease of haploinsufficiency.6 We hypothesized that ubiquitination of a 
distinct CRBN substrate explains the efficacy of lenalidomide in del(5q) MDS. 
Lenalidomide induces ubiquitination and degradation of casein kinase 1a1 
In order to identify lenalidomide-regulated CRBN-CRL4 substrates in myeloid cells, we 
applied stable isotope labeling of amino acids in cell culture (SILAC)-based quantitative mass 
spectrometry to assess global changes in ubiquitination and protein levels in the myeloid 
cell line KG-1 (Fig. 1a-b). Lenalidomide altered the ubiquitination and protein levels of 
strikingly few proteins, demonstrating the highly specific effects of this drug on ubiquitin 
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ligase function. Consistent with previous studies, lenalidomide treatment decreased 
ubiquitination of CRBN (p=0.026) and increased ubiquitination of IKZF1 (p=7.23 x 10-6 and 
p=4.97 x 10-4 for two distinct sites), with a reciprocal decrease in IKZF1 protein abundance 
(p=0.006)1-3 
In addition to IKZF1, we detected increased ubiquitination (p=0.04) and decreased 
protein abundance (p=0.006) of casein kinase 1A1 (CSNK1A1, p=0.006) following treatment 
with 1 µM lenalidomide. The CSNK1A1 gene is located in the del(5q) common deleted 
region and is expressed at haploinsufficient levels in del(5q) MDS.6 Furthermore, CSNK1A1 
has been implicated in the biology of del(5q) MDS and has been shown to be a therapeutic 
target in myeloid malignancies, so it is an attractive candidate for mediating the effects of 
lenalidomide in del(5q) MDS.7 
Figure 1: a, Log2 ratios for individual K-ε-GG sites of lenalidomide- (1 µM) versus DMSO-treated KG-1 cells for 
biological replicates 1 and 2. Each point represents a unique K-ε-GG site. Significantly regulated sites (P < 0.05) are 
red. b, Log2 ratios of protein abundance for lenalidomide- (1 µM) versus DMSO-treated KG-1 cells for biological 
replicates 1 and 2. Each point represents a unique protein group. Significantly regulated proteins (P < 0.05) are 
red. c, Effects of lenalidomide (Len) on endogenous CK1α protein levels in KG-1 cells after 24-h treatment. Data 
are representative of 5 independent experiments (n = 5). IB, immunoblot. d, CSNK1A1 mRNA levels in KG-1 cells 
following lenalidomide treatment. Data are mean ± s.d., n = 3 biological replicates.
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CSNK1a1 is a lenalidomide-dependent substrate of the CRBN-CRL4 e3 ubiquitin 
ligase
We next sought to determine whether CSNK1A1  is a lenalidomide-dependent 
substrate of the CRBN-CRL4 E3 ubiquitin ligase. We first confirmed that lenalidomide 
decreases CSNK1A1 protein levels in multiple human cell lines (Fig. 1c), as well as in primary 
AML cells obtained from the bone marrow of patients following a 6 day treatment with 
lenalidomide (Fig. 1d, Extended Data Fig 2).  Lenalidomide decreased the half-life of the 
CSNK1A1 protein without altering CSNK1A1 mRNA levels (Fig. 1e), consistent with a post-
translational mechanism of regulation. The lenalidomide-dependent decrease in CSNK1A1 
protein levels was abrogated by treatment with the proteasome inhibitor MG132 and the 
NEDD8-activating enzyme inhibitor MLN4924, which interferes with the activity of cullin-
RING E3 ubiquitin ligases (Fig 2a). Homozygous genetic inactivation of the CRBN gene by 
CRISPR-Cas9 genome editing eliminated lenalidomide-dependent degradation of CSNK1A1 
(Fig. 2B). 
Figure 2: a, CK1α protein levels in KG-1 cells treated with DMSO or lenalidomide alone or in the presence of 
10 μM MG132 or 1 μM MLN4924 for 6 hours. b, CK1α protein levels in CRBN knockout 293T cells treated with 
lenalidomide. c, Immunoprecipitation of FLAG-CRBN in 293T cells treated with DMSO or 1 μM lenalidomide in the 
presence of 1 μM MG132. d, Ubiquitination of endogenous CK1α in KG-1 cells treated with DMSO or lenalidomide 
analyzed by TUBE2 pull-down of ubiquitinated proteins followed by staining with a CK1α-specific antibody. Higher 
molecular weight bands represent ubiquitinated CK1α. e, Ubiquitination of CK1α by CRBN in vitro using lysine-
free ubiquitin. Arrowheads indicate ubiquitinated CK1α. Results are representative of two (a, b, d, n=2) or three 
independent experiments (c, e, n=3).We next examined whether CSNK1A1 binds CRBN and is ubiquitinated by 
the CRBN-CRL4 E3 ubiquitin ligase. CSNK1A1 co-immunoprecipitated with FLAG-tagged CRBN (Fig. 2c) only in the 
presence of lenalidomide. Lenalidomide treatment increased the ubiquitination of FLAG-CSNK1A1 in 293T cells (Fig. 
2d) and in the presence of CRBN in vitro, confirming that CSNK1A1 is a direct target of CRBN-CRL4 (Fig. 2e). Taken 
together, these experiments demonstrate that CSNK1A1 is a CRBN-CRL4 E3 ligase substrate that is ubiquitinated 
and degraded in the presence of lenalidomide. 
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We sought to identify a degron domain of CSNK1A1 that is required for lenalidomide-
dependent degradation. Using a series of chimeric proteins of CSNK1A1 and a lenalidomide-
insensitive homolog, CSNK1E, we identified a region in the N-terminus of CSNK1A1 that is 
essential for lenalidomide-induced degradation. Sequence alignment of this region with the 
previously delineated lenalidomide-responsive degron in IKZF1 and IKZF32 did not reveal 
any significant homology.    
CSNK1a1 insufficiency sensitizes human cells to growth inhibition by lenalidomide
We next sought to explore the biological effects of CSNK1A1 depletion. CSNK1A1 is a serine/
threonine kinase with multiple cellular activities, including negative regulation of the TP53 
and β-catenin pathways.8-10 In a conditional knockout of Csnk1a1 in the murine hematopoietic 
system, homozygous inactivation induces apoptosis in normal and leukemic stem cells via 
tp53 activation,7 while heterozygous loss of CSNK1A1 causes β-catenin accumulation and 
stem cell expansion.7,11 Similarly, cells haploinsufficient for Csnk1a1 preferentially undergo 
apoptosis in response to a nonselective casein kinase 1 inhibitor, D447612. Based on these 
findings, and since del(5q) cells express about 50% of normal levels of CSNK1A1 6, we 
hypothesized that these cells would be more sensitive to further degradation of CSNK1A1 
as compared to normal cells with two copies of the gene. 
To evaluate whether decreased CSNK1A1 expression sensitizes cells to lenalidomide, 
we transduced primary human CD34+ hematopoietic stem and progenitor cells with GFP-
tagged lentiviral vectors expressing CSNK1A1 or control shRNAs. Cells expressing CSNK1A1 
shRNAs were depleted in the absence of treatment, demonstrating that low levels of 
CSNK1A1 inhibit the growth of hematopoietic cells (Fig. 3a). Treatment with lenalidomide 
enhanced the depletion of cells expressing CSNK1A1 shRNAs relative to cells expressing 
control shRNAs, demonstrating that reduced CSNK1A1 levels sensitize hematopoietic cells 
to lenalidomide.
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Figure 3: ectopic CSNK1A1 overexpression reduces lenalidomide sensitivity in primary MDS del(5q) cells
CD34+ cells derived from patient or control bone marrow were transduced with a lentiviral vector overexpressing 
CSNK1A1 and GFP or an empty control vector and treated with DMSO or 1 μM lenalidomide. Results are reported 
as a ratio of the percentage of GFP+ cells in the lenalidomide condition to the percentage of GFP+ cells in the DMSO 
condition after 5 days of treatment. A ratio greater than 1 for the CSNK1A1 vector but not for the empty vector 
indicates that CSNK1A1 expression reduces lenalidomide sensitivity.
We next evaluated whether overexpression of CSNK1A1 in del(5q) MDS could rescue sensitivity of these cells 
to lenalidomide treatment.  We obtained samples from MDS patients with large heterozygous deletions of 
chromosome 5q, including heterozygous deletion of CSNK1A1, obtained prior to treatment with lenalidomide. 
We isolated CD34+ cells from the MDS patients and transduced the cells with a lentivirus expressing GFP and a 
CSNK1A1 cDNA. Forced expression of CSNK1A1 conferred resistance to lenalidomide in cells isolated from del(5q) 
MDS patients, but not in cells from MDS patients with a normal karyotype or normal adult CD34+ cells  (Fig 3b, 
Extended Data Table 1). Therefore, although the del(5q) cells were haploinsufficient for a large number of genes, 
expression of CSNK1A1 alone was sufficient to confer lenalidomide resistance.
Non-conserved amino acids in Crbn abolish lenalidomide activity in murine cells
We next sought to determine whether haploinsufficiency for Csnk1a1 sensitizes cells 
to lenalidomide treatment using a Csnk1a1 conditional knockout mouse model.  In initial 
experiments, we found that lenalidomide did not decrease Csnk1a1 protein levels in murine 
Ba/F3 cells or primary murine leukemia cells. Consistent with this finding, mice do not 
develop the limb malformations observed in human embryos exposed to thalidomide13 
and primary murine multiple myeloma does not respond to lenalidomide14, suggesting that 
murine cells are intrinsically resistant to IMiDs. Since CRBN is the direct protein target of 
lenalidomide, we examined whether expression of human CRBN could confer lenalidomide 
sensitivity to murine cells. Overexpression of human but not murine CRBN in murine Ba/F3 
cells resulted in a lenalidomide-dependent decrease of CSNK1A1 protein levels, implying 
that amino acid differences between murine CRBN (mCRBN) and human CBRN (hCRBN) are 
responsible for the species-specific response to lenalidomide (Fig. 4a,b).
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Figure 4: amino acid changes in CRBN explain species-specific lenalidomide effects
a, Effect of the expression of human CRBN (h), mouse Crbn (m), chimeras of human and mouse CRBN (m-h and 
h-m, breakpoint at residue 221 (human) / 225 (mouse)) and variants of the m-h chimera where single amino-
acids in the C-terminus were mutated to their corresponding mouse residue on lenalidomide-dependent CK1α 
degradation in mouse Ba/F3 cells. b, Expression of mouse CrbnI391V restores lenalidomide-dependent CK1α 
degradation in mouse Ba/F3 cells. c, Effect of hCRBN, mCrbn and mCrbnI391V on lenalidomide sensitivity of an 
IKZF1-luciferase fusion protein expressed in human 293T cells. Data are mean ± s.e.m. (n=3 biological replicates). 
d, Alignment of human and mouse CRBN IMiD binding region. Non-conserved amino acids are red. Amino acids 
involved in IMiD binding are indicated by blue bars. Mouse W403 is indicated with a green bar. e, Superposition 
of the IMiD binding domains of human CRBN (blue, PDB accession 4TZ4) and mouse Crbn (yellow, PDB accession 
4TZC). Residues are labeled according to human isoform 2 (blue numbers) and mouse isoform 2 (yellow numbers). 
f, The V387 residue is indicated on the surface of human CRBN with a black arrow. g, The corresponding mouse 
residue, I391, is indicated on the surface of mouse Crbn with a black arrow. Mouse W403 is indicated by a red 
arrow. Results are representative of 3 (a, b, c) independent experiments.
In order to identify the amino acids responsible for this difference, we tested a series 
of human/mouse CRBN chimeric cDNAs for their ability to confer lenalidomide-induced 
CSNK1A1  degradation in murine Ba/F3 cells (Fig. 4a). We found that lenalidomide sensitivity 
was determined by the C-terminal half of CRBN, which contains only 5 non-conserved amino 
acids between human and mouse. Substitution of these positions in human CRBN with the 
corresponding amino acid in murine CRBN revealed only one substitution, V387I (human 
CRBN isoform 2), that disrupted the lenalidomide-responsiveness of human CRBN (Fig. 4a). 
Remarkably, substitution of the isoleucine at this position in murine CRBN for the human 
valine (mCRBNI391V) was sufficient to confer lenalidomide-induced CSNK1A1 degradation 
in murine cells (Fig. 4b). Similar effects of these two point mutants were observed on 
lenalidomide-induced degradation of IKZF3 in human 293T cells (Fig. 4c), suggesting that 
a single amino acid change in CRBN determines lenalidomide-responsiveness for multiple 
substrates. 
We modeled the effects of this murine-human amino acid substitution based on 
recently published crystal structures of the CRBN-DDB1-IMiD complex15,16. V387 of human 
CRBN (equivalent to I391 of murine CRBN) is located in the IMiD binding region of CRBN, but 
does not directly interact with lenalidomide (Fig. 4d). To investigate how the substitution of 
isoleucine for valine in murine CRBN confers lenalidomide-responsiveness, we superimposed 
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the structures for the murine and human IMiD-binding regions bound to lenalidomide as 
solved in Chamberlain et al. (2014). There are no backbone changes present at the site of 
the valine-isoleucine species differences (Fig. 4e), but the isoleucine residue is well-defined 
and oriented towards the indole NH moiety of W403 in the murine structure (Fig. 4g,h). The 
increase in steric bulk and rigid position of the isoleucine side-chain relative to the valine 
side-chain results in a bulge in the solvent accessible surface in the murine protein adjacent 
to both W403 and lenalidomide (Fig. 4f,). It has been proposed that IMiD binding produces a 
hotspot for local interactions by placement of the hydrophobic phthalimide or isoindolinone 
ring in an environment of potential hydrogen bond donors and acceptors from the surface 
of CRBN.16 In this case, the larger side chain of the isoleucine residue found in rodents may 
sterically clash with substrate proteins such as IKZF1 and CSNK1A1 , blocking access to key 
hydrogen bonds from CRBN, such as from the indole NH from tryprophan 403 (human 
numbering). Steric clash with substrate proteins provides one potential explanation of why 
IMiDs bind murine CRBN1 but do not promote degradation of IKZF1 and CSNK1A1.
Having determined the mechanism of lenalidomide resistance in mouse cells, we 
expressed the mCrbnI391V cDNA in hematopoietic cells from Csnk1a1 conditional knockout 
mice to determine the effects of Csnk1a1 haploinsufficiency on lenalidomide sensitivity. 
We isolated CD45.2+ c-Kit+ hematopoietic stem and progenitor cells from Csnk1a1+/−
Mx1Cre+ and Mx1Cre+ control littermates treated with poly (I:C) to induce gene excision 
in hematopoietic cells. We transduced these cells with a retroviral vector expressing 
mCrbnI391V, and cultured them in competition with similarly transduced isogenic CD45.1 
c-Kit+ cells in the presence or absence of lenalidomide (Fig. 5a). Lenalidomide had no 
effect on control cells, but Csnk1a1+/−Mx1Cre+ cells were significantly depleted in the 
presence of lenalidomide (Fig. 5b). The enhanced sensitivity of Csnk1a1+/−Mx1Cre+ cells 
to lenalidomide was associated with induction of the p53 target gene p21 (Fig. 5c) and 
increased levels of apoptosis (Fig. 5d), and was rescued by heterozygous deletion of Trp53 
(Fig. 5b), demonstrating a critical downstream role for the p53 pathway. These results are 
consistent with the clinical observation that TP53 mutations confer lenalidomide resistance 
in MDS with del(5q).
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Figure 5: effects of lenalidomide treatment on Csnk1a1+/− mouse hematopoietic cells
a, Csnk1a1+/−Mx1Cre+ or Mx1Cre+ c-Kit+ hematopoietic stem and progenitor cells (CD45.2) and competitor cells 
(CD45.1) were transduced with mCrbnI391V, mixed in equal ratios, and treated with lenalidomide or DMSO. The 
relative percentage of CD45.1+ and CD45.2+ cells was followed by flow cytometry over 5 days. b, Effects of 0.1 μM 
lenalidomide on the chimerism of Csnk1a1+/− Mx1Cre+, Csnk1a1+/− Trp53+/− Mx1Cre+, Trp53+/− Mx1Cre+, or 
Mx1Cre+ cells (CD45.2) transduced with mCrbnI391V in comparison to CD45.1 competitor cells. Data are shown as 
mean ± s.e.m, n=3 biological replicates. c, Quantitative RT-PCR analysis of p21 expression in Csnk1a1+/− or control 
cells transduced with mCrbnI391V and treated with DMSO or lenalidomide. Data are normalized to DMSO and 
shown as mean ± s.d, n=3 biological replicates. d, Ratio of CD45.2+ cells and CD45.1+ cells in late apoptosis (Annexin 
V+ DAPI+) after transduction with mCrbnI391V and four day treatment with 0.1 μM lenalidomide. CD45.2+ cells 
are either Csnk1a1+/− Mx1Cre+ or Mx1Cre+. Data are normalized to DMSO treatment. Data are mean ± s.e.m, n=4 
biological replicates. Results for b, c, and d are representative of three independent experiments with hCRBN or 
mCrbnI391V. P-values are from an unpaired two-sided t-test.
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Differential degradation of CSNK1a1 by lenalidomide and other IMiDs
Thalidomide, lenalidomide, and pomalidomide target IKZF1 and IKZF3 for ubiquitination and 
degradation and are active in multiple myeloma, but only lenalidomide has been shown to be 
clinically effective in del(5q) MDS.2  We therefore asked whether IMiDs induce degradation 
of the same substrates. We used tandem mass tag (TMT) quantitative proteomics in the 
MDS-L cell line to compare the activities of lenalidomide and CC-122, a third generation 
IMiD that also has a glutarimide ring and that has entered clinical trials (Fig. 6a). As expected, 
treatment with lenalidomide significantly decreased expression of both IKZF1 and CSNK1A1. 
In striking contrast, treatment with 1 µM CC-122 caused an even greater decrease in IKZF1 
(log
2
 fold change= -3.121, p=2.77 x 10-10, 72 hours) than 10 µM lenalidomide (log
2
 fold 
change= -2.406 p=2.10 x 10-8, 72 hours), but had no effect on CSNK1A1  protein levels (log
2
 
fold change= -0.082, p>0.05)(Fig. 6b).   
We confirmed the TMT mass spectrometry findings by western blot for IKZF1 and 
CSNK1A1  in KG-1 and MDS-L cells (Fig. 6c). While all IMiDs induced degradation of IKZF1 
with a potency reflecting their clinical activity in multiple myeloma, thalidomide and CC-122 
did not affect CSNK1A1 protein levels even at high concentrations. Although pomalidomide 
has a higher potency than lenalidomide in inducing the degradation of IKZF1 and IKZF3, it 
was less efficient in decreasing CSNK1A1 protein levels than lenalidomide, suggesting that 
the addition of single carbonyl group can affect substrate preference (Fig. 6a,c) Furthermore, 
treatment with excess CC-122 abrogated the lenalidomide-induced degradation of 
CSNK1A1, demonstrating that lenalidomide and CC-122 compete for the same binding site 
on CRBN (Fig. 6d) These experiments demonstrate that CSNK1A1 is specifically targeted by 
lenalidomide, indicating that lenalidomide may indeed be the best IMiD for the treatment 
of del(5q) MDS (Fig. 6e).
Intriguingly, lenalidomide, but not thalidomide and pomalidomide, was reported to 
induce the formation of two β-strands composed of CRBN residues 346-363.16 Although 
conformational changes are difficult to interpret from structural data, the formation of 
these β-strands is expected to make significant changes in the surface of CRBN near the 
IMiD binding site16 and thus it may contribute to the differential recruitment of IKZF1 
and CSNK1A1. The interaction of specific IMiDs with particular substrates is therefore be 
governed by unique structural determinants, revealing the biological and clinical potential 
for members of this class of drugs to induce degradation of distinct sets of proteins.
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Figure 6: Substrate specificity of thalidomide analogues
a, Structures of thalidomide, lenalidomide, pomalidomide and CC-122. b, Protein levels of IKZF1 and CK1α assessed 
by tandem mass tag quantitative proteomics in MDS-L cells treated with DMSO, 10 μM lenalidomide, or 1 μM CC-
122 for 24 hours (left panel) or 72 hours (right panel). n=3 (drug treatment) or n=4 (DMSO). c, Western blot analysis 
of CK1α and IKZF1 protein levels in MDS-L cells treated with DMSO or different concentrations of thalidomide, 
lenalidomide, pomalidomide, or CC-122. Results are representative of two independent experiments (n=2). d, KG-1 
cells were treated with DMSO or lenalidomide in the absence or presence of different concentrations of CC-122. 
Results are representative of five independent experiments in various cell lines. e, Schematic presentation of the 
interaction of different thalidomide analogues with CRBN, substrates, and therapeutic indications.
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DISCuSSIoN
We demonstrate that lenalidomide targets CSNK1A1 for degradation in myeloid cells, and 
that heterozygous deletion of CSNK1A1 in del(5q) MDS provides a therapeutic window for 
selective targeting of the malignant cells by lenalidomide. The concept that genes within 
heterozygous deletions could cause vulnerabilities in cancer cells was first proposed 
20 years ago18 and  has been more recently demonstrated as CYCLOPS genes (cancer 
vulnerabilities unveiled by genomic loss) in cell lines.19 In del(5q) MDS, loss of CSNK1A1 
induces TP53 activity.  Deletion of contiguous genes on chromosome 5q, such as RPS14, may 
further sensitize del(5q) cells to TP53 activation.20,21 This mechanism of activity is consistent 
with the acquisition of TP53 mutations in del(5q) MDS patients who develop resistance 
to lenalidomide. Degradation of CSNK1A1 may also contribute to other clinical effects of 
lenalidomide such as myelosuppression and the activity of lenalidomide in the activated 
B-cell (ABC) subtype of diffuse large B-cell lymphoma22.
Lenalidomide, like thalidomide and pomalidomide, binds CRBN and induces degradation 
of specific substrates. We found that a single amino acid difference between murine 
and human CRBN renders murine cells insensitive to IMiDs. This discovery enabled us to 
demonstrate, using a genetically engineered murine model, that Csnk1a1 haploinsufficiency 
sensitizes cells to lenalidomide. This single amino acid change may also explain why 
thalidomide does not cause teratogenicity in mice and was approved for use in pregnant 
women, leading to the birth of more than 10,000 newborns with limb malformations and 
other disabilities. 
Thalidomide, lenalidomide, and pomalidomide all induce CRBN-CRL4-mediated 
degradation of IKZF1 and IKZF3, but the subtle differences between these molecules cause 
dramatic changes in potency. We now find that thalidomide and a novel compound, CC-
122, induce the degradation of IKZF1 and IKZF3 but not CSNK1A1. Since CSNK1A1 may also 
be involved in causing side effects like myelosuppression, CC-122 may be more specific in 
the treatment of multiple myeloma and other diseases that depend on IKZF1 and IKZF3, 
but would not be predicted to have activity in del(5q) MDS. CC-122, like the other IMiDs, 
has a glutarimide ring that anchors the molecule in CRBN, and structural variation in the 
remainder of the molecule is thought to determine substrate specificity.15,16 These findings 
provide evidence that novel thalidomide-related molecules may have distinct biological 
activities, mediated by degradation of distinct sets of substrates, and that these IMiDs will 
be the first in a larger class of drugs with therapeutic utility through the targeting of specific 
proteins for degradation.
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BaCKGRouND
Bone marrow (BM) niches are often inaccessible for controlled experimentation due to their 
difficult accessibility, biological complexity, and three-dimensional (3D) geometry.
MeThoDS
Here, we report the development and characterization of a BM model comprising of cellular 
and structural components with increased potential for hematopoietic recapitulation at 
ectopic transplantation sites. Cellular components included mesenchymal stromal cells 
(MSCs) and hematopoietic stem and progenitor cells (HSPCs). Structural components 
included 3D β-tricalcium phosphate (β-TCP) scaffolds complemented with Matrigel or 
collagen I/III gels for the recreation of the osteogenic/extracellular character of native BM.
ReSuLTS
In vitro, β-TCP/Matrigel combinations robustly maintained proliferation, osteogenic 
differentiation, and matrix remodeling capacities of MSCs and maintenance of HSPCs function 
over time. In vivo, scaffolds promoted strong and robust recruitment of hematopoietic cells 
to sites of ectopic transplantation, vascularization, and soft tissue formation.
CoNCLuSIoNS
Our tissue-engineered BM system is a powerful tool to explore the regulatory mechanisms 
of hematopoietic stem and progenitor cells for a better understanding of hematopoiesis in 
health and disease.
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INTRoDuCTIoN 
The different components of the bone marrow (BM) microenvironment—consisting of 
(a) hematopoietic cells, (b) stromal cells and vasculature, (c) extracellular matrix, and (d) 
bone—are critical to explore for a better understanding of hematopoiesis during health and 
disease. These components are often inaccessible for controlled and rapid experimentation, 
thus limiting studies to the evaluation of conventional cell culture and transgenic animal 
models. The rationale to develop ectopic transplantable BM niches arises from the need 
to dissect regulatory mechanisms in the BM and the hematopoietic-stroma interaction. 
So far, no gold standard exists to specifically analyze the role of the BM stroma in vivo 
or to genetically modify stroma in its natural environment as stroma is not sufficiently 
transplantable in contrast to hematopoietic cells [1, 2].
Few approaches including in vivo imaging [3, 4], the design of three-dimensional (3D) 
environments using biomaterials [5, 6, 7, 8, 9, 10], and BM-on-a-chip [11] for the study of 
hematopoiesis have been introduced to date, but these system lack full BM recreation, as 
hematopoietic stem and progenitor cell (HSPC) interaction with the endosteal niche or with 
the supporting stroma is compromised or simply the geometry beneficial for a controlled 
manipulation is still missing.
Bioceramics such as β-tricalcium phosphate (β-TCP) are particularly interesting for bone 
tissue engineering as they provide characteristics for cellular interactions while ensuring 
superior biomechanical properties [12]. Matrigel is a basement membrane protein mixture 
typically used in vivo to stimulate tissue formation. [8]. Here, we combined 3D β-TCP 
scaffolds with defined and controlled geometry (bone component) with an extracellular 
matrix component composed of either collagen I/III or Matrigel (matrix component) to 
establish co-cultures of HSPCs and mesenchymal stromal cells (MSCs) (cellular component). 
The ultimate goal of the current study is to create artificial, transplantable BM niches that 
support hematopoiesis while allowing for the genetic modification of both hematopoietic 
and mesenchymal cells as to dissect their interaction.
MeThoDS
β-TCP scaffolds
β-TCP scaffolds were fabricated using slip casting into 3D-printed wax molds. First, two 
virtual models were constructed using computer-aided design (3-matic, Materialise, 
Leuven, Belgium). The models had a cylindrical shape with an inner diameter of 9.6 mm and 
a height of 4.9 mm. A rectangular lattice with 500-μm struts was incorporated into one of 
the models. The struts had a spacing of 2 mm and were connected to the cylinder. Into the 
second virtual model, a lattice with 800-μm struts (spacing 2.5 mm) was incorporated in the 
An engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at 
ectopic transplantation sites
124
same way. Finally, a sprue with a diameter of 9.6 mm and a height of 2.1 mm was added 
on one side of the cylinders. Both models were printed using a 3D wax printer (T76®PLUS, 
Solidscape, Idar-Oberstein, Germany) to generate the wax molds for the slip casting process. 
A suspension consisting of 68.7 wt% β-TCP, 29.3 wt% distilled water, and 2 wt% organic 
additives (0.2 wt% Contraspun, 1.4 wt% Optapix, 0.4 wt% Dolapix, Zschimmer und Schwarz, 
Lahnstein, Germany) was synthesized. The suspension was homogenized for 30 s using a 
SpeedMixerTM, (DAC 150.1 FVZ, Hauschild, Hamm, Germany) at a mixing rate of 3000 rpm. 
Afterwards, the suspension was filled with a pipette into the wax molds. The filled molds 
were devolatilized in a desiccator, and the suspension within was dried for 24 h at room 
temperature. The sprue was cut off with a scalpel until the ends of the vertical wax struts 
were exposed. The samples were heat treated for 30 min at 105 °C to melt out the wax 
(heating rate 2.5 K/min) and subsequently sintered for 3 h at 1200 °C (heating rate 3 K/min). 
The generated β-TCP scaffolds were cleaned in an ultrasound bath to remove particulate 
matter and dried at 80 °C for 24 h. Finally, the scaffolds were sterilized by autoclaving and 
dried at 80 °C for 24 h before they were used for cell culture.
Collagen I/III gels and Matrigel®
Collagen I/III were produced as previously described [13–16], and human mesenchymal 
stromal cells (hMSCs) or murine BM-derived mesenchymal stem cells (mBMSCs) were 
seeded at a density of 1 × 106 cells/mL. Matrigel® basement membrane matrix complex 
(BD Biosciences, 354234) was handled according to the manufacturer’s instructions, and 
mBMSCs were seeded at a density of 1 × 106 cells/mL. Two hundred microliters of either 
collagen I/III gel or Matrigel® was combined with each one β-TCP scaffold. Gel polymerization 
was achieved by 1-h incubation at 37 °C in a 20 %-O2/5 %-CO2-humidified atmosphere.
Isolation and culture of hMSCs
MSCs from human femoral head spongiosa were collected after hip replacement surgeries 
and followed approved guidelines of the Ethics Committee of RWTH Aachen University. 
Cell isolation was performed according to previously described protocols [13–16]. For all 
experiments, hMSCs were passaged between 2–4 times before use. hMSCs were seeded on 
the β-TCP scaffolds at a density of ca. 1.5 × 105 cells/scaffold. Osteogenic differentiation was 
performed according to published protocols [8, 14].
Isolation and culture of human CD34+ progenitors
CD34+ progenitors were obtained by immunomagnetic bead selection (Miltenyi Biotec, 
Bergisch-Gladbach, Germany) from human umbilical cord blood units collected according 
to the guidelines of the Ethics Committee of RWTH Aachen University (EK187/08). CD34+ 
progenitors were cultured in StemSpan serum-free medium in the presence of SCF (50 ng), 
TPO (20 ng), Flt3-L (50 ng), and IL-6 (10 ng, all Peprotech, London, UK) as before [7, 8].
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Isolation and culture of mBMSCs
mBMSCs were isolated from BM aspirates of 6–8-week-old C57BL/6 mice by mechanical 
crushing and collagenase treatment to liberate the stromal cells from the endosteal bone as 
described before [17]. Cells from six pooled mice were used for each experiment. mBMSCs 
were expanded in DMEM/F-12 with Glutamax™ (Life Technologies) supplemented with 
1 nM dexamethasone (Sigma, Steinheim, Germany), 1 ng/mL fibroblast growth factor-2 
(Peprotech, London, UK), 5 ng/mL epidermal growth factor (Peprotech), 2 % fetal calf serum 
(PAN Biotech), and 2 % penicillin/streptomycin (Life Technologies). mBMSCs were used 
between passages 2–4 for seeding.
Isolation and culture of murine c-kit+ cells
The hematopoietic cell fraction was collected by mechanical crushing/flushing of long bones 
and the pelvis, and c-kit+ cells were isolated by immunomagnetic bead selection using 
mouse CD117 (c-kit) microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany). Purity 
was confirmed by flow cytometry. Freshly isolated c-kit+ cells were used for co-cultures at 
ca. 1.5 × 105 cells/well and maintained in StemSpan serum-free expansion medium (SFEM) 
(Stem Cell Technologies Inc., Vancouver, Canada) containing 50 ng/mL stem cell factor 
(Peprotech), 50 ng/mL thrombopoietin (Peprotech), and 1 % penicillin/streptomycin (Life 
Technologies).
Culture conditions in β-TCP scaffolds
β-TCP scaffolds were transferred to 48-well tissue culture plates (Corning, Wiesbaden, 
Germany), and hMSCs embedded in the collagen I/III gels or directly seeded on the β-TCP 
scaffolds were kept in culture for 8 weeks. mBMSCs embedded in gels were pre-expanded 
for 1 week, and c-kit+ cells were seeded and co-cultures kept at 37 °C in a 20 %-O2/5 %-CO2-
humidified atmosphere. Cells were recovered by vigorous pipetting and subsequent gel 
digestion using collagenase II (Life Technologies) for collagen I/III gels and dispase II (Life 
Technologies) for Matrigel® gels.
Flow cytometry
For analysis of maintenance of primitive phenotype in the human setting, 5-day cultured 
CD34+-isolated cells co-cultured with hMSCs for 5 days in β-TCP scaffolds with or without 
matrix component were assessed for the combined expression of CD34-FITC and CD38-
PE (Miltenyi Biotec). For analysis of primitive phenotype and differentiation ability in the 
murine setting, c-kit+ cells from in vitro co-cultures were recovered at days 4, 7, 10, 14, 
and 18. In the in vivo setup, cells were recovered from explanted scaffolds 4 and 8 weeks 
after transplantation. Antibodies CD117-allophycocyanin, Sca1-phycoerythrin, lineages 
(CD3, CD5, B220, G1, CD11b, Ter119)-eFluor®450, Gr-1-allophycocyanin-cyanine7, CD11b-
allophycocyanin, CD19-phycoerythrin-cyanine7, CD3-phycoerythrin, and Ter119-peridinin 
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chlorophyll-cyanine5.5 (all eBiosciences, Frankfurt, Germany) were used at 1:100, except 
for lineage antibodies used at 1:200 as recommended, in PBS/1 %-FCS for 30 min at 4 °C. 
A minimum of 100,000 events were acquired on a FACSCantoII flow cytometer (Becton 
Dickinson). Data were further analyzed using FlowJo (Tree Star Inc., Ashland, USA).
Methylcellulose colony assays
C-kit+ cells derived from 4-day or 14-day cultures were plated at 1 × 105 cells per 35-mm 
petri dish in duplicates of serum-free methylcellulose medium (MethoCult GF M3434, Stem 
Cell Technologies Inc., Vancouver, Canada). After 12 days of incubation at 37 °C and 5 % 
CO2 in a humidified atmosphere, colonies were scored using an inverted light microscope 
(Leica, Wetzlar, Germany). Colony-forming unit granulocyte-macrophages (CFU-GM) and 
colony-forming unit granulocyte-erythrocyte-macrophage-megakaryocyte (CFU-GEMM) 
were assayed according to morphological criteria.
SeM and FeSeM in cryo-mode
β-TCP scaffolds from in vitro cultures and in vivo explantations were prepared for scanning 
electron microscopy (SEM) by fixation in 3 % glutaraldehyde for at least 24 h at 4 °C. A 
graded ethanol series of 30, 50, 70, 90, and 100 % followed for sample dehydration. Sample 
preservation was achieved by hexamethyldisilizane (HMDS) drying. Before gold sputtering 
and fixation on SEM stubs, scaffolds were sectioned one time longitudinal and orientated 
in the cross-sectional area for visualization. A field emission SEM microscope (ESEM XL 30 
FEG, FEI, Philips, Eindhoven, The Netherlands) with a high-vacuum environment was used.
For a more detailed analysis of gel structure, field emission scanning electron 
microscopy (FESEM) in cryo-mode was performed for collagen I/III and Matrigel®. Gels 
were rapidly frozen in liquid nitrogen and transferred to the high-vacuum Balzers BF freeze-
etching chamber of a FESEM instrument in cryo-mode (HITACHI S-4800, Hitachi, Tokyo, 
Japan) with secondary electron image resolution of 1.0–1.4 nm at voltages of 1–15 kV. Gels 
were sublimated for 1 h at 80 °C before image acquisition.
TeM
Freshly isolated, 4- and 14-day cultured c-kit+ cells were recovered from the scaffolds as 
already described, pelleted and fixed in 3 % glutaraldehyde, and processed for transmission 
electron microscopy (TEM) as described previously [13]. Cells were visualized using a 
transmission electron microscope at 60 kV (EM 400 T, Philips, Eindhoven, The Netherlands).
IhC
At the indicated time points, culture medium was removed and samples fixed in 10 % 
formalin for at least 24 h at 4 °C. Scaffolds were decalcified using EDTA for 48 h, sectioned, 
ethanol fixed and embedded in paraffin according to the standard protocols of the Institute 
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of Pathology, University Hospital Aachen. Paraffin sections of 3 μm were deparaffinized, 
hydrated using decreasing ethanol series and subject to heat-induced antigen retrieval 
using citrate buffer pH = 6.0. Immunohistochemistry stainings were performed using 
an Autostainer platform for immunohistochemistry (IHC) (Dako Cytomation). Primary 
antibodies used were specific for CD31 (1:100, rabbit polyclonal, Abcam), CD45(1:100, 
rabbit polyclonal, Abcam). Primary antibodies were diluted in Dako antibody diluent and 
incubated for 1 hour at room temperature. StreptABC complex/HRP followed by DAB for 
color development was used according to the Dako real detection system instructions 
(Dako Cytomation, K5001). Reticulin stain and hematoxilin-eosin stains were additionally 
performed according to routine histology protocols.
RT-qPCR
Isolation of total RNA from cultures was done with Tripure Isolation Reagent (Roche, 
Mannheim, Germany) [13, 14]. In brief, a high-capacity cDNA Reverse Transcriptase Kit 
(Applied Biosystems, Darmstadt, Germany) was used for RNA reverse transcription product 
amplification that was done using a 7300 Real-Time PCR System and SYBR green (Applied 
Biosystems, Darmstadt, Germany) running an amplification cycle consisting of 10-min 
denaturation at 95 °C, additional 40 cycles of denaturation at 95 °C for 15 s, and final extension 
of 1 min at 60 °C. The housekeeping gene GAPDH was used for normalization of data. 
Gene expression on collagen I/III gel controls was set to one using the 2−∆∆ct method [8]. 
Calcium and phosphate assays
Calcium and phosphate content of culture supernatants was measured at weeks 1, 2, and 
3 after cell seeding using a standard autoanalyzer. Alternatively, a commercially available 
colorimetric-based calcium assay kit (RANDOX, Crumlin, UK) was used to determine the 
amount of calcium released from the β-TCP scaffolds. The assay was carried out according 
to the manufacturer’s instructions and absorbance measured at 578 nm using an Infinite® 
M200 microplate reader (Tecan, Männedorf, Switzerland).
Mouse transplantations
Six- to eight-week-old C57BL/6 mice were obtained from Jackson Laboratories (Maine, 
USA). Animals were kept at the Animal Research Facility Children’s Hospital, Harvard 
Medical School, Boston, USA. Animals were handled according to institutional regulations 
and transplantations done according to standard protocols (mouse protocol number 13-04-
2393R). mBMSCs were expanded in vitro for 1 week and then seeded on 500- and 800-μm 
β-TCP scaffolds in combination with collagen I/III or Matrigel®. Cell/matrix/scaffold hybrids 
were transplanted subcutaneously into the C57BL/6 mice.
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Statistical analysis
Data presented was obtained from at least three independent donors. Results express 
mean ± SD, unless stated otherwise. Statistics as well as graphical representations were 
performed using GraphPad PrismTM 5.0 (GraphPad Software Inc., San Diego, USA). Statistical 
significance of data results from one-way ANOVA followed by Tukey’s post hoc test (analysis 
of three or more groups). Significant differences were considered when p < 0.05.
ReSuLTS
β-TCP scaffold characterization
We first characterized the 3D porous β-TCP scaffolds, which were designed to mimic the 
spongious, structural part of the bone in terms of (i) osteoconductivity (porosity allowing 
for cell penetration and/or attachment and growth), (ii) osteogenicity (local osteoblastic 
mineral formation allowing for matrix calcification) [18], (iii) transplantability, (iv) inertness, 
and (v) hematopoiesis-supporting capacities. As pore size is known to affect cell attachment, 
proliferation, and migration [19], we tested the biological performance of β-TCP scaffolds 
with two different pore sizes—500 and 800 μm in diameter—similar to the geometry of 
the human bone and as used for replacement strategies [20, 21]. We applied scaffolds with 
500- and 800-μm pore sizes in order to (a) simulate human bone properties, (b) maximize 
the surface area and volume available for stromal cell expansion, and (c) support bone 
ingrowth. As the literature reports strongly variable pore sizes ranging from 300 to 900 μm 
to be optimal, we analyzed if pore size matters for the recapitulation of extramedullary 
niches containing two cell types—adhering stromal cells and hematopoietic stem and 
progenitor cells [22].
β-TCP scaffolds were generated with interconnected macropore geometries for better 
cell growth, migration, and nutrient flow (Fig. 1a–g). The porosity of 500- and 800-μm 
scaffold was 14 and 17 vol.-%, respectively (Fig. 1e), comparable to the porosity of human 
cortical bone that is known to go from up to 8 % in young individuals to 24–28 % in elderly 
individuals [23, 24]. Maximized 500/800-μm scaffold magnitudes were provided for 3D 
culture including a surface area of 648/584 mm2 for stromal cell expansion and a volume of 
51/60 mm3 for HSPC expansion.
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Figure 1: Characterization of β-TCP scaffolds. a Negative mold used for wax casting during production of the 
different β-TCP scaffold geometries. b Macroscopic view of the β-TCP scaffolds. c SEM view of the β-TCP scaffolds. 
d Schematic illustration of the long-term cultures consisting of three main components: mesenchymal stromal cells 
(MSCs; pink), β-TCP (blue), and collagen I/III (green). e Table of porosites. f Cell morphology and cell spreading 
on scaffolds analyzed by SEM. g Release of calcium (Ca2+) and phosphate (PO4 3−) to the culture supernatant. 
Concentrations were measured in the supernatants of β-TCP cultures at days 3, 11, and 21 after the beginning of 
the culture. Concentrations were normalized to 1 at day 3 and are presented in mmol/L. Results depict mean ± SD 
of three independent experiments
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For scaffold characterization experiments, we seeded hMSCs onto 500- and 800-
μm β-TCP in the presence or absence of collagen I/III (Fig. 1c, d, f). We first assessed the 
inertness of β-TCP scaffolds indicated by release of Ca2+ and PO43− in culture supernatants 
after 3, 11, and 21 days of culture (Fig. 1g). Analysis confirmed a minor increase in Ca2+ 
concentration in the culture medium of β-TCP-containing scaffolds, ca. 0.1 mmol/L for 
500- or 800-μm β-TCP scaffolds. The PO43− concentration (Fig. 1g) increased over time 
in all β-TCP-containing supernatants (increase of 0.2–0.4 mmol/L) within ranges that are 
negligible and cannot be considered as indicators of spontaneous osteogenesis.
assessment of the β-TCP scaffold potential for osteogenic differentiation
To determine if β-TCP induces a spontaneous osteogenic differentiation, we next analyzed 
the effect of β-TCP and collagen I/III on hMSC growth, osteogenic differentiation, and matrix 
production assessed by gene expression (Fig. 2). β-TCP scaffolds had good osteoconductivity 
as indicated by hMSC attachment, migration, and survival in the interconnected macropores 
of β-TCP scaffolds (Fig. 1f).
To analyze if the scaffold induced a spontaneous osteogenic differentiation of hMSCs, 
we seeded hMSCs in direct contact to 500/800-μm β-TCP scaffolds (Fig. 2). To dissect the 
additional effect of an extracellular matrix, we compared the spontaneous differentiation 
potential side-by-side to β-TCP/collagen I/III scaffolds and looked at hMSCs subjected to 
standard osteogenic differentiation protocols as a positive control (Fig. 2). BMP-2 and RUNX2 
as early markers of osteogenic differentiation as well as the late marker osteopontin were 
not significantly up-regulated after 3 weeks of culture under nearly all β-TCP conditions, 
independent of the presence of collagen I/III gels (not shown). After 8 weeks of culture, the 
induction of early and late markers was maintained for cells cultured in β-TCP scaffolds in 
the absence of collagen I/III gels and decreased in the presence of collagen I/III gels (Fig. 2). 
This effect might be due to significant matrix remodeling that occurs in the presence of 
collagen I/III-containing scaffolds as indicated by the up-regulation of collagen I, fibronectin, 
laminin, and collagen IV in 8-week cultures (Fig. 2). Taken together, gene expression analysis 
provides no evidence for spontaneous osteogenesis upon in vitro culture or co-culture of 
hMSCs.
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Figure 2: Osteogenic marker and extracellular matrix expression analysis of long-term MSC cultures on β-TCP 
scaffolds. The osteogenic markers BMP-2, RUNX2, and OPN as well as the extracellular matrix proteins collagen I, 
fibronectin, collagen IV, and laminin were analyzed after 8 weeks in culture. Data were calibrated relative to MSCs 
growing in collagen I/III gels, where gene expression was set to 1 for all genes. GAPDH was used as a housekeeping 
gene for normalization. Gene expression is presented as mean ± SD of three independent experiments and 
depicted on a logarithmic scale
Characterization of the β-TCP/matrix hybrids as extramedullary hematopoietic niches 
in vitro
We aimed to generate transplantable extramedullary hematopoietic niches and next 
analyzed the effect of β-TCP constructs on murine hematopoiesis in vitro. We combined 
500- and 800-μm β-TCP scaffolds with either collagen I/III [8] or Matrigel® to improve cell 
engraftment and proliferation [25]. mBMSCs were cultured for 1 week on β-TCP scaffolds 
(with and without collagen I/III) before freshly isolated c-kit+ HSPCs from murine BM were 
added. In order to decide on the optimal combination of extracellular matrix and β-TCP pore 
size for future transplantation experiments, we assessed (i) viability, (ii) maintenance of a 
primitive HSPC phenotype and lineage differentiation, (iii) proliferation, and (iv) extracellular 
matrix remodeling.
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Maintenance of the primitive hematopoietic stem and progenitor cell phenotype was 
monitored after 5 and 12 days for the human setting and 4, 7, and 14 days for the murine 
setting (Fig. 3a–c). Murine hematopoietic stem cells can be characterized in the bone 
marrow by being lineage-marker negative, c-kit+ and Sca1+ (LSK population; lin−Sca1+c-
kit+), while hematopoietic progenitor cells are lineage-marker negative, Sca1− and c-kit+ 
(LK population; lin−Sca1−c-kit+). After 14 days, the viability in the β-TCP scaffolds alone or 
in combination with Matrigel® was independent of the pore size (Fig. 3a). The presence of 
a collagen matrix reduced the cell viability, probably due to significant matrix remodeling, 
as discussed before. The stromal cells in the collagen scaffolds can be characterized as lin−
Sca1+c-kit−. We quantified the percentage of lin−Sca1+c-kit− stromal cells at day 4 and 
monitored their increase/decrease over time (Fig. 3b, c). In particular, 500-μm scaffolds had 
a positive effect on stromal cell expansion. We next assessed the maintenance of the LSK 
and LK phenotypes in vitro. Our results showed that β-TCP/extracellular matrix hybrids more 
robustly maintained a phenotypical LSK fraction over time compared to β-TCP alone. C-kit+ 
expression was shown to decrease over time in vitro independent of the hematopoietic stem 
and progenitor phenotype [26]. We thus quantified lineage-negative cells in the scaffolds 
over time as this population is enriched in hematopoietic stem and progenitor cells. The 
presence of 500-μm scaffolds showed a relative expansion of lineage-negative cells while 
this population maintained stable in the other conditions. We confirmed these results by 
using human HSPCs. In humans, the subset of CD34+CD38− HSPCs corresponds to a more 
primitive phenotype. Our data in short-term co-cultures showed that CD34+CD38− HSPCs 
were maintained most sufficiently in β-TCP scaffold containing collagen I/III, comparable to 
our results in the murine system
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Figure 3: Hematopoietic stem cell characterization in β-TCP scaffolds in vitro. C-kit+ cells were subjected to the 
different β-TCP/matrix hybrids over 14 days in vitro. a Percentage of DAPI−-viable cells after 14 days of c-kit+ cell 
culture with and without collagen I/III/Matrigel® on β-TCP scaffolds in the presence of MSC support. b Expansion/
decrease of lin−Sca1+c-kit− stromal cells normalized to day 4 of the culture. c Expansion/decrease of lin− normalized 
to day 4 of the culture. Mean ± SD of three independent experiments. d Colony-forming potential of cells isolated 
from 500- and 800-μm β-TCP scaffolds with and without collagen I/III/Matrigel® in the presence of MSC support 
at day 4 and day 14. Results are mean ± SD of three independent experiments. CFU colony-forming unit, GEMM 
granulocyte-erythrocyte-macrophage-megakaryocyte, GM granulocyte-monocyte.  without.
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Figure 4: Analysis of trilineage differentiation of c-kit+ HSPCs on β-TCP scaffolds in vitro. a Differentiation potential 
of c-kit+ cells cultured for 4 and 14 days on β-TCP scaffolds with and without collagen I/III gel/Matrigel® in the 
presence of MSC support: granulocytes (Gr1+CD11b+), monocytes (Gr1−CD11b), erythroid precursor cells (Gr1−
CD11b−CD3−CD19−), and T cells (Gr1−CD11b−CD3+). Percentage of viable cells is shown as mean ± SD of three 
independent experiments. b SEM of c-kit+ cells cultured on 500-μm β-TCP/Matrigel® scaffolds. Very left column 
highlights cell spreading and detailed cell morphology of day 4 and day 14 cultures. C-kit+-derived cells (red arrows) 
are in close contact to MSCs (white arrows). Cell extensions at day 4 in detail (green arrow). View from the interior 
of the β-TCP macropores at day 14 (asterisk)
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In order to evaluate not only the HSPC phenotype but also their function among 
the different scaffold combinations as the ultimate readout for the maintenance of 
hematopoietic stem cell capacities, we performed colony-forming assays at day 4 and 
day 14 (Fig. 3d). Our data showed that murine cells cultured on β-TCP scaffolds alone for 
4 days had significantly impaired CFU potential and HSPC function compared to all the 
other conditions. The presence of Matrigel® alone resulted in the significantly highest total 
number of colonies, and the combination of β-TCP/Matrigel® led to the highest number of 
CFU-GEMM colonies, representing multipotent myeloid progenitor cells. As expected, the 
CFU potential globally decreased after 14 days, but HSPCs cultured in the combination of 
β-TCP/Matrigel® scaffolds (p < 0.001 compared to 500-μm β-TCP and p < 0.002 compared 
to 800-μm β-TCP) gave rise to the significantly highest number of colonies, in particular to 
primitive CFU-GEMM colonies, indicating that the function of HSPCs was maintained under 
these conditions.
We next analyzed the lineage differentiation potential and asked whether or not 
scaffold combinations induce a lineage bias (Fig. 4a; Additional file 5: Figure S4). We analyzed 
granulocytes (Gr1+CD11b+), monocytes (Gr1−CD11b+), B-cells (Gr1−CD11b−CD19+), T cells 
(Gr1−CD11b−CD3+), and erythroid cells (Gr1−CD11b−CD3−CD19−) in the murine in vitro 
culture system at day 4 and day 14. All culture conditions induced myeloid differentiation 
into granulocytes and monocytes. The frequency of granulocytes decreased in tendency 
over the culture of 14 days, while the frequency of monocytes increased. After 14 days, the 
presence of Matrigel® in 500 and 800 μm significantly stimulated monocyte differentiation 
as compared to β-TCP scaffolds alone. We also detected both lymphoid (mainly T cells) and 
erythroid differentiation in all culture conditions, indicating that the scaffold-matrix hybrids 
support both trilineage differentiation as well as maintenance of primitive, functional HSPCs.
Next, we dissected the spatial distribution of human CD34+ HSPCs and murine c-kit+ 
cells in β-TCP/matrix hybrids combinations (Fig. 4b). HSPCs growing on β-TCP/Matrigel® 
were spread on top of the scaffolds as single cells or in close proximity to mBMSCs (Fig. 4b) 
or growing inside scaffold pores attached to the Matrigel® surface (Fig. 4b). After 14 days, 
the cell density was significantly increased but cells were predominantly positioned on top 
of the scaffolds/Matrigel, indicating that Matrigel does not support the migration of HSPCs 
due to high density and overall low porosity. This hypothesis was supported by imaging 
using SEM in cryo-mode. The Matrigel® porosity—as a result of the gelation process—was 
higher at the top part of the gel and lower at the bottom, a limitation which eventually led 
to the rare cell migration into the Matrigel®. Collagen I/III gels showed high cell densities on 
top as well as significant migration of hematopoietic cells inside the gel and cells growing in 
close proximity to mBMSCs and collagen fibers. Similarly, the addition of β-TCP to collagen 
I/III gels supported cell proliferation as well as migration both in the murine and human 
settings. In β-TCP scaffolds, the cell proliferation and density appeared significantly impaired 
despite the presence of a robust mBMSC layer covering the β-TCP surfaces. This leads to 
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the suggestion that β-TCP scaffolds are supportive of the growth of mBMSCs but that 
hematopoietic cells require an additional matrix structure.
Characterization of the β-TCP/matrix hybrids as extramedullary hematopoietic niches 
in vivo
To test the capacity of β-TCP scaffolds for supporting recruitment of hematopoietic cells 
and extramedullary hematopoiesis, 500- and 800-μm β-TCP scaffolds pre-seeded with 
mBMSCs were transplanted subcutaneously into C57BL/6 mice in the presence and absence 
of collagen I/III or Matrigel®. Hematopoiesis in the explanted scaffolds was evaluated 4 and 
8 weeks after transplantation by flow cytometry, immunohistochemistry, and SEM (Figs. 5 
and 6).
We performed H&E staining (Fig. 5a, b) in order to analyze the tissue and cell organization 
within the scaffolds. Histomorphological overviews in low magnification demonstrated that 
all scaffold pores—both in the periphery and in the central areas—were composed of a 
strongly vascularized extracellular matrix, partially adipose tissue, prominent histocyte-like 
cells aligning the β-TCP surface, and accumulations of hematopoietic cells in close proximity 
to vessels and the β-TCP surface (Fig. 5a). Higher magnification demonstrated dense clusters 
of hematopoietic cells in particular at the scaffold/matrix interface (Fig. 5b).
CD31 immunohistochemistry confirmed a dense vascular network in the scaffold, 
an important requisite for successful long-term engraft of scaffolds and recruitment of 
hematopoietic cells (Fig. 5c). CD31-positive cells were also seen at the β-TCP/tissue interface. 
CD45 staining highlighted the spatial organization of hematopoietic cells in dense clusters 
in proximity to both the vasculature and the scaffold interfaces (Fig. 5c). As observed in 
vitro, the β-TCP surface seeded with mBMSCs appears to provide appropriate conditions 
for the development of a bone-like niche, as we also noted the presence of multinucleated 
osteoclasts and osteoblasts. The presence of osteoclasts was confirmed by SEM showing 
spindle-shaped cells with brush-like microvilli (Fig. 5d).
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Figure 5: Histomorphology. 500μm or 800 μm β-TCP scaffolds were pre-seeded with mBMSC in the presence or 
absence of Matrigel®. Scaffolds were transplanted subcutaneously into C57B1/6 mice and analyzed for hematopoietic 
cell recruitment to sites of extramedullar hematopoiesis and hematopoietic tissue formation after 4 and 8 weeks. 
a Hematoxilin-eosin (HE) staining of the explanted scaffolds 8 weeks after transplantations. Magnification 100x. b 
Higher magnification of the explanted scaffolds after 8 weeks. Magnification 200x. c Immunohistochemistry for 
the endothelial surface marker CD31 and the pan-hematopoietic marker CD45 in explanted scaffolds 8 weeks after 
transplantation. d HE staining and by SEM for the identification of osteoclasts at the border of the β-TCP scaffold 
macropores in explants 4 weeks after transplantation.
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Figure 6: a SEM imaging ft he explanted scaffolds 4 weeks after transplantation. White arrows: erythrocytes; 
black arrows: T cells; red arrows: thrombocytes; gray arrow: neutrophils/granulocytes; asterisk: β-TCP. b-c Gating 
strategy ft he flow cytometry: Hematopoietic stem (LSK) and progenitor cells (LK) were identified by being negative 
for lineage markers and by the expression of Sca1 and c-kit. Lineages were identified by the following stainings: 
granulocytes (Gr1+CD11b+), monocytes (Gr1−CD11b−), erythroid precursor cells (Gr1−CD11b−CD3−CD19−), T cells 
(Gr1−CD11b−CD3+), B cells (Gr1−CD11b−CD19+). d Flow cytometry analysis ft he explanted scaffolds 4 weeks after 
transplantations. Surface marker expression is shown as a percentage ft he viable cell population; mean ± SD of 
three independent experiments.
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We next sought to characterize the identity of hematopoietic cells (Fig. 6a–d). All 
β-TCP/matrix hybrid combinations were able to recruit hematopoietic cells to the site of 
transplantation as SEM confirmed hematopoietic cells inside the pores of the transplanted 
scaffolds (Fig. 6a).
Our first question was whether the implanted scaffolds promote extramedullary 
hematopoiesis including the presence of hematopoietic stem and progenitor cells. 
Flow cytometry confirmed the presence of cells of all hematopoietic lineages: myeloid 
(CD11b+Gr1+), lymphoid (Gr1−CD11b−CD19+ or CD3+), and erythroid (Gr1−CD11b−CD19−
CD3− Ter119+) lineages (Fig. 6c, d). We did not detect an HSC-enriched LSK population 
but hematopoietic progenitor cells as indicated by the presence of lineage-negative and 
also myeloid progenitor cells (LK population). These data indicate that the majority of 
hematopoietic cells were recruited to the site of transplantation and do not represent 
in situ, extramedullary hematopoiesis. We did not observe significant differences in the 
recruitment of cell lineages in the different culture conditions, demonstrating that all 
conditions are suitable for ectopic transplantation independently of β-TCP pore size or 
presence of extracellular matrix. Discussion
 
DISCuSSIoN
The BM microenvironment is not transplantable making it challenging to dissect the 
regulatory mechanisms within the BM niche. We envisioned a widely available, easy 
reproducible, simple, and well-defined system for the creation of a transplantable 
human BM microenvironment. Establishing such a system would include not only a 
detailed characterization of the hematopoietic and mesenchymal fractions upon culture/
transplantation but also the design of an appropriate scaffold material and structure. For 
the co-culture of HSPCs and mBMSCs/hMSCs, we applied β-TCP-printed scaffolds containing 
macro- and micropores similar to the bone—of inorganic (hydroxyapatite mineral) 
composition—in combination with an extracellular matrix gel—of organic (collagen type I 
matrix) composition.
As β-TCP materials are unstable when exposed to body fluids due to their small granule 
size, porosity, and higher dissolution rate compared to other types of bioceramics [27], 
we first set up to analyze the effects of β-TCP dissolution on the cultured cells. Typically 
high phosphate levels induce osteogenic differentiation, so we asked whether or not β-TCP 
scaffolds in our setting induced spontaneous osteogenic differentiation of MSCs by Ca/P 
release to the culture media. Our analysis revealed negligible Ca/P release and the exclusion 
of the possibility for spontaneous MSC-derived osteogenesis that could be detrimental 
for hematopoietic production. Importantly, we showed that our β-TCP scaffolds have the 
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ability to support MSC growth and extracellular matrix production in cultures up to 8 weeks 
without limiting effects.
Our in vitro data suggest that complete hematopoiesis is promoted by β-TCP scaffolds 
in combination with structural proteins and cytokines provided by Matrigel®. First, β-TCP/
Matrigel® scaffolds more robustly maintained a primitive LSK fraction over time, with the 
Matrigel® component being responsible for maintenance of HSPCs within the scaffolds. 
Second, hematopoietic differentiation in both myeloid and lymphoid lineages was supported 
after 14 days in Matrigel®-containing conditions. Third, the CFU potential of β-TCP/Matrigel® 
scaffolds was significantly increased compared to other conditions implicating that Matrigel 
supports both the functional maintenance of HSPCs and their differentiation capacity. 
Fourth, β-TCP/Matrigel® scaffolds supported the remodeling of the ECM as an important 
requisite for cell differentiation and growth.
In vivo, β-TCP/Matrigel® scaffolds resulted in strong hematopoietic recruitment to the 
sites of the ectopic transplantations as confirmed by the detection of myeloid and lymphoid 
fractions 4 weeks after transplantations at levels comparable to the relative composition 
of the BM. Multinucleated osteoclasts and typically spindle-shaped osteoblasts were seen 
at the β-TCP scaffold/ECM interface. CD31-positive layers of recruited endothelial cells and 
adipose cells, typical for vascular niches, were both identified in explants showing the most 
efficient collagen matrix deposition. Adipose cells were regarded as simple as BM fillers 
but are now known to be negative regulators of the hematopoietic microenvironment [28]. 
BM tissue formation in our setting was mainly promoted by Matrigel®, a biodegradable 
basement membrane protein extracted from Engelbreth-Holm-Swarm sarcoma mouse 
cells, typically used to recreate 3D environments stimulating tissue formation. The main 
components of Matrigel® are known to be structural proteins laminin, collagen IV, and 
enactin, but numerous other intracellular proteins are present. Around 1300 proteins (either 
cytoplasmatic or nuclear) were identified in Matrigel® composition, and among those were 
collagen IV; actin; spectrin; tubulin; dynactin; filamin structural proteins like fibronectin, 
dynein, desmin, myosin, transferrin; and intracellular proteins such as adenylate kinase 
and heat shock family members [29]. Additionally, specific growth and transcription factors 
such as kruppel-like factor 6, kruppel-like factor 15, and connective tissue growth factor 
were identified. Future studies will be necessary to dissect which of these factors are most 
important to support both hematopoiesis and osteogenesis to generate more defined 
environments.
Our study demonstrates that varying pore sizes of the β-TCP scaffolds from 500 to 
800 μm was irrelevant in terms of hematopoietic support function. This is an interesting 
finding as particle geometry, porosity, pore size distribution, and scaffold continuity are 
properties known to determine cell/scaffold interactions and thus cell fate [20, 30, 31]. 
Pore size, however, has been only considered crucial within three main pore size intervals. 
According to Petite et al., pore sizes smaller than 15–50 μm result in fibrovascular growth, 
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medium-sized pores of 50–150 μm encourage osteogenesis, while pores larger than 150 μm 
support the ingrowth of mineralized bone [20]. Contradicting studies even report that bone 
ingrowth is optimal for pore sizes varying from 300 to 900 μm [22].
The β-TCP scaffolds applied in our study had an interconnected net-like structure in 
the absence of dead-end pockets, macropores with mean pore size 500 or 800 μm, and 
micropores smaller than 15 μm. Our scaffolds were designed to maximize the surface area 
for stromal cell expansion, and we were able to demonstrate that these characteristics 
successfully promote vascular ingrowth as well as promotion of hematopoiesis.
Our engineered bone marrow has the potential to be applied for drug discovery studies 
and leukemia therapy as well as stem cell transplantation research [32, 33].
CoNCLuSIoNS
We introduce a multicomponent system that is optimal for the study of hematopoietic-
mesenchymal interactions and the recapitulation of the native BM microenvironment in a 
transplantable mouse model. Macro- and microporous β-TCP scaffolds in combination with 
a Matrigel®-based component optimally supported hematopoiesis, including hematopoietic 
recruitment, proliferation, and differentiation as well as ECM remodeling. β-TCP/Matrigel® 
scaffolds further promoted vascularization and allowed for mature bone deposition and 
hematopoiesis—stroma interactions in subcutaneous ectopic transplantations of the BM 
niche in a murine model.
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1. SuMMaRy
The studies presented in this thesis focused on the identification of genes that play a central 
role in the pathogenesis of myelodysplastic syndromes with a deletion of the short arm (q) of 
chromosome 5, the del(5q) MDS in chapters 2-4. The overall goal of the projects was to gain 
a better understanding of how gene haploinsufficiency in (del)5q MDS leads to a clonal advan- 
tage, ineffective hematopoiesis and how haploinsufficiency can be targeted (chapter 2-4).
Heterozygous deletion of RPS14 occurs in del(5q) myelodysplastic syndrome (MDS) 
and has been linked to impaired erythropoiesis, characteristic of this disease subtype. So 
far, it was not well understood how ribosomal haploinsufficiency affects protein synthesis 
and if differentially translated proteins have a impact on the erythroid differentiation 
defect (chapter 1). We generated a murine model with conditional inactivation of Rps14 
and demonstrated a p53-dependent erythroid differentiation defect with apoptosis at the 
transition from polychromatic to orthochromatic erythroblasts resulting in age- and erythroid 
stress dependent progressive anemia, megakaryocyte dysplasia, and loss of hematopoietic 
stem cell (HSC) quiescence (chapter 2). Protein synthesis was significantly reduced in Rps14 
haploinsufficient hematopoietic stem cells and in particular in erythroid progenitor cells 
relative to wild-type cells. As assessed by quantitative proteomics, Rps14 haploinsufficient 
erythroblasts expressed higher levels of proteins involved in innate immune signaling, 
notably the heterodimeric S100 calcium-binding proteins S100a8 and S100a9 (alarmins). 
S100a8 is functionally involved in the erythroid defect caused by the Rps14 deletion, as 
addition of recombinant S100a8 was sufficient to induce a differentiation defect in wild-
type erythroid cells (phenocopy), and genetic inactivation of S100a8 expression rescued 
the erythroid differentiation defect of Rps14-haploinsufficient HSCs. Our data link Rps14 
haploinsufficiency in del(5q) MDS to activation of the innate immune system and induction 
of S100A8-S100A9 expression, leading to a p53-dependent erythroid differentiation defect. 
In future experiments I aim to focus on the role of chronic inflammation on myelodysplasia 
and on the role of monocytes and macrophages as disease-mediating, inflammatory 
bystander cells and ultimately, on how to therapeutically target this process.
A key question in the field is, which genes within the commonly deleted region (CDR) 
are necessary and sufficient for del(5q) HSC to achieve clonal dominance over normal HSC. 
Csnk1a1 haploinsufficiency conferred increased intrinsic self-renewal of HSC and nuclear 
β-Catenin accumulation (chapter 3). In striking contrast, Csnk1a1 homozygous inactivation 
is not tolerated in HSC due to activation of p53. The sensitivity of hematopoietic cells to 
Csnk1a1, β-catenin and p53 gene dosage provides a therapeutic window for targeting 
haploinsufficiency in del(5q) MDS cells. 
The finding of targeting haploinsufficiency as a vulnerability of the hematopoietic stem 
cell in del(5q) MDS was a central concept in the study described in chapter 4. Here, we 
demonstrate that lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1α) by the 
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E3 ubiquitin ligase CRL4(CRBN), resulting in CK1α degradation. Haploinsufficient expression 
sensitizes cells to lenalidomide therapy, providing a mechanistic basis for the therapeutic 
window of lenalidomide in del(5q) MDS. In future experiments I would like to test candidate 
molecules to specifically target the gene dosage effect in del(5q) HSC with limited effects on 
normal hematopoiesis, overcoming the problems of resistance to lenalidomide therapy and 
maintenance of the del(5q) MDS clone under therapy.
In the last part of the thesis (chapter 5) we aimed to create an artificial, transplantable 
BM niche that supports hematopoiesis while allowing for the genetic modification of 
both hematopoietic and mesenchymal cells as to dissect their interaction in steady state 
and under pathopyhsiological conditions (chapter 5). We established and characterized 
a multicomponent system that is optimal for the study of hematopoietic-mesenchymal 
interactions and the recapitulation of the native BM microenvironment in a transplantable 
mouse model. The combination of macro- and microporous β-TCP scaffolds and Matrigel 
optimally supports hematopoiesis, including hematopoietic recruitment, proliferation, and 
differentiation as well as ECM remodeling. In future experiments we intend to genetically 
modify stromal cells and study their impact on the HSC regulation in myeloproliferative 
neoplasms and their role in fibrotic transformation in myelofibrosis.
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2. GeNeRaL DISCuSSIoN
In this final part, the different findings described in the thesis will be placed in perspective of 
the current knowledge and their implications for a better understanding of myelodysplastic 
syndromes and targeted therapy will be discussed. 
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by 
S100a8 and S100a9
Summary of findings: Heterozygous deletion of RPS14 occurs in del(5q) myelodysplastic 
syndrome (MDS) and has been linked to impaired erythropoiesis. We generated a murine 
model with conditional inactivation of Rps14 which recapitulates the erythroid phenotype 
of del(5q) MDS. Protein synthesis was significantly reduced in Rps14 haploinsufficient cells 
relative to wild-type cells, in particular in erythroid progenitor cells. Using quantitative 
proteomics and functional experiments in erythroblasts, we identified an unexpected link 
between Rps14 haploinsufficiency in del(5q) MDS, induction of S100A8-S100A9 expression 
and the p53-dependent erythroid differentiation defect. 
2.1.1 Innate immune system and inflammation in del(5q) MDS
Overexpression of immune-related genes is reported in MDS and hyperactivation of 
immune/toll-like receptor (TLR) signaling is a feature of MDS. We showed for the first 
time a functional link between activation of the innate immune system and ineffective 
hematopoiesis by induction of S100A8 and S100A9.
The heterodimeric protein complex S100A8/S100A9 is an endogenous TLR4 ligand 
upstream of TNFa leading to NF-kB activation and secretion of pro-inflammatory cytokines 
(Ehrchen et al. 2009). Our data demonstrate that S100a8 acts upstream of Tlr4 and Tnfα 
in the Rps14 haploinsufficiency induced erythroid differentiation defect. Overactivation of 
TLRs has been implicated in HSC development, suggesting that changes in TLR expression 
and function could lead to dysregulated hematopoiesis (Maratheftis et al. 2007; Sioud 
and Floisand 2007; Boiko and Borghesi 2012). Further, overexpression or gain-of-function 
mutations in a subset of TLR4s has been described in MDS, but so far their direct functional 
effect on HSC remained elusive (Maratheftis, Andreakos et al. 2007).
MicroRNAs (miRNAs) further play a role in MDS as negative regulators of innate immune 
signaling in MDS (Starczynowski et al. 2010). miR-146a lies within chromosome 5q33.3 and 
its deletion occurs in 80% of all del(5q) MDS patients. Consistent with deletion of a single 
miR-147a allele, expression in HSC from del(5q) MDS patients is reduced by greater than 
50%. miR-146a is also down-regulated in non-del(5q) MDS patients, suggesting that other 
mechanisms may contribute to its reduced expression in MDS. Concomitant knockdown 
of miR-145 and -146a using a miRNA decoy approach in mouse HSC resulted in elevated 
platelets, neutropenia, megakaryocytic dysplasia and myeloid leukemia (Starczynowski and 
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Karsan 2010; Starczynowski, Kuchenbauer et al. 2010). MiR-146a deficient HSCs produce 
higher levels of pro-inflammatory cytokines, such a IL-6, TNFα, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and IL-1ß, in response to TLR activation. 
Of note, RPS14 and miR-145/miR-146a are universally co-deleted in the 5q- syndrome, 
and converge on TLR4 signaling (Starczynowski and Karsan 2010; Starczynowski, Kuchenbauer 
et al. 2010; Reynaud et al. 2011; Starczynowski et al. 2011; Rhyasen et al. 2013; Chang et al. 
2014), highlighting the cooperating effects of genes on 5q (Figure 1). In future experiments, 
we will transduce Rps14 and Csnk1a1 haploinsufficient mice with the miR decoy leading to 
haploinsufficient expression of miR-145/146a. We hypothesize that combination of these 
lesions will recapitulate the complete del(5q) MDS phenotype by activating TLR4 signaling 
and and a downstream inflammatory environment, including an increase of Tnfα.
Specific cytokines are elevated in the serum of MDS patients (Kordasti et al. 2009) 
and these inflammatory signals can alter proliferation and apoptosis of MDS HSPCs 
(Kristinsson et al. 2011; Takizawa et al. 2012). Indeed, chronic immune stimulation, coupled 
with senescence-dependent changes (Verschoor et al. 2013) in both HSPCs and the BM 
microenvironment (Raaijmakers et al. 2010) may be central to disease pathogenesis. Our 
analysis of Rps14 haploinsufficient HSCs suggests that inflammatory cues induced by 
Rps14 haploinsufficiency impact HSC aging and quiescence (Rossi et al. 2007; Pang et al. 
2011; Reynaud, Pietras et al. 2011; Du et al. 2013). In patients with chronic inflammation, 
cytokines in bone marrow have been associated with inhibition of erythropoiesis (Means 
1995). In particular, TNFα expression has been implicated in erythroid defects observed in 
patients with DBA (Bibikova et al. 2014) and is up-regulated in the bone marrow serum 
of MDS patients (Jacobs-Helber et al. 2003; Sawanobori et al. 2003). TNFα was shown to 
increase TLR4-expression in a dose-dependent manner, whereas depletion of TNFa with 
anti-TNFα treatment of MDS bone marrow cells resulted in decreased TLR4 expression, 
suggesting that the TLR4 expression is TNFα dependent. Furthermore, Maratheftis et al. 
found a significant correlation between TLR4 expression and apoptosis in CD34+ MDS BM 
cells, providing evidence for increased TLR4 expression and cell-intrinsic defects associated 
with MDS HSCs (Maratheftis, Andreakos et al. 2007). 
Taken together, these studies and our study provide evidence for the role of HSC-
expressed TLRs in the pathogenesis of MDS. Inhibition of TLRs or the inflammatory 
environment may represent an attractive therapeutic strategy in the treatment of MDS. 
Our data suggest that inhibiting TLRs, Nfkb signaling or S100A8/S100A9 might be the best 
strategy as inhibition of Tnfα alone was not sufficient to rescue the erythroid differentiation 
defect.
S100 proteins participate in an autoregulatory feedback loop with p53, serving both as 
upstream drivers of p53 transcription and as direct downstream p53 transcriptional targets 
(Tan et al. 1999; Mueller et al. 2005; Li et al. 2009; Bresnick et al. 2015). Consistent with 
these reports, our data demonstrate that p53 is required for induction of S100a8 expression 
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Figure 1: Proposed mechanism how compound haploinsufficiency of Rps14 (chapter 2), Csnk1a1 (chapter 3 and 4) 
and miRNA145/146a (Starczynowski, Kuchenbauer et al. 2010) converge on TLR4 signaling and induction of p53.
in Rps14 haploinsufficient cells, and that recombinant S100a8 is sufficient to induce p53
activity in erythroid progenitor cells, leading to a block in terminal erythroid differentiation 
(Figure 1). It was shown in recent reports that S100 proteins can be intracellularly located and 
regulate cell growth, cell-cycle progression and apoptosis by interacting with the relevant 
intracellular signal-regulation pathways. S100 proteins can interact with p53 and affect 
p53 transcriptional activity, resulting in expression changes of p53 target genes (Ehrchen, 
Sunderkotter et al. 2009).
In summary, chronic innate immune signaling and activation is widely reported in MDS. 
Our studies in non-del(5q) MDS (normal karyotype) indicate that induction of S100A8 occurs 
as a stress response upon genetic abnormalities in MDS. The consequences of increased 
TLR signaling in MDS can result in systemic effects on hematopoiesis, such as those due 
to inflammation and abnormal adaptive and innate immunity in HSCs. In addition to these 
non-cell-autonomous consequences of chronic innate immune activation, increased TLR 
signaling within HSC from MDS patients was also reported and thought to contribute to cell-
intrinsic defects in HSCs. We also demonstrated that S100A8/S100A9 exerts both extrinsic 
and intrinsic effects on hematopoiesis. 
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Open questions yet need to be answered in future studies:
1) How is chronic innate immune signaling and activation in MDS best measured?
2)  How exactly is the innate immune pathway activated in MDS and in which hematopoietic 
lineage?
3) Which MDS subtypes (which mutations) exhibit activation of the innate immune system?
2.1.2 The erythroblastic island in MDS
In addition to granuloyctes and macrophages, which produce these proteins under steady-
state conditions, other cell types induce S100A8/S100A9 expression in response to stress 
(Hiratsuka et al. 2006). We found significant induction of S100A8 in both CD11b+ monocytes 
and F4/80+ macrophages and concomitant increased expression of S100A8 in late-stage 
erythroblast, which was associated with p53 induction. Spatially, erythroid progenitor 
cells interact with a central macrophage in the erythroblastic island. Our data indicate 
that disruption of the regulatory mechanisms in the erythroblastic island contribute to the 
erythroid differentiation defects in Rps14 haploinsufficient bone marrows. 
S100A9 activation has been described in MDS patient samples and myeloid-derived 
suppressor cells (MDSC) driven by the S100A9/CD33 pathway perturb hematopoiesis (Chen 
et al. 2013). Elevated levels of circulating cytokines, chemokines, and interleukins, including 
interleukin 6 (IL6), transforming growth factor (TGF-ß), tumor necrosis factor-α (TNF-a), and 
interferon (INF-y), characterize chronic inflammation and malignancy and are commonly 
found to be up-regulated in MDS (Flores-Figueroa et al. 2002). It is also likely that local 
concentrations may be even higher within erythroid niches because of direct secretion by 
central macrophages (Chasis and Mohandas 2008). In patients with chronic inflammation, 
cytokines in bone marrow have been associated with inhibition of erythropoiesis. This 
suppression is mechanistically complex and multifactorial, not only because it is induced by 
multiple cytokines, chemokines and interleukins but also because each of these proteins by 
itself may have more than one effect upon erythroid development. 
TNF-α inhibits erythropoiesis either by caspase-mediated cleavage of the major 
erythroid transcription factor GATA-1 resulting in apoptosis and/or by retarding proliferation; 
the precise mechanism(s) remains controversial (Dai et al. 2003). In MDS, macrophages have 
been shown to produce high levels of TNF-α (Flores-Figueroa, Gutierrez-Espindola et al. 
2002). Elevated levels of INF-y induce both macrophages and erythroblasts to secrete soluble 
TRAIL (TNF-related apoptosis inducing ligand), which inhibits erythroblast differentiation 
(Zamai et al. 2000). IL-6 up-regulates hepcidin expression, which inhibits iron export by 
binding to the iron exporter ferroportin and inducing its internalization and degradation, 
thereby blocking availiability of iron for erythropoiesis (Nemeth and Ganz 2006; Nemeth 
and Ganz 2006). 
In summary, there are myriad means by which elevated cytokines, chemokines and 
interleukins in MDS lead to disordered erythropoiesis. It remains an open question how MDS 
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Figure 2: The erythroblastic island is the regulatory unit of erythropoiesis. From the CFU-E stage to the formation 
of the reticulocyte, developing erythroblasts attach to the macrophage. The underlying mechanisms of ineffective 
erythropoiesis and dysregulation in the erythroblastic island in del(5q) MDS and in ribosomopathies are not well 
understood. Our data revealed that Rps14 haploinsufficiency leads to induction of S100A8/S100A9 expression in 
macrophages and erythroblasts and leads to the terminal erythroid differentiation block.
contributes to elevated cytokines and how cytokines contribute to the disturbed regulation 
in the erythroblastic island. We demonstrated that an increase of S100A8 in macrophages 
and in erythroblasts causes a block in erythroid differentiation. 
Future studies will dissect 1) how S100A8 in macrophages affects the erythroid 
differentiation and 2) if dysfunction in macrophages is sufficient to induce a block in 
erythroid differentiation (Figure 2).
2.1.3 Reduced protein synthesis in ribosomopathies
Ribosome biogenesis is a highly regulated, complex process (Fatica and Tollervey 2002). 
Eukaryotic ribosomes are comprised of 2 subunits: the small 40S subunit and the large 
60S subunit. These subunits join together to form the active 80S ribosome. Ribosomes 
contain 4 structural ribosomal RNAs (rRNAs). The 40S subunit contains the 18S rRNA, and 
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the large 60S subunit contains the 28S, 5.8S, and 5S rRNAs. These rRNAs are complexed 
with approximately 79 ribosomal proteins in eukaryotic ribosomes. Ribosome assembly is a 
complex and highly regulated process using a significant investment of cellular biosynthetic 
energy. More than 200 assembly factors and small nucleolar RNAs (snoRNAs) are required 
to synthesize ribosomes. 
The relative functional significance of rRNAs and the ribosomal proteins has been a 
matter of interest for many years. In the 1970s it was believed that ribosomal proteins were 
the functionally active part of the ribosome, whereas rRNA was essentially a scaffold to keep 
proteins in the optimal position. Since the 1980s this hypothesis was completely turned 
around and it was shown that ribosomal proteins are the scaffold for rRNAs. The crystal 
structure of the ribosome confirmed the predominance of rRNA sites, but also revealed 
that a number of ribosomal proteins were located in positions of functional importance, 
e.g. RPS12 at the decoding center, RPL11 and RPL10 as components involved in translation 
factor binding (Wool 1996). Over the years specific functions of many individual ribosomal 
proteins were identified and it is accepted that both proteins and RNA are essential for the 
optimal functioning of the ribosome. 
Several ribosomal proteins have been found to have extraribosomal functions including 
DNA repair, autoregulation of ribosomal protein synthesis and translation and regulation of 
development of malignant transformation on mainly through interaction with p53 (Warner 
and McIntosh 2009). Ribosomopathies are disorders resulting from impaired ribosome 
biogenesis and function. Diamond-Blackfan-Anemia (DBA) and 5q- syndrome are the two 
clinical syndromes for which there is abundant genetic and experimental evidence that the 
impairment in erythropoiesis is due to mutations in ribosomal genes (Shimamura 2006; 
Ganapathi and Shimamura 2008). The mechanism by which translation control is perturbed 
in ribosomopathies still remains an outstanding question. 
We demonstrated in our studies that Rps14 haploinsufficiency leads to significantly 
decreased protein synthesis in bone marrow cells, in particular in erythroid cells. So far, it 
remains elusive which proteins were less translated in Rps14 haploinsufficient erythroblasts 
and how they contribute to the erythroid differentiation defect and to induction of S100A8 
in steady state hematopoiesis and under cellular stress conditions. It is reasonable to 
believe that the anemia in DBA is due to similar mechanisms. Future studies will clarify 
which proteins are less translated in Rps14 haploinsufficiency and how they additionally 
contribute to the block in erythroid differentiation.
2.1.4 Functional relevance of ribosomal proteins in malignancies 
Both tumor suppressor genes and oncogenes have been shown to modulate the ribosome 
protein biosynthesis as well as ribosome translation. The interaction of p53 with ribosomal 
proteins seems to be involved in the association between ribosomal proteins and cancer 
(Ruggero and Pandolfi 2003; Deisenroth and Zhang 2010). 
Chapter 6
155
We demonstrated a p53-dependent erythroid differentiation defect in Rps14 
haploinsufficiency and we were able to rescue the block in erythroid differentiation in a p53 
null background. These findings indicate that p53 induction is critical for the anemia caused 
by ribosomal dysfunction. It was shown in cell lines that the combination of a defective 
ribosome biogenesis pathway and p53 activation results in strong antiproliferative responses 
(Lindstrom and Nister 2010). So far, it remains elusive if loss of p53 does not only rescue the 
erythroid differentiation defect but contributes to malignant transformation. 
Ribosomopathies in general are characterized by hypoproliferative phenotypes such 
as bone marrow failure and anemia early in life, followed by elevated cancer risks later in 
life. This transition from hypo- to hyperproliferation presents an intriguing paradox in the 
field of hematology known as the “Dameshek’s riddle” (Dameshek 1967). Recent cancer 
sequencing studies also revealed somatically acquired mutations and deletions in ribosomal 
proteins in T-cell acute lymphoblastic leukemia and solid tumors, further extending the 
list of ribosomopathies and strengthening the association between ribosomal defects and 
oncogenesis (De Keersmaecker et al. 2013). Future experiments will need to determine if 
Rps14 haploinsufficiency leads to malignant transformation in long-term studies by itself or 
with additional loss of p53.
2.2 Role of casein kinase 1a1 in the biology and targeted therapy of del(5q) MDS and 
as a target of lenalidomide 
Summary of findings: The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor 
gene located in the common deleted region for del(5q) myelodysplastic syndrome 
(MDS). We demonstrated in a murine model with conditional inactivation of Csnk1a1 
that haploinsufficiency induces hematopoietic stem cell expansion and a competitive 
repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell 
failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitizes 
cells to a CSNK1 inhibitor relative to cells with two intact alleles. We further demonstrated 
that lenalidomide induces the ubiquitination of casein kinase 1A1 by the E3 ubiquitin ligase 
CUL4-RBX1-DDB1-CRBN, resulting in CK1α degradation. In addition, we identified recurrent 
somatic mutations in CSNK1A1 on the non-deleted allele of patients with del(5q) MDS. These 
studies demonstrate that CSNK1A1 plays a central role in the biology of del(5q) MDS and is 
a promising therapeutic target.
  β-catenin is a major driver of stem cell self-renewal and neoplasia in multiple cellular lineages 
(Willert et al. 2003; Baba et al. 2005; Yeung et al. 2010; Elyada et al. 2011). Hematopoietic 
stem cells have a graded response to b-catenin, with modest levels leading to increased 
stem cell self-renewal (Baba, Garrett et al. 2005), and more marked induction leading to 
stem cell exhaustion (Albuquerque et al. 2002; Kirstetter et al. 2006; Lane et al. 2010; Luis 
et al. 2011). Forced expression of β-catenin, in combination with HOXA9 and MEIS1, induces 
leukemia in progenitor cells (Wang et al. 2010), and β-catenin is essential for leukemia cells 
driven by the MLL-AF9 oncogene (Miller et al. 2013). 
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CK1a is a member of the β-catenin destruction complex and is therefore a known, 
central regulator of β-catenin activity (Cheong and Virshup 2011). In our studies, Csnk1a1 
haploinsufficiency conferred to increased intrinsic self-renewal of HSC, with associated 
nuclear β-catenin accumulation, cyclin D1 induction, and exit from quiescence in LT-
HSCs. Increased LT-HSC proliferation and expansion was a cell-intrinsic effect in our study. 
Inactivation of Csnk1a1 in stromal cells in our model caused stromal b-catenin levels 
to increase, with consequent effects on hematopoiesis, including pancytopenia and 
hematopoietic stem and progenitor cell depletion. This observation is consistent with recent 
studies demonstrating that b-catenin accumulation in the stroma negatively regulates HSC 
maintenance and might also contribute to leukaemogenesis (Lane, Sykes et al. 2010; Kode 
et al. 2014). 
APC, another member of the β-catenin destruction complex, is also deleted in the 
vast majority of del(5q) MDS cases. Hematopoietic cells with Apc haploinsufficiency have 
been shown to have enhanced repopulation potential, indicating a cell intrinsic gain of 
function in the LT-HSC population. However, in contrast to Csnk1a1 haploinsufficiency, 
Apc haploinsufficient bone marrow was unable to repopulate secondary recipients due to 
loss of the quiescent HSC population (Lane, Sykes et al. 2010; Wang et al. 2010). Different 
levels of Wnt activation may explain these findings. Similarly, deletions of Csnk1a1 and of 
Apc in the gut have significantly different effects. While Csnk1a1 deletion led to robust 
activation of Wnt target genes and proliferation without invasion, Apc deletion induced 
immediate dysplastic transformation and rapid death (Elyada, Pribluda et al. 2011). CK1a 
has many phosphorylation targets that could alter stem cell function (Bidere et al. 2009; 
Elyada, Pribluda et al. 2011; Wu et al. 2012). As has been postulated previously, it is possible 
that CK1a inactivation restrains hyperactive Wnt signaling through mechanisms yet to be 
defined. We aim to elucidate further mechanisms and targets of Csnk1a1 in future studies 
which might explain the discrepany on the stem cell phenotype caused by Csnk1a1 and Apc 
haploinsufficiency. 
Our sequencing studies revealed recurrent mutations in a gene located in an MDS 
common deleted region on chromosome 5q. SNP array studies have not identified any genes 
on 5q that undergo homozygous deletion in del(5q) MDS (Gondek et al. 2008; Graubert 
et al. 2009; Heinrichs et al. 2009). Indeed, our studies would indicate that homozygous 
inactivation of CSNK1A1 would be highly deleterious to a hematopoietic cell. In functional 
studies, expression of the identified CSNK1A1 E98V allele, in the setting of inactivation of 
both wild-type alleles to mimic the genetic context of the mutations observed in patients, 
caused an induction of nuclear β-catenin and a significant HSC cell cycle progression 
compared to expression of the wild-type CSNK1A1. 
These specific mutations were confirmed in three independent studies. Heuser et 
al. found CSNK1A1 mutations in 17 of 237 patients with MDS or sAML and del(5q) (7.2%), 
comparable to our study (Heuser et al. 2015). Thirteen of the patients had missense 
mutations affecting glutamic acid E98 in exon 3 (76%) and four patients (24%) had missense 
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mutations affecting aspartic acid (D140), confirming these mutational hotspots. Bello et 
al. confirmed these mutations a few months later in 5 out of 104 del(5q) MDS patients 
(approximately 5%) and demonstrated concomitant up-regulation of ß-Catenin in those 
patients by gene expression analysis, similar to our results in the functional characterization 
of the mutation (Bello et al. 2015). In the most recent publication Alexander Smith and 
colleagues investigated the frequency and clinical associations of mutations of the CSNK1A1 
gene. Using whole exome sequencing and targeted next-generation re-sequencing, they 
detected mutations in seven (18%) out of 39 patients with isolated del(5q) at the time of 
diagnosis. Interestingly, they found that the mutation was higher in patients that progressed 
to AML (four out of 10; 40%) than it was in those who did not (three out of 29; 10%). 
Further they demonstrated that six out of seven patients (85%) with a CSNK1A1 with del(5q) 
MDS did not achieve a complete cytogenetic response to lenalidomide and that the median 
progression free survival for patients with the mutation was significantly lower than in those 
without the mutation (Smith et al. 2015). Larger studies are clearly needed to establish 
the effect of CSNK1A1 mutations on patient survival and response to treatment. Strikingly, 
the mutation in the CSNK1A1 gene was only found in patients with del(5q) not in MDS 
with normal karyotype. Future experiments using a conditional knock-in mouse strain will 
be helpful to study the long-term hematopoietic effects of the mutant allele expressed at 
physiological levels.
Targeting haploinsufficiency as a vulnerability in del(5q) MDS
The concept that genes within heterozygous deletions could cause vulnerabilities 
in cancer cells was first proposed 20 years ago (Frei 1993) and  has been more recently 
demonstrated as CYCLOPS genes (cancer vulnerabilities unveiled by genomic loss) in cell 
lines (Nijhawan et al. 2012). We found that heterozygous inactivation of Csnk1a1 causes 
hematopoietic stem cell expansion and β-catenin activation. In addition, we found that 
Csnk1a1 haploinsufficiency sensitizes cells to casein kinase inhibition, demonstrating an 
approach for the targeting of heterozygous deletions in cancer. 
Thus, it was of particular interest for us that lenalidomide targets CSNK1A1. We 
demonstrate that lenalidomide targets CSNK1A1 for degradation in myeloid cells, and 
that heterozygous deletion of CSNK1A1 in del(5q) MDS provides a therapeutic window 
for selective targeting of the malignant cells not only by CSNK1 inhibitors but also by 
lenalidomide, explaining the good response in del(5q) MDS. Deletion of contiguous genes 
on chromosome 5q, such as RPS14, may further sensitize del(5q) cells to lenalidomide 
therapy by TP53 activation (Ebert et al. 2008; Narla and Ebert 2010). This mechanism of 
activity is consistent with the acquisition of TP53 mutations in del(5q) MDS patients who 
develop resistance to lenalidomide. In the future, we will combine Rps14 and Csnk1a1 
haploinsufficiency and analyze if the compound haploinsufficiency sensitizes Rps14/Csnk1a1 
compound haploinsufficient cells even more for the treatment.
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Figure 3: Csnk1a1 haploinsufficient cells are sensitized for treatment with a CSNK1 inhibitor and additional Csnk1a1 
inhibition induces p53 and apoptosis while wild-type cells are not affected.
2.3 Dissecting hematopoietic-stromal interactions in a transplantable bone marrow 
niche at extramedullary sites
Summary of findings: We characterized a multicomponent system that is optimal for the 
study of hematopoietic-mesenchymal interactions and the recapitulation of the native 
BM microenvironment in extramedullary sites. Macro- and microporous β-TCP scaffolds in 
combination with Matrigel optimally supported hematopoiesis, including hematopoietic 
recruitment, proliferation, and differentiation as well as ECM remodeling. β-TCP scaffolds 
in combination with Matrigel further promoted vascularization and allowed for mature 
bone deposition and hematopoiesis—stroma interactions in subcutaneous ectopic 
transplantations of the BM niche in a murine model.
The rationale of our approach was inspired by extramedullary hematopoiesis in which the 
body develops hematopoietic-inductive spaces for the ectopic growth of HSPCs during states 
of bone marrow failure. This compensatory process is a well-recognized clinical observation 
that occurs in a variety of non-osseous tissues including the spleen, liver, and skin (Koch et 
al. 2003). Although extramedullary sites do not have the same microenvironment as the 
endogenous bone marrow, they are assumed to retain the essential elements involved in 
Chapter 6
159
HSPC migration and engraftment. We used a bioengineering approach to recapitulate this 
functional microenvironment to study hematopoietic biology. For the co-culture of HSPCs 
and mBMSCs/hMSCs, we applied β-TCP-printed scaffolds containing macro- and micropores 
similar to the bone—of inorganic (hydroxyapatite mineral) composition—in combination 
with an extracellular matrix gel—of organic (collagen type I matrix) composition.
Subdermally implanted scaffolds induced the development of two important tissue 
structures found in the bone marrow niche: a sinusoidal-like vasculature and interstitial space 
for the housing of a large number of hematopoietic cells. Previous studies of similar scaffold 
designs have shown that the pores 30–40 µm in diameter efficiently promote vascularization 
upon implantation (Fukano et al. 2006). These designs, although promoting vasculature, 
do not create a separate organized hematopoietic cavity for the influx and efflux of cells. 
Our study demonstrates that varying pore sizes of the β-TCP scaffolds from 500 to 800 μm 
was irrelevant in terms of hematopoietic support function. This is an interesting finding as 
particle geometry, porosity, pore size distribution, and scaffold continuity are properties 
known to determine cell/scaffold interactions and thus cell fate (Dazzi et al. 2006; Prockop 
2009; Prockop et al. 2010). Pore size, however, has been only considered crucial within 
three main pore size intervals. According to Petite et al., pore sizes smaller than 15–50 μm 
result in fibrovascular growth, medium-sized pores of 50–150 μm encourage osteogenesis, 
while pores larger than 150 μm support the ingrowth of mineralized bone (Sacchetti et 
al. 2007). Contradicting studies even report that bone ingrowth is optimal for pore sizes 
varying from 300 to 900 μm (Tsigkou et al. 2010). The β-TCP scaffolds applied in our study 
had an interconnected net-like structure in the absence of dead-end pockets, macropores 
with mean pore size 500 or 800 μm, and micropores smaller than 15 μm. Our scaffolds 
were designed to maximize the surface area for stromal cell expansion, and we were able 
to demonstrate that these characteristics successfully promote vascular ingrowth as well as 
promotion of hematopoiesis. In the future, it will be sufficient to use larger pores which will 
make the production of the scaffolds easier. Our data so far show that the combination of a 
matrix component with b-TCP is more important than the geometry of a scaffold.
Our in vitro data suggest that complete hematopoiesis is promoted by β-TCP scaffolds in 
combination with structural proteins and cytokines provided by Matrigel as an extracellular 
matrix. First, β-TCP/Matrige scaffolds more robustly maintained a primitive LSK fraction over 
time. Second, hematopoietic differentiation in both myeloid and lymphoid lineages was 
supported after 14 days in Matrigel-containing conditions. Third, the CFU potential of β-TCP/
Matrigel scaffolds was significantly increased compared to other conditions implicating 
that Matrigel supports both the functional maintenance of HSPCs and their differentiation 
capacity. Fourth, β-TCP/Matrigel scaffolds supported the remodeling of the ECM as an 
important requisite for cell differentiation and growth.
In vivo, β-TCP/Matrigel scaffolds resulted in strong hematopoietic recruitment to the 
sites of the ectopic transplantations as confirmed by the detection of myeloid and lymphoid 
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fractions 4 weeks after transplantations at levels comparable to the relative composition 
of the BM. Multinucleated osteoclasts and typically spindle-shaped osteoblasts were seen 
at the β-TCP scaffold/ECM interface. CD31-positive layers of recruited endothelial cells 
and adipose cells, typical for vascular niches, were both identified in explants showing 
the most efficient collagen matrix deposition. These data show that we generated sites of 
extramedullary hematopoiesis. One important question is which cytokines/growth factors/
extracellular matrix components in matrigel lead to the significant support of hematopoiesis. 
It will be important to define these important factors better in order to standardize the 
scaffolds and use them as a „screening tool“ for drug discovery studies and for dissecting 
the regulatory mechanisms of stromal cells and hematopoeitic cells in health and disease.
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eNGLISh SuMMaRy
The studies presented in this thesis focused on the identification of genes that play a central 
role in the pathogenesis of myelodysplastic syndromes with a deletion of the short arm (q) 
of chromosome 5, the del(5q) MDS in chapters 2-4. The overall goal of the projects was to 
gain a better understanding of how gene haploinsufficiency in (del)5q MDS leads to a clonal 
advantage, ineffective hematopoiesis and how haploinsufficiency can be targeted (chapter 2-4).
Heterozygous deletion of RPS14 occurs in del(5q) myelodysplastic syndrome (MDS) and 
has been linked to impaired erythropoiesis, characteristic of this disease subtype. So far, 
it was not well understood how ribosomal haploinsufficiency affects protein synthesis 
and if differentially translated proteins have a impact on the erythroid differentiation 
defect (chapter 1). We generated a murine model with conditional inactivation of Rps14 
and demonstrated a p53-dependent erythroid differentiation defect with apoptosis at 
the transition from polychromatic to orthochromatic erythroblasts resulting in age- and 
erythroid stress dependent progressive anemia, megakaryocyte dysplasia, and loss of 
hematopoietic stem cell (HSC) quiescence (chapter 2). Protein synthesis was significantly 
reduced in Rps14 haploinsufficient hematopoietic stem cells and in particular in erythroid 
progenitor cells relative to wild-type cells. As assessed by quantitative proteomics, Rps14 
haploinsufficient erythroblasts expressed higher levels of proteins involved in innate 
immune signaling, notably the heterodimeric S100 calcium-binding proteins S100a8 and 
S100a9 (alarmins). S100a8 is functionally involved in the erythroid defect caused by the 
Rps14 deletion, as addition of recombinant S100a8 was sufficient to induce an erythroid 
differentiation defect in wild-type erythroid cells (phenocopy), and genetic inactivation of 
S100a8 expression rescued the erythroid differentiation defect of Rps14-haploinsufficient 
HSCs. Our data link Rps14 haploinsufficiency in del(5q) MDS to activation of the innate 
immune system and induction of S100A8-S100A9 expression, leading to a p53-dependent 
erythroid differentiation defect. In future experiments I aim to focus on the role of chronic 
inflammation on myelodysplasia and on the role of monocytes and macrophages as disease-
mediating, inflammatory bystander cells and ultimately, on how to therapeutically target 
this process.
A key question in the field is, which genes within the commonly deleted region (CDR) 
are necessary and sufficient for del(5q) HSC to achieve clonal dominance over normal HSC. 
Csnk1a1 haploinsufficiency conferred increased intrinsic self-renewal of HSC and nuclear 
ß-Catenin accumulation (chapter 3). In striking contrast, Csnk1a1 homozygous inactivation 
is not tolerated in HSC due to activation of p53. The sensitivity of hematopoietic cells to 
Csnk1a1, β-catenin and p53 gene dosage provides a therapeutic window for targeting 
haploinsufficiency in del(5q) MDS cells. 
English summary
The finding of targeting haploinsufficiency as a vulnerability of the hematopoietic stem 
cell in del(5q) MDS was a central concept in the study described in chapter 4. Here, we 
demonstrate that lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1α) by the 
E3 ubiquitin ligase CRL4(CRBN), resulting in CK1α degradation. Haploinsufficient expression 
sensitizes cells to lenalidomide therapy, providing a mechanistic basis for the therapeutic 
window of lenalidomide in del(5q) MDS. In future experiments I would like to test candidate 
molecules to specifically target the gene dosage effect in del(5q) HSC with limited effects on 
normal hematopoiesis, overcoming the problems of resistance to lenalidomide therapy and 
maintenance of the del(5q) MDS clone under therapy.
In the last part of the thesis (chapter 5) we aimed to create an artificial, trans-
plantable BM niche that supports hematopoiesis while allowing for the genetic 
modification of both hematopoietic and mesenchymal cells as to dissect their interaction 
in steady state and under pathopyhsiological conditions (chapter 5). We established 
and characterized a multicomponent system that is optimal for studying hematopoietic-
mesenchymal interactions and for the recapitulation of the native BM microenvironment 
in a transplantable extramedullary niche (mouse model). The combination of macro- and 
microporous β-TCP scaffolds and Matrigel optimally supports hematopoiesis, including 
hematopoietic recruitment, proliferation, and differentiation as well as ECM remodeling. In 
future experiments we intend to genetically modify stromal cells and study their impact on 
the HSC regulation in myeloproliferative neoplasms and their role in fibrotic transformation 
in myelofibrosis.
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DuTCh SuMMaRy (NeDeRLaNDSe SaMeNVaTTING)
De studies besproken in dit proefschrift richtten zich op de identificatie van genen die 
een belangrijke rol spelen in de pathogenese van het myelodysplastisch syndroom (MDS) 
met een deletie van de korte arm (q) van chromosoom 5, de del(5q).  Het doel van deze 
studies was om beter te begrijpen hoe haploinsufficiëntie in (del)5q MDS kan leiden tot 
klonale uitgroei en ineffectieve hematopoiese, en hoe deze haploinsufficiëntie kan worden 
behandeld. 
Heterozygote deletie van RPS14 komt voor in del(5q) MDS en is geassocieerd met 
een dysfunctionele erythropoiese, karakteristiek voor dit subtype van MDS. Het is echter 
niet goed bekend op welke manier deze ribosomale haploinsufficiëntie  invloed uitoefent 
op de eiwit synthese, en of differentieel getransleerde eiwitten een rol spelen bij het 
erythroïde differentiatie defect dat wordt gezien in dit subtype van MDS (hoofdstuk 1). 
Om deze vraag te kunnen beantwoorden hebben wij een muismodel gemaakt waarin 
sprake is van conditionele inactivatie van Rps14. In dit muismodel vonden wij een p53-
afhankelijk erythroïde differentiatie defect, waarbij apoptose optreedt in de transitie van 
polychromatische naar orthochromatische erytroblasten. Dit leidde tot een leeftijd- en 
erythroïde stress-afhankelijke progressieve anemie, dysplasie van megakaryocyten en een 
verlies van hematopoietische stamcel (HSC) “quiescence” (hoofdstuk 2). 
De eiwitsynthese is significant verminderd in Rps14 haploinsufficiënte HSCs in 
vergelijking met wild type cellen, met name in erythroïde voorloper cellen. Middels 
kwantitatieve proteoom studies konden we aantonen dat Rps14 haploinsufficiënte 
erytroblasten een hogere expressie hebben van eiwitten die betrokken zijn bij de aangeboren 
immuun respons, in het bijzonder de heterodimerische S100 calcium bindende eiwitten 
S100a8 en S100a9 (alarmins) (Hoofdstuk..). Wij hebben laten zien dat S100a8 functioneel 
betrokken is bij het erythroïde defect ten gevolge van Rps14 haploinsufficientie: Toevoeging 
van recombinant S100a8 bleek voldoende om een differentiatie defect te induceren in wild 
type erythroïde cellen (phenocopy), en omgekeerd bleek dat genetische inactivatie van 
S100a8 het erythroïde differentiatie defect  van Rps14-haploinsufficiënte HSCs opheft.. Deze 
data verbindt Rps14 haploinsufficiëntie in del(5q) MDS met inactivatie van het aangeboren 
immuun systeem en de inductie van S100A8-S100A9 expressie, wat leidt tot een p53 
afhankelijk differentiatie defect. In vervolg experimenten ben ik van plan mij te richten op 
de rol van chronische ontsteking in myelodysplasie en op de functie van monocyten en 
macrofagen als bij deze ziekte betrokken zijnde ontstekingscellen. Tot slot zal ik mij richten 
op de vraag hoe dit proces het beste therapeutisch behandeld kan worden.  
Een belangrijke vraag in dit vakgebied is welke genen in de “common deleted 
region” (CDR) noodzakelijk en voldoende zijn voor de klonale uitgroei van HSCs die wordt 
gezien bij del(5q) MDS. Csnk1a1 haploinsufficiëntie leidt tot een verhoogde, intrinsieke 
zelfvernieuwing van HSCs en tot opstapeling van nucleair β-catenine (hoofdstuk 3). 
Dutch summary
Daarentegen wordt homozygote inactivatie van Csnk1a1 niet getolereerd in HSC, vanwege 
de activatie van p53. Deze genuanceerde gevoeligheid van HSCs voor de hoeveelheid 
Csnk1a1,  e en p53 activiteitbiedt aangrijpingspunten voor therapeutische manipulatie van 
de haploinsufficiëntie in del(5q) MDS. 
Deze mogelijkheid om de haploinsufficiënte status van HSCs in del(5q) MDS als doelwit 
te gebruiken staat centraal in de studie die beschreven wordt in hoofdstuk 4. In dit hoofdstuk 
tonen wij dat lenalidomide de ubiquitinatie van casein kinase 1A1 (CK1α) induceert middels 
de E3 ubitiquitin ligase CRL4 (CRBN), wat resulteert in de degradatie van CK1α. Aangezien 
haploinsufficiëntie cellen gevoelig maakt voor behandeling met lenalidomide, geeft deze 
bevinding een mechanistische basis voor het therapeutische gebruik van lenalidomide 
in del(5q) MDS. In vervolg experimenten zou ik graag kandidaat moleculen testen die 
aangrijpen op het gen-doserings effect in del(5q) HSCs en minimale effecten hebben op de 
normale hematopoiese, om zo het probleem van therapie resistentie voor lenalidomide, en 
de persistente aanwezigheid van de del(5q) MDS kloon tijdens behandeling te voorkomen. 
In het laatste deel van dit proefschrift (hoofdstuk 5) hebben we gepoogd een 
transplanteerbaar beenmerg niche model te maken waarinde normale hematopoiese 
wordt ondersteund, en de mogelijkheid biedt  voor genetische modificatie van zowel 
de hematopoietische als de mesenchymale cellen, zodat de interacties in normale en 
pathofysiologische condities onderzocht kunnen worden (hoofdstuk 5). We hebben hiervoor 
een multi-componenten systeem gemaakt en gekarakteriseerd, dat optimaal is voor 
onderzoek naar de hematopoietische-mesenchymale interacties en voor het nabootsen 
van het micromilieu in het beenmerg in een transplanteerbaar model. De combinatie van 
macro- en microporeuze β-TCP “scaffolds”  en Matrigel ondersteunt optimale hematopoiese, 
inclusief hematopoietische recruitering , proliferatie en differentiatie van hematopoietische 
stam en progenitor cellen, en extracellulaire matrix (ECM) re-modellering. In toekomstige 
studies streven wij ernaar stromale cellen genetisch te modificeren en hun rol in HSC 
regulatie in myeloproliferatieve maligniteiten, en fibrotische transformatie in myelofibrose 
te onderzoeken.  
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1. PhD training
Year Workload 
(Hours/ECTS)
General academic skills/Research skills
• Biomedical English Writing and Communication
• Research Management for PhDs and Postdocs
• Laboratory animal science
• Basic introduction course SPSS
• Photoshop and Illustrator CS5 workshop
• Flow cytometry introduction/FlowJo
                      
2012
2012
2012
2012
2012
2015
1
1
3
0.6
0.3
1
In-depth courses and workshops
• Hematopathology clinical conference
• Analysis of microarray and RNA seq data
•  Genome engineering course Broad Institute,  
Cambridge, 
•  Molecular Cancer work discussion Broad Institute,  
Cambridge, USA (weekly, Tuesdays)
•  Work in progress meeting Department of Hematology,  
Brigham and Women’s hospital, Boston, USA
•  Hematology lunch meeting, Dana Farber cancer Institute,  
Boston, USA
• Journal Club
2012-2015
2013
2015
2012-2015
2012-2015
2012-2015
2012-2015
4
1
1
3
2
2
2
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Summary of PHD traiing and teaching activities
Year Workload 
(Hours/ECTS)
Presentations
• 55th Annual Meeting American Society of Hematology (oral)
• 56th Annual Meeting American Society of Hematology (oral)
• 57th Annual Meeting American Society of Hematology (oral)
•  13th International Symposium on Myelodysplastic Syndromes 
Washington DC, USA (oral)
•  Grand Rounds Hematology, Department of Hematology, Brigham 
and Women’s Hospital, Harvard Medical School, Boston (oral)
• SFB Dresden invited talk (oral)
• D-A-CH MDS meeting 2013, Düsseldorf (oral)
•  Myeloid Malignancies Meeting, Department of Hematology, 
Brigham and Women’s Hospital, Harvard Medical School, 
Boston (oral)
•  Cancer Biology Meeting, Department of Hematology, Brigham and 
Women’s Hospital, Harvard Medical School, Boston (oral)
• D-A-CH MDS meeting 2014, Düsseldorf (oral)
• Deutsche Krebskonferenz, Berlin 2014 (oral)
•  Ribosome Function and Ribosomopathies Expert meeting, Stowers 
Institute, Kansas City, MO, USA (oral)
• FASEB Hematological Malignancies Meeting 2015 (oral)
• Work discussion meeting (9x)
• Journal club (4x)
2013
2014
2015
2015
2015
2015
2013
2014
2014
2014
2014
2013
2015
2012-2015
2012-2015
International conferences
• 54th Annual Meeting American Society of Hematology 
• 55th Annual Meeting American Society of Hematology 
• 56th Annual Meeting American Society of Hematology 
• 57th Annual Meeting American Society of Hematology 
• 13th International Symposium on Myelodysplastic Syndromes. 
• FASEB Hematological Malignancies Meeting 2015
2012
2013
2014
2015
2015
2015
1
1
1
1
1
1
2. Teaching activities
Lecturing
• Bone marrow histopathology (weekly) 2012-2015 2
Teaching activities
• Supervising master students
• Supervising international summer students
• Supervising ASH honors students
2012-2015
2012-2015
2012-2015
3
2
2
total 56.4
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